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Zusammenfassung 
 
Die Familie der Sp-Transkriptionsfaktoren charakterisiert sich durch ihre DNA-
Bindungsdomäne, bestehend aus drei C-terminalen Zinkfingern vom Typus C2H2. 
Als Folge dieses hochkonservierten DNA-Bindungsmotivs erkennen die einzelnen 
Mitglieder der Sp-Familie jeweils mit gleicher Spezifität und Affinität sogenannte GC- 
(GGGGCGGGG) und GT- (GGTGTGGGG) Boxen. GC- und GT-Boxen sind von 
großer Bedeutung für die Expressionsregulation verschiedenster ubiquitärer, 
gewebespezifischer und viraler Gene. Bis jetzt wurden neun Mitglieder der Sp-
Familie identifiziert (Sp1 bis Sp9). Zusätzlich zur charakteristischen DNA-
Bindungsdomäne besitzen die Transkriptionsfaktoren Sp1 bis Sp4 weitere 
strukturelle Gemeinsamkeiten, wie z.B. zwei glutaminreiche Transaktivierungs-
domänen oder zwei serin-/threoninreiche Regionen. Molekulare sowie funktionelle 
Eigenschaften sind für die Faktoren Sp1, Sp3 und Sp4 beschrieben. Entsprechende 
Maus-Knockouts belegen ihre vielfältige Funktion und essentielle Bedeutung bei der 
Säugerentwicklung. Seit der Klonierung von Sp2, dem am wenigsten konservierten 
Mitglied der aus Sp1-4 bestehenden glutaminreichen Unterfamilie, wurden keine 
weiteren Daten hinsichtlich seiner Funktion in vivo oder in vitro publiziert. Aus diesem 
Grunde war das Ziel der vorliegenden Arbeit, die Untersuchung der Sp2-Funktion 
mittels zwei verschiedener Ansätze: einer funktionellen molekularen 
Charakterisierung, welche unter anderem Expressions-, Transaktivierungs- und 
DNA-Bindungsstudien beinhaltete, sowie der Herstellung von Sp2-Knockout-Mäusen. 
 
Zur Untersuchung der Sp2-Funktion auf molekularer Ebene wurden polyklonale, Sp2-
spezifische Antikörper hergestellt und für Expressionsstudien eingesetzt. Es zeigte 
sich, daß Sp2 ausschließlich im Zellkern lokalisiert ist und in allen getesteten 
Zelllinien und Mausgeweben exprimiert wird, wenn auch in unterschiedlichen 
Mengen. Dies spricht für eine weitläufige bis ubiquitäre Expression in der Maus. In 
einem zweiten Schritt wurde die Fähigkeit von Sp2 analysiert, Promotoren zu 
aktivieren, die GC- bzw. GT-Boxen als Regulationselemente beinhalten. Hierzu 
wurden Reporterassays mit Wildtyp-Sp2-Protein sowie verschiedenen Sp2-
Deletionsmutanten durchgeführt. Im Gegensatz zum Transkriptionsfaktor Sp1, der 
einen starken Aktivator darstellt, aktivierte keines der untersuchten Sp2-Varianten die 
Expression der Reportergene. Auch wenn Sp2-Fragmente an eine heterologe DNA-
Bindungsdomäne fusioniert waren, konnte keine Aktivierung festgestellt werden. 
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Zusätzlich wurde mittels Gelretardationsexperimenten die Fähigkeit und Spezifität 
von Sp2, DNA zu binden, untersucht. Es zeigte sich, daß Wildtyp-Sp2-Protein nicht in 
der Lage war, an DNA zu binden, weder an GC-Boxen („klassische“ Sp1-
Bindungsstelle) noch an GC-Box-Varianten oder andere DNA-Bindungssequenzen, 
wie GT- oder CT-Boxen. Wurden jedoch die N-terminalen Aminosäuren 1-179 
deletiert, erfolgte die Bindung an die DNA. Diese Befunde sprechen dafür, daß der 
Prozeß der Sp2-DNA-Interaktion in vivo reguliert ist. Zur Ermittlung der 
physiologischen Funktion von Sp2, wurden Sp2-Knockout-Mäuse hergestellt. Diese 
Mäuse sind nicht lebensfähig; sie sterben kurz vor bzw. nach der Geburt. Während 
Sp2-mutierte Embryonen bis zum Tag E12,5 keine erkennbaren Abnormalitäten 
aufweisen, sind die Körpergröße und das -gewicht von Embryonen am Tag E18,5 im 
Vergleich zum Wildtyp deutlich reduziert, wenn auch mit großer Varianz. Diese 
Ergebnisse verdeutlichen, daß der Transkriptionsfaktor Sp2 essentiell für eine 
normale Mausentwicklung ist. In welche Differenzierungsprozesse er im Detail 
involviert ist, müssen weitere Untersuchungen zeigen. 
 
 II
Summary 
 
The Sp family of transcription factors is characterised by its DNA-binding domain, an 
array of three conserved C2H2 zinc fingers. As a consequence of the conserved 
DNA binding motif, Sp members recognize GC (GGGGCGGGG) and GT 
(GGTGTGGGG) boxes with similar specificity and affinity. GC and GT boxes are 
important for the expression of many different ubiquitous as well as tissue-specific 
cellular and viral genes. To date, nine members of the Sp family (Sp1 - Sp9) have 
been identified. In addition to their DNA-binding domain, Sp1 - Sp4 also share other 
structural features like two glutamine-rich transactivation domains and two 
serine/threonine-rich regions. Molecular and functional properties have been 
described for Sp1, Sp3 and Sp4. Mouse deletion mutants, which have been 
generated for these factors, demonstrate their manifold function and essential 
importance for mammalian development. Since the cloning of Sp2, which is the less 
conserved factor among Sp1 - Sp4, no reports about its function, neither in vitro nor 
in vivo have been published. Therefore, the aim of this thesis work was to unravel 
Sp2 function by two parallel approaches: a functional molecular characterization 
(including expression, transactivation and DNA binding studies) and the generation of 
Sp2 gene targeted mice. 
 
To study the Sp2 protein at the molecular level, Sp2-specific rabbit polyclonal 
antibodies were generated. Sp2 protein, which is exclusively localized to the nucleus, 
was detected in all analyzed cell lines and adult mouse tissues, although in different 
amounts. This favours at least a widely expression of the transcription factor Sp2. To 
explore Sp2 transactivation properties, reporter assays were performed with full-
length Sp2 protein as well as various Sp2 deletion mutants using different GC- and 
GT-box-containing promoters. Unlike transcription factor Sp1, which is a strong 
activator, Sp2 proteins did not activate reporter gene expression. Also, when fusing 
Sp2 deletions to a heterologous Gal4 DNA binding domain, no activation was 
detectable. In addition, the DNA binding capacity and specificity of full-length Sp2 
protein and a series of Sp2 deletion mutants were investigated by Electrophoretic 
Mobility Shift Assays. Full-length Sp2 protein was not able to bind to DNA, neither to 
GC boxes (the “classical” Sp1 binding site) and GC box variants, nor to other DNA 
binding sequences like GT and CT boxes. However, when deleting the N-terminal 
amino acids 1-179, GC box binding was possible. These results suggest that the 
 III
DNA binding activity is regulated in vivo. To unravel the physiological function of 
transcription factor Sp2, targeted mice were generated. These mice are not viable; 
they die shortly before or after birth. Whereas Sp2-targeted embryos develop normal 
until day E12.5, day E18.5 embryos are characterized by a strongly reduced body 
size and weight, however with strong variations. These results demonstrate a 
fundamental role of the transcription factor Sp2 for normal mouse development. 
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1. Introduction 
 
1.1 Regulation of gene expression 
 
Multicellular organisms like mammals are composed of various cell types with 
different functions. Although displaying different functions, nearly all nuclear cells 
contain the same genetic information. Apart from so-called house-keeping genes, 
which are expressed in all cells, the expression of genes is cell-type-dependent. But 
also cell development or environmental conditions requiring different gene products 
in the cell influence gene expression. This differential gene expression is the basis for 
the formation of complex, multicellular organisms with a great diversity of cell types, 
each of them characterized by a special set of proteins. 
 
Differential gene expression as well as the formation of a functional protein can be 
regulated on different levels, like e.g. transcription, mRNA procession, mRNA 
transport and stability but also translation and stability or activity of the translated 
protein. The regulation on the transcriptional level hereby plays a crucial role. 
 
In eukaryotic cells, gene transcription is driven by three RNA polymerases, RNA 
polymerase I, II and III (Roeder and Rutter, 1969). Protein-coding genes are 
transcribed into mRNA by RNA polymerase II. Transcription of DNA into mRNA by 
RNA polymerase II is one of the most highly regulated processes in the cell. This 
regulation depends on a complex molecular machinery (Fig. 1.1) consisting of 
numerous transcription factors (Lemon and Tjian, 2000). 
 
Eukaryotic promoters generally are composed of a core promoter, a distal promoter 
region and several enhancer or silencer elements. Core promoters often contain the 
so-called TATA-box (25-30 nucleotides upstream of the transcription start point), a 
pyrimidine-rich initiator sequence (Inr) or a so-called downstream core promoter 
element (DPE; approximately 30 nucleotides downstream of the transcription start 
point) (Krajewska, 1992; Mitchell and Tjian, 1989). Enhancer and silencer elements, 
on the other hand, are DNA regions in great distances upstream or downstream to 
the transcription start point. Transcription factors bind to these regions and can 
enhance or silence gene transcription (Brand et al., 1985; Dynan 1989; Levine and 
Manley, 1989; Voss and Pongs, 1986). 
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To initiate transcription, transcription factors bind to the distal promoter and enhancer 
elements and by this enable the recruitment of RNA polymerase II to the core 
promoter region (Orphanides et al., 1996; Roeder, 1996). The first step in 
transcription initiation is the remodeling of chromatin giving access of the pre-
initiation complex to the promoter (Fig. 1.1). The pre-initiation complex is assembled 
stepwise starting with the attachment of the multi-protein complex TFIID to the TATA-
box via its subunit TBP (TATA-box-binding protein; Weinzierl et al., 1993) together 
with the attachment to the DPE element (Drosophila) via a TBP-associated subunit 
(TAF), followed by the association of further general transcription factors like TFIIA, 
B, F, E and H as well as the RNA polymerase II. Assembly of the pre-initiation 
complex is sufficient for a basal promoter activity in vitro (Lewin, 1990; Roeder, 
1991). In vivo, however, other factors like specific transcription factors or different co-
regulators are necessary (Faisst and Meyer, 1992; Roeder, 1991; Wingender, 1988). 
 
Many promoters, enhancers and silencers contain characteristic DNA sequence 
motifs, like e.g. GC or CAAT boxes. These boxes are bound by specific transcription 
factors like Sp factors and can either be located close to the transcription start point 
or as enhancer or silencer in great distance to it. Interaction of these factors with 
factors of the pre-initiation complex can e.g. result in conformational changes and 
initiation of transcription (Kornberg, 1996; Roeder, 1996). 
 
 
 
 2
 
 
Fig. 1.1. Transcription initiation (Lemon and Tjian, 2000). A. Chromatin remodeling to make the 
promoter accessible for the pre-initiation complex formation. B. Stepwise assembly of transcription 
factors and co-regulators at the core promoter. C. Transcription initiation complex. 
 
 
1.2 Transcription factors 
 
Transcription factors can be divided into general or basal transcription factors 
(Roeder, 1991; Goodrich and Tjian, 1994) and specific transcription factors (Lewin, 
1990; Krajewska, 1992). General or basal transcription factors are associated with 
the pre-initiation complex at the core promoter as described in 1.1. Specific 
transcription factors bind to promoter and enhancer or silencer regions, thus directly 
or indirectly regulating transcription. 
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According to their regulatory function, specific transcription factors are composed of 
several functional domains, like e.g. a DNA-binding domain, which enables the 
factors to sequence-specifically bind to regulatory elements on the DNA, as well as 
one or more transactivation domain(s), essential for transcriptional activation 
(Kadonaga, 2004; Mitchell and Tjian, 1989; Ptashne, 1988;). The sequence 
specificity of DNA-binding domains is achieved by a structural diversity of DNA 
binding motifs. Such binding motifs are e.g. leucine-zipper, helix-turn-helix, helix-
loop-helix or zinc finger motifs and enable the specific recognition of a broad variety 
of DNA sequences, like e.g. CAAT or GC boxes (Landschulz et al., 1988; Krajewska, 
1992; Kadonaga et al., 1987; Pabo and Sauer, 1992). High diversity also exists for 
transactivation domains, which can be glutamine-rich as in transcription factor Sp1 
(Courey and Tjian, 1988), proline-rich as in the factors CTF/NF1 and Jun (Mermod et 
al., 1989; Struhl, 1988) or rich in acidic amino acids as in the yeast Gal4 transcription 
factors (Ma and Ptashne, 1987). 
 
In addition, further functional domains, like inhibitory, dimerization or ligand-binding 
domains (e.g., Kadonaga, 2004) regulate transcription by influencing the 
transactivation or DNA binding capability of the transcription factor. DNA binding 
capacity e.g. can be regulated through protein-protein interactions (e.g. Vallian et al., 
1998) or posttranslational protein modifications, like phosphorylation or glycosylation 
(e.g. Rohlff et al., 1997; Armstrong et al., 1997; Han and Kudlow, 1997; Yang et al., 
2001). 
 
 
1.3 The Sp/XKLF super-family of transcription factors 
 
Many different prokaryotic and eukaryotic proteins use zinc-coordinated motifs to 
bind to DNA. One common type of these so-called zinc fingers consists of two beta 
sheets and one alpha helix that contain two cysteine and two histidine residues that 
contact a zinc atom. These C2H2 zinc fingers are often found in clusters that allow 
each of their alpha helices to tightly interact with the major groove of the double-
stranded DNA helix (Pavletich and Pabo, 1991). The amino acid composition of the 
zinc fingers determines their DNA binding specificity and by using them in different 
arrangements zinc finger proteins can recognize the specific sequences of 
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nucleotides to which they bind, thus ensuring a highly specific transcriptional 
regulation. 
 
One particular combination of three conserved C-terminal C2H2 zinc fingers forms 
the DNA binding motif of the still expanding Sp/XKLF super-family of transcription 
factors (reviewed e.g. in Bouwman and Philipsen, 2002; Suske et al., 2005; see also 
Fig. 1.3.1). Sp represents the Sp family of transcription factors, consisting to date of 
nine family members, Sp1-9, which are described in more detail in chapter 1.4. The 
Sp family is named after “specificity protein” or “sephacryl and phosphocellulose” 
columns originally used to purify family founder Sp1 (Kadonaga et al., 1987)). The 
XKLF family, on the other hand, consists of the numerous so-called Krüppel-like 
factors (reviewed in Bouwman and Philipsen, 2002; Suske et al., 2005), named after 
the Drosophila segmentation gene Krüppel displaying a similar zinc finger 
arrangement (Schuh et al., 1986). X hereby represents the main location of 
expression, like erythrocytes for EKLF (erythroid Krüppel-like factor; Miller and 
Bieker, 1993) or lung in the case of LKLF (lung Krüppel-like factor; Anderson et al., 
1995). 
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Fig. 1.3.1. Sp/XKLF super-family of transcription factors (Suske et al., 2005). Relationships 
between the Sp factors and KLFs of human, Drosophila, and C. elegans. Of each factor, the 110-aa 
domain containing the Btd/zinc finger motifs was used for the multiple alignment with ClustalW 
(http://www.ebi.ac.uk/clustalw/). This alignment was used to construct the cladogram. *The current 
sequence of C. elegans F45H11.1 contains only the Btd motif and the first finger. **One amino acid 
was removed from finger 3 of Ce-T22C8.5 (HXXXH instead of HXXXXH), because the extra amino 
acid is not handled appropriately in the multiple alignment generated with ClustalW. ***The sequence 
of D-CG3065 was deduced from the Drosophila genome sequence; the current annotation does not 
contain the complete Btd/zinc finger motif. 
 
 6
The zinc fingers of the Sp/XKLF super-family are structurally related to those of the 
transcription factor ZIF268. Therefore Sp/XKLF factors are likely to contact the DNA 
in the same fashion as has been determined for this protein. Following a so-called 
zinc finger code, each zinc finger of ZIF268 contributes with (at least) three DNA-
contacting amino acids to its DNA binding properties (Jamieson et al., 2003; Fairall et 
al., 1993; Kriwacki et al., 1992; Kuwahara et al., 1993; Narayan et al., 1997; 
Pavletich and Pabo, 1991). According to that, Sp family founder Sp1 is thought to 
contact the DNA with the amino acids KHA in the first, RER in the second and RHK 
in the third zinc finger as depicted in Fig. 1.3.2 (Dynan and Tjian, 1983; Philipsen and 
Suske, 1999). 
5’
 
Fig. 1.3.2. Scheme of the Sp1 zinc fingers interacting with a classical GC box (modified after 
Jamieson et al., 2003). The three individual fingers consist of each one alpha helix and two beta 
sheets and are connected by a zinc ion (depicted in grey). At least three amino acids in each alpha 
helix (the critical residues are depicted in black) contact each one nucleotide on the DNA (dotted 
lines), as indicated on the right. Sp1 zinc fingers (as well as the bases which they contact) are 
depicted as follows: finger 1 in red, finger 2 in yellow and finger 3 in violet. DNA is depicted in blue. 
 
As a consequence of the conserved DNA binding motif, Sp/XKLF members all 
recognize the same GC (GGGGCGGGG) and GT/CACC (GGTGTGGGG) boxes 
albeit with different affinities due to substitutions of critical amino acids in the first 
(H→L in Sp2) or in the third (L→K in e.g. BKLF, EKLF, UKLF) finger of some of the 
factors (Bouwman and Philipsen, 2002; Gidoni et al., 1985; Giglioni et al., 1989; 
3’
G
G
G
G
C 
G
G
G
G
A
3’ 
C 
C 
C 
C 
G 
C 
C 
C 
C 
T 
C
K
L
S
D
H
S
R
DNA 
R
ZF 3
L
Q
D
E
S
R
AZF 2
L
R
ZF 1 
S
H
T
K
N
5’ 
 7
Kingsley and Winoto, 1992; Letovsky and Dynan, 1989). GC (commonly referred to 
as “Sp1-binding site”) and GT boxes are frequently found in promoters and 
enhancers/ silencers of many different ubiquitous (e.g. house-keeping genes) as well 
as specifically regulated cellular and viral genes. In addition, these motifs are 
required for the maintenance of the methylation-free status of CpG islands (Brandeis 
et al., 1994; Macleod et al., 1994). 
 
A third subgroup belonging to the Sp/XKLF super-family comprises the transcription 
factors BTEB1/KLF9, BTEB4/KLF16 and BTEB5/KLF14 (basic transcription element 
binding protein 1; Imataka et al., 1992), RFLAT-1/KLF13 (RANTES factor of late 
activated T-lymphocytes 1) as well as TIEG1/KLF10 and TIEG2/KLF11 (TGFß-
inducible early gene 1 and 2; Cook et al., 1998; Subramaniam et al., 1995). Based on 
their zinc finger structure, these factors also primarily bind to the classical GC boxes 
(Bouwman and Philipsen, 2002; Philipsen and Suske, 1999; Suske et al., 2005). 
 
Whereas the DNA binding domain is highly conserved among the Sp/XKLF super-
family members, also eminent structural differences can be observed like the 
presence or absence of inhibitory domains or various transactivation domain 
structures. Together with differences in posttranslational protein modifications, 
protein-protein interactions, expression patterns, etc., this contributes to enhance 
specificity of transcriptional regulation (Bieker and Southwood, 1995; Gillemans et al., 
1998; Bouwman and Philipsen, 2002; Philipsen and Suske, 1999; Suske et al., 
2005). 
 
 
1.4 The Sp family of transcription factors: protein structure and function 
 
To date, the Sp family of transcription factors consists of nine mammalian members, 
Sp1-9 (Fig. 1.4.1; e.g. Bouwman and Philipsen, 2002; Suske et al. 2005). As 
described in 1.3, Sp transcription factors bind to GC and GT/CACC boxes found in a 
variety of promoters and enhancers/ silencers through three characteristic zinc 
fingers of the C2H2 type. The zinc fingers are located at the C terminus of the 
proteins and are formed by a stretch of 81 highly conserved amino acids (Fig. 1.4.2). 
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A B C D 
 
Fig. 1.4.1. Transcription factors Sp1-9 (modified after Bouwman and Philipsen, 2002 and Suske 
et al., 2005). Structural motifs like Sp and Btd boxes, zinc finger, glutamine-rich, serine/threonine-rich, 
proline-rich and highly charged regions, as well as transactivation (AD) and inhibitory (ID) domains are 
indicated following the colour code given above. A, B, C, and D modules of Sp1 (Courey and Tjian, 
1988) are marked with black bars. On the right: lengths in amino acids according to accession 
numbers NM_013672.1 (Sp1), NM_030220.2 (Sp2), BC079874.1 (Sp3), NM_009239.1 (Sp4), 
NM_022435.2 (Sp5), XP_064386 (Sp6/KLF14), NM_130458.1 (Sp7), NM_177082.3 (Sp8), AY591908 
(Sp9). 
 
In addition to their DNA-binding region, Sp transcription factors also share further 
structural features, like the Sp box and the Buttonhead box, of which as yet the 
function is unclear. The Sp box is located at the N terminus of the proteins (Harrison 
et al., 2000) and is characterized by the highly conserved sequence 
SPLALLAATCSR/KI (Bouwman and Philipsen, 2002). It contains a potential 
endoproteolytic cleavage site and is situated close to a region at the N terminus of 
Sp1 that targets proteasome-dependent degradation in vitro (Su et al., 1999). 
Although not required to direct cleavage, the fact that the Sp box is highly conserved 
indicates that it has a putative function in the regulation of Sp factor proteolysis. 
Another possible role for the Sp box may lie in the control of the transactivation 
capacity through interaction with a putative repressor (Murata et al., 1994). 
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The Buttonhead box (Btd) is situated at the C terminus of the proteins, directly N-
terminally to the zinc finger domain. It consists of 11 conserved amino acids and was 
originally described in the Drosophila Sp1 homologue Buttonhead (Btd; Wimmer et 
al., 1993). A deletion of the highly charged C domain (see Fig., 1.4.2) comprising the 
Btd box results in a reduced transactivation potential of Sp1 in vitro (Courey and 
Tjian, 1988). Furthermore, the Btd box appears to be involved in synergistic 
activation by Sp1 or Sp3 with sterol regulatory element-binding proteins (SREBPs; 
Athanikar et al., 1997). 
 
Although the functions of the Sp and Btd boxes are not clear at the moment, their 
absence in the XKLF family confirms the relationship between the Sp transcription 
factors. Besides these structural similarities, the close relationship between these 
factors is also demonstrated in human by their co-localization with the four homeobox 
gene clusters (HOX) on chromosome 12.q13.13 (Sp1 and 7 / HOX C), 17q21.31/32 
(Sp2 and 6 / HOX B), 2q31.1 (Sp3, 5 and 9 / HOX D), 7p21.2 (Sp4 and 8 / HOX A) 
(Bouwman and Philipsen, 2002; Kalff-Suske et al., 1995 and 1996; Matera and Ward, 
1993; Scohy et al., 1998; Suske et al. 2005). 
 
Apart from the Sp and Btd boxes, the N-terminal regions of Sp5-9 are completely 
different from those of Sp1-4 and more closely related to each other (Bouwman and 
Philipsen, 2002; Suske et al., 2005). Since this thesis is focused on transcription 
factor Sp2, the factors Sp5-9 will not be discussed in the following, especially as they 
have not been studied yet in detail. 
 
The protein structure of the transcription factors Sp1-4 is characterized by several 
domains located N-terminally to the highly conserved zinc finger region (Fig. 1.4.2; 
Bouwman and Philipsen, 2002; Philipsen and Suske, 1999). These are two 
glutamine-rich domains (A and B), two serine/threonine-rich regions and a region of 
highly charged amino acids (domain C) directly N-terminally to the zinc finger 
domain. The existence of the first transactivation domain and serine/threonine region 
in Sp2 was unclear when starting this thesis. In addition, the D domain is absent in 
Sp2. The glutamine-rich domains of Sp1, Sp3 and Sp4 harbour the transactivating 
function of these factors, the serine/threonine regions are possible targets of 
posttranslational modifications like phosphorylation. In addition to that, transcription 
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factor Sp3 is characterized by an inhibitory domain located near the C domain 
(Dennig et al., 1996). 
A A B C D 
 
Fig. 1.4.2. Structural features of Sp proteins (Suske, 1999). A. Scheme of the transcription factors 
Sp1-4. Their length in amino acids is indicated on the right. Coloured boxes indicate the zinc finger 
region (black) as well as glutamine- (red) and serine/threonine-rich (yellow) protein domains; (+/−) 
represents a region of highly charged amino acids. Lines above the draw of the Sp1 protein indicate 
the extent of four regions (A, B, C and D) which contribute to the transcriptional properties of Sp1 as 
defined by Courey and Tjian (1988). Known activation (AD) and inhibitory domains (ID) are indicated. 
B. Protein sequence alignment of the zinc finger domains. Stars below the sequence indicate 
sequence identity. Cysteine and histidine residues which coordinate zinc ions are underlayed in 
green, protein regions which contact the DNA in blue. Arrows point to the amino acids which 
determine the recognition specificity by contacting specific bases of the DNA (adapted from Fairall et 
al., 1993; Pavletich and Pabo, 1991). Black lines and the zig-zag lines indicate alpha-helical and beta 
sheet regions, respectively. 
 
Transcription factor Sp1 
As first member of the Sp family, Sp1 was isolated from HeLa cells and described as 
transcription factor binding to the GC boxes of the Simian Virus 40 (SV40) promoter, 
thus leading to transcriptional activation in vitro (Dynan and Tjian, 1983) caused by 
two glutamine-rich domains (A and B, Fig. 1.4.2) (Courey and Tjian, 1988; Gill et al., 
1994; Kadonaga et al., 1988). Human Sp1 consists of 785 amino acids with a 
calculated molecular weight of 80.6 kDa and is ubiquitously expressed. 
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It was discovered that Sp1 can directly interact with itself which has important 
implications for its transactivation capacity (Pascal and Tjian, 1991). Sp1 stimulates 
transcription from promoters as well as from enhancers (Courey et al., 1989). In vitro 
experiments suggest that this synergistic activation is mediated by Sp1 molecules 
bound to proximal and distal sites, which interact with each other thus forming 
stacked tetramers (Mastrangelo et al., 1991), thereby looping out the intervening 
DNA (Li et al., 1991; Mastrangelo et al., 1991; Su et al., 1991). For the 
multimerization, activation domain B appeared to be of critical importance (Pascal 
and Tjian, 1991). Together with domain A, domain B also mediates superactivation of 
Sp1-dependent transcription which can be achieved by non-DNA-binding mutants in 
case of multiple binding sites (Courey et al., 1989; Hagen et al., 1995). For 
synergistic activation by binding to multiple sites, domain D is required in addition to 
both transactivation domains (Pascal and Tjian, 1991). 
 
Moreover, Sp1 interacts with components of the basal transcription machinery (e.g. 
TBP (Emili et al., 1994), several TAFs (Hoey et al., 1993; Tanese et al., 1996)) as 
well as with transcription factors like E2F (Karlsreder et al., 1996) and YY1 (Lee et 
al., 1993). Sp1 is able to recruit the co-activator complex CRSP (cofactor required for 
Sp1 activation), thus stimulating transcription of the respective genes (Ryu et al., 
1999). In addition to that, Sp1 is target of posttranslational modifications like 
glycosylation (Jackson and Tjian, 1988) and phosphorylation (Jackson et al., 1990), 
both being able to influence e.g. its DNA binding or transactivation properties (e.g. 
Armstrong et al., 1997; Merchant et al., 1999; Roos et al., 1997; Yang et al., 2001). 
 
To investigate the physiological function of Sp1, knockout mice were generated 
exhibiting deletion of the exons encoding the zinc finger domain (Marin et al., 1997). 
Sp1-deficient mice display a broad spectrum of abnormalities and die early during 
embryonic development (day E10.5 at the latest). 
 
Transcription factor Sp2 
Among Sp1-4, transcription factor Sp2 is the less explored factor. Sp2 was cloned 
from a T-cell library, which has been screened with a Sp1 zinc finger probe for 
homologous DNA sequences (Kingsley and Winoto, 1992). Due to the exchange of a 
critical amino acid in the first zinc finger necessary for contacting the DNA (Fig. 1.4.2 
and Fig. 1.3.2), Kingsley and Winoto claim a higher binding affinity towards GT than 
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GC boxes. However, investigation of Sp2 binding capacity with a GT box 
oligonucleotide derived from the T-cell antigen receptor α (TCRα) only results in a 
low binding affinity (Kingsley and Winoto, 1992). In comparison to Sp1, Sp3 and Sp4, 
Sp2 exhibits the most structural differences among these factors, e.g. the existence 
of the first transactivation domain and serine/threonine region in Sp2 was unclear 
when starting the thesis. In addition, the D domain is absent. Data from the only 
report of a promoter that is affected by co-transfected N-terminally truncated Sp2 
protein suggest that this factor may function in a cell-type-dependent manner 
(Bacovic et al., 2000). Sp2 repressed Sp1- or Sp3-driven activation of a construct 
containing the murine CTP:phosphocholine-cytidylyltransferase-α promoter in 
Drosophila SL2 cells but activated the same construct in C3H10T1/2 mammalian 
cells. Apart from that, no further reports about Sp2 were available when initiating the 
thesis. 
 
Transcription factor Sp3 
Transcription factor Sp3 was parallely cloned in 1992 by Hagen et al. and Kingsley 
and Winoto. Sp3 is ubiquitously expressed and exists in four different isoforms, two 
of them with a molecular weight of ca. 97-115 kDa and two of them in a range of ca. 
58-70 kDa. Whereas the long isoforms exhibit both transactivation domains (A and B; 
see Fig. 1.4.2), the two short isoforms only contain the B domain (Kenneth et al., 
1997). Mutation analyses suggest that all four isoforms derive from alternative 
translational start sites. Moreover, an upstream open reading frame seems to 
regulate expression of the two long isoforms (Sapetschnig et al., 2004). 
 
Concerning transactivation properties in vivo, Sp3 functions as a transcriptional 
activator (Ihn and Trochanowska, 1997; Liang et al., 1996; Udvadia et al., 1995; 
Zhao et al., 1997), but also displays no or only weak activity (Dennig et al., 1995; 
Majello et al., 1994), depending on the investigated promoter. In addition, the number 
of Sp3 binding sites inside a promoter seems to influence Sp3 activation capacity 
(Dennig, 1996) as well as the respective cell type (Hansen et al., 1999; Sjottem et al., 
1996). Moreover, Sp3 binds to GC boxes with similar affinity as transcription factor 
Sp1, thus being able to repress Sp1-mediated activation by competition (Birnbaum et 
al., 1995; Hagen et al., 1994). 
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Responsible for Sp3 transcriptional inactivity is a so-called inhibitory domain (Dennig 
et al., 1996), located near the C region of the Sp3 protein (Fig. 1.4.2). The inhibitory 
domain is characterized by the amino acid motif IKEE, which can be SUMOylated 
(Sapetschnig et al., 2002). In addition to that, yeast-two-hybrid screens led to the 
identification of PIAS1 (Doll, diploma work, 1998; Liu et al., 1998), an E3 ligase, 
which is involved in the SUMOylation process of proteins and binds to the Sp3 
inhibitory domain (Sapetschnig et al., 2002). 
 
To investigate Sp3 physiological function, knockout mice were generated exhibiting a 
deletion of exon 4, which encodes the two glutamine-rich transactivation domains 
(see Fig. 1.4.2). Heterozygous Sp3 knockout mice develop and reproduce normal 
and display no obvious phenotype apart from a slight growth retardation. In contrast 
to this, homozygous Sp3 knockout mice immediately die after birth due to a lung 
failure. However, the molecular mechanisms behind this are unclear. In addition, they 
are characterized by abnormalities in tooth (lack of amelogenin and ameloblastin) 
and bone development (reduced ossification due to the lack of osteocalcin) 
(Bouwman et al., 2000; Göllner et al., 2001b). Moreover, homozygous Sp3 knockout 
mice exhibit an impaired hematopoiesis (Van Loo et al., 2003). 
 
Transcription factor Sp4 
Transcription factor Sp4 was identified and cloned along with Sp3 due to its capacity 
to bind to GT boxes (Hagen et al., 1992). In contrast to Sp1 and Sp3, Sp4 is 
predominantly expressed in brain, heart, testicles and the epithelial tissue (Hagen et 
al., 1992; Supp et al., 1996). Sp4 also exhibits two glutamine-rich transactivation 
domains but in contrast to Sp1, Sp4 is unable to generate synergistic effects on 
multiple binding sites (Hagen et al., 1995). However, Sp4 can be super-activated by 
zinc-finger-less Sp1 and repressed by Sp3 (Hagen et al., 1995). 
 
Heterozygous Sp4 knockout mice based on the deletion of exon 2 and 3 encoding 
the two transactivation domains exhibit no obvious phenotype. In contrast to this, 
Sp4-deficient mice are characterized by a general growth and weight reduction as 
well as a high post-natal mortality. Moreover, Sp4 knockout males display an 
abnormal reproduction behaviour and females a pronounced delay in sexual 
maturation (Göllner et al., 2001a). 
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1.5 Generation of transgenic mice by “gene targeting” 
 
The principle utilized to target genes of an organism and to generate knockout mice 
is the process of so-called homologous recombination (Smithies et al., 1985). 
Homologous recombination occurs in eukaryotes during meiosis to preserve genomic 
diversity and is characterized by an exchange of identical or similar (= homologous) 
DNA sequences. 
 
To generate knockout mice via “gene targeting”, totipotent embryonic stem (ES) cells 
are isolated from the inner cell mass of an agouti blastocyst (day E3.5) and 
transfected with a linearized knockout construct harbouring the desired mutation (e.g. 
point mutation, deletion, insertion) flanked by sequences that are homologous to the 
genomic region of interest (Fig. 1.5.1). Nowadays, different ES cell lines are 
available, which are mostly transfected by electroporation (e.g., Evans and Kaufman, 
1981; Martin, 1981). By homologous recombination, the genomic regions being 
homologous to the vector sequences are exchanged and the mutation integrated into 
the genome. 
 
As the homologous integration of vector sequences into the genome is a rare event, 
the targeted ES cells have to be selected. In general, this is done by two selection 
markers, a positive and a negative one (Mansour et al., 1988). Positive selection 
normally occurs by antibiotic resistance of the targeted ES cells. Commonly, a 
resistance gene for neomycin or its analogon G418 is integrated into the mouse 
genome together with the homologous genomic DNA sequences (Mansour et al., 
1988; Southern and Berg, 1982). 
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Fig. 1.5.1. Generation of transgenic mice by “gene targeting”. Embryonic stem (ES) cells derived 
from an agouti mouse are transfected with the linearized knockout construct and cultured on selection 
medium containing G418 and/or Gancyclovir. G418 and Gancyclovir enable the selection for the 
integration of the knockout construct into the ES cell genome based on homologous recombination. 
ES cells, which have been integrated the knockout construct by homologous recombination, are 
G418- and Gancyclovir-resistant (by Neo gene but not hsv-TK gene integration, the latter located 
outside the homologous region). These cells are injected into a blastocyst of an albino mouse and 
implanted into a pseudo-pregnant foster mouse, resulting in chimeric mice. Chimeric males are 
crossed with albino mice. In the case of germline transmission of the targeting mutation, mice being 
heterozygous for the entire construct in all body cells can be generated. In contrast to mice without 
germ line transmission, these mice are characterized by a brown coloured coat. If the knockout 
construct contains loxP sites, Cre-driven recombination can be performed either on the ES cell as well 
as on the mouse level enabling the generation of conditional knockout mice. 
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To test, whether the vector DNA integration is locus-dependent or spontaneous, 
which also occurs, a negative selection marker, located outside the homologous 
regions is used. Commonly, the gene coding for the herpes simplex Thymidine 
Kinase (hsv-TK) is used (Mansour et al., 1988). ES cells exhibiting Acyclovir or 
Gancyclovir sensitivity are characterized by spontaneous integration (i.e. also 
integrate the hsv-TK gene), whereas ES cells being resistant display vector DNA 
integration by homologous recombination (i.e. without the hsv-TK gene, located 
outside the homologous region). Thymidine Kinase expression in the cell results in 
phosphorylation of the selective reagent Gancyclovir. Phosphorylated Gancyclovir 
can be integrated during recombination into the DNA instead of thymidine, thus 
leading to replication incapability and cell death. 
 
ES cells selected by G418 and Gancyclovir, thus exhibiting homologous integration 
of the entire knockout construct at one allele, are injected into an albino blastocyst, 
which is then implanted into a pseudo-pregnant foster mouse. Resulting embryos are 
chimeric, i.e. consist of wildtype and targeted cells (Bradley et al., 1984). As wildtype 
cells derived from an albino and targeted cells from an agouti mouse, they can be 
distinguished by their coat colours: wildtype cells display a white, targeted cells a 
brown coloured coat. To select mice with targeted germ cells, chimeric males are 
crossed with albino females. In the case of germline transmission, brown coloured 
embryos are obtained. In these embryos, all cells are heterozygous for the targeted 
gene locus. By intercrossing heterozygous animals, homozygous knockout mice can 
be generated (Bradley et al., Doetschman et al., 1987; Robertson et al., 1986). 
 
An option in gene targeting is the generation of conditional ES cells and knockout 
mice. Conditional gene targeting is characterized by the replacement of a genomic 
sequence by the same sequence that is flanked by two so-called loxP sites. LoxP 
sites (loci of crossing over derived from the recombination machinery of the P1 
phage) consists of 34 highly conserved basepairs (Fig. 1.5.2). Eight central basepairs 
form the core sequence, which is flanked on each side by a 13 bp symmetry element 
in reverse orientation. Four monomers of the P1 phage enzyme Cre recombinase 
(causes recombination) bind to each two symmetry elements of two loxP sites 
(Hoess et al., 1982), thus forming a so-called Holliday intermediate complex (Fig. 
1.5.2). The Cre recombinase monomers cut in the middle of the core sequence and 
either delete (if both loxP sites display the same orientation) or invert (if both loxP 
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sites display an opposite orientation) the DNA sequence between the two loxP sites 
(Stark et al., 1992). 
A.   loxP sites 
5`-ATAACTTCGTATAATGTATGCTATACGAAGTTAT-3’ 
 
Fig. 1.5.2. The Cre-loxP system. A. Scheme of a loxP site. A loxP site consists of a 34 bp double 
strand. The 8 bp core sequence (green) is located in the center of the loxP site and is cut in the middle 
by the Cre recombinase. The core sequence is flanked on each side by a stretch of 13 bp, which are 
symmetrical (red arrows). B. Process of Cre-driven recombination. Four Cre recombinase monomers 
form a complex with two loxP sites by binding to their symmetry elements (red and pink arrows), thus 
resulting in a so-called Holliday intermediate. If the loxP sites display the same orientation (black 
arrows), Cre recombinase cuts in the middle (dashed) of the core sequence (green) and deletes the 
DNA sequence between the two loxP sites (black cord). C. Situation after Cre recombination. After 
sequence deletion, one loxP site remains consisting of two halves of each loxP site depicted in (B). 
 
To enable the generation of conditional knockout mice, it has to be ensured that 
exon-intron structures of the targeted locus remain like in wildtype. For this, it is often 
necessary to delete at first the positive selection cassette via the Cre-loxP system, 
which can be done on the ES cell as well as on the mouse level. Depending on the 
research interests, these mice then can be crossed with mice expressing Cre 
C.   sequence between the two loxP sites is deleted
B.   complex of four recombinase monomers and two loxP sites 
3’-TATTGAAGCATATTACATACGATATGCTTCAATA-5’ 
element of
symmetry symmetry
element of
CORE
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recombinase in a tissue-specific manner or at specific developmental time points, 
leading to a knockout of the gene. 
 
 
1.6 Thesis aims 
 
As mentioned above, no data concerning Sp2 protein expression as well as Sp2 
function in vitro and in vivo were available when starting this thesis work. Therefore, 
the aims were the following: 
 
To enable the analysis of Sp2 protein expression in various cell lines and adult 
mouse tissues as well as Sp2 subcellular localization, a first aim of this thesis was 
the generation of Sp2-specific rabbit polyclonal antibodies. 
 
To characterize Sp2 at the molecular level, Sp2 transactivation function and DNA 
binding properties were investigated. 
 
To study Sp2 function in vivo, the generation of Sp2 gene targeted mice was a 
further major aim of this thesis. 
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2. Materials and methods 
 
2.1. Materials 
 
2.1.1 Laboratory materials and devices 
 
Unless stated otherwise, all laboratory materials and devices used for this work were 
obtained from: Amersham (Freiburg), Biometra (Göttingen), Biorad (München), 
Eppendorf (Hamburg), Falcon (Hamburg), Greiner (Frickenhausen), Heidolph 
(Schwabach), Heraeus/Kendro (Hanau), NanoDrop (USA: Wilmington), Nunc 
(Denmark: Roskilde) and Kodak (Stuttgart). 
 
 
2.1.2 Chemicals 
 
All chemicals used for this work were obtained in p.A. quality from Amersham 
(Freiburg), BD Becton & Dickinson (France: Le Pont de Claix), Calbiochem (Canada: 
La Jolla), Difco (USA: Sparks), Invitrogen (Karlsruhe), Gibco (Karlsruhe), Merck 
(Darmstadt), Perbio (Bonn), Riedel-de-Haen (Seelze), Roche (Mannheim), Roth 
(Karlsruhe), Serva (Heidelberg) and Sigma (München). 
 
 
2.1.3 General solutions 
 
50x Denhardts: 1% (w/v) Ficoll; 1% (w/v) Polyvinylpyrollidon and 1% (w/v) BSA in 
H2O (bidest.). 
DEPC-H2O: 1 ml Diethylpyrocarbonat (DEPC); 9 ml 100% EtOH; 990 ml H2O 
(bidest.). Dissolving of DEPC by stirring o/n at 37°C, followed by autoclaving of the 
solution. 
6x DNA loading buffer: 0.25% Bromphenol blue; 0.25% Xylene-Cyanol FF; 30% 
Glycerol H2O (bidest.). 
Orange G: 1 g Orange G; 20 g Ficoll ad 100 ml H2O (bidest.). 
1x PBS pH 7.4: 8 g NaCl; 0.2 g KCl; 1.15 g Na2HPO4 x 7 H2O; 0.2 g KH2PO4 in 1 l 
H2O (bidest.). 
1x TBE: 89 mM Tris/HCl pH 8.0; 89 mM Boric acid; 2.5 mM EDTA in H2O (bidest.). 
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10/1 TE: 10 mM Tris/HCl pH 8.0; 1 mM EDTA pH 8.0 in H2O (bidest.). 
1x TFB pH 6.3: 10 mM K-Mes; 100 mM KCl; 45 mM MnCl2 x 4 H2O; 10 mM CaCl2 x 
2 H2O; 3 mM Hexamine cobalt chloride in H2O (bidest.). 
20x SSC pH 7.0: 3 M NaCl; 0.3 M Sodium citrate in H2O (bidest.). 
 
 
2.1.4 Culture media 
 
2.1.4.1 Media to culture bacteria 
 
Luria Bertani medium (LB): 10 g/l Select Peptone 140 (Invitrogen, Karlsruhe); 5 g/l 
Bacto™ Yeast Extract (BD, USA: Sparks); 10 g/l NaCl. 
 
LB agar plates (with antibiotics): 15 g Select Agar (Invitrogen, Karlsruhe) per 1 l 
LB-Medium (with 50 mg/l of each antibiotic). 
 
SOB medium: 20 g/l Select Peptone 140 (Invitrogen, Karlsruhe); 5 g/l Bacto™ Yeast 
Extract (BD, USA: Sparks); 0.548 g/l NaCl; 0.186 g/l KCl. 
 
SOC medium: 10 ml SOB-Medium; 100 µl 2 M Mg2+ (1 M MgCl2; 1 M MgSO4); 100 
µl Glucose. 
 
 
2.1.4.2 Media to culture eukaryotic cells 
 
Schneider medium: 500 ml Schneider's Drosophila medium (Gibco, Karlsruhe); 55 
ml FBS (Sigma, München; suitable for insect cells); 5.5 ml 100x Penicillin/ 
Streptomycin (Cambrex, Belgium: Verviers); 5.5 ml L-Glutamine (Gibco, Karlsruhe). 
Culture medium for Drosophila SL2 cells (Schneider, 1972). 
 
Fibroblast medium: 200 ml DMEM with GlutaMAX™ I (Gibco, Karlsruhe); 200 ml 
Nutrimix F10 (HAM) (Gibco, Karlsruhe); 45 ml FBS (PAA Laboratories, Austria: 
Parsching); 5 ml 100x Penicillin/ Streptomycin (Cambrex, Belgium: Verviers). Culture 
medium for mouse embryonic fibroblasts (MEFs). 
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HEK medium: 500 ml Nutrimix F10 (HAM) with GlutaMAX™ I (Gibco, Karlsruhe); 55 
ml FBS (PAA Laboratories, Austria: Parsching); 5.5 ml 100x Penicillin/ Streptomycin 
(Cambrex, Belgium: Verviers). Culture medium for human embryonic kidney 293 cells 
(HEK-293). 
 
Ishikawa medium: 500 ml 10x MEM-E (Gibco, Karlsruhe); 55 ml FBS (Gibco, 
Karlsruhe); 5.5 ml 100x Penicillin/ Streptomycin (Gibco, Karlsruhe); 5.5 ml 200 mM L-
Glutamine (Gibco, Karlsruhe); 5.5 ml non-essential amino acids; 20 ml 7.5% 
NaHCO3. Culture medium for Ishikawa cells. 
 
 
2.1.5 Restriction enzymes and DNA-modifying enzymes 
 
Restriction enzymes and DNA-modifying enzymes were obtained from Boehringer 
(Mannheim), Gibco (Karlsruhe), Invitrogen (Karlsruhe), New England Biolabs 
(Frankfurt), Promega (Mannheim) and Roche (Mannheim). 
 
 
2.1.6 Antibiotics 
 
Ampicillin 
Kanamycin 
G418 
Penicillin/ Streptomycin 
Bayer (Leverkusen) 
Boehringer (Mannheim) 
Gibco (Karlsruhe) 
Gibco (Karlsruhe) 
 
 
2.1.7. Antibodies 
 
anti-Sp1; rabbit p.cl. antibody 
anti-Sp2; rabbit p.cl. antibody 
(no. 193, “Zwick”; 10 days after 1. boost) 
anti-Sp3; rabbit p.cl. antibody; sc-644 
anti-Gal4-DBD; rabbit m.cl. antibody; sc-577 
anti-rabbit; HRP-conj.; m.cl. sec. antib.; NA934V 
anti-rabbit; FITC-conj.; m.cl. sec.; 111-095-003 
Hagen et al. 1994 (Marburg) 
generated during this thesis 
 
Santa Cruz (USA: St. Cruz) 
Santa Cruz (USA: St. Cruz) 
Amersham Biosciences (Freiburg)
Jackson IR (USA: West Grove) 
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2.1.8 Radioactive substances 
 
[α-32P] dCTP (3000 Ci/ mmol) 
[α-32P] dATP (3000 Ci/ mmol) 
Amersham Biosciences (Freiburg)
Amersham Biosciences (Freiburg)
 
 
2.1.9 Oligonucleotides 
 
Oligonucleotides were synthesized by Eurogentec Deutschland (Köln), Invitrogen 
(Karlsruhe) and MWG AG Biotch (Ebersberg). The purpose of each oligonucleotide is 
also described in the chapters 2.2.2-4. 
 
 
2.1.9.1 Oligonucleotides to generate Sp2 deletion mutants 
 
Sp2-Coli-Expr-fw 
Sp2-Coli-Expr-rev 
Del1-Sp2-fw 
Del1-1-Sp2-fw 
Del1-2-Sp2-fw 
Del1-3-Sp2-fw 
Del1-4-Sp2-fw 
Del2-Sp2-fw 
Del3-Sp2-fw 
Del4-Sp2-fw 
Del1-Sp2-rev-sh 
Sp2FL-XhoI-fw 
Del1-2-BamHI-rev 
Del2-BamHI-fw 
Del1-BglII-rev-sh 
Gal4-Sp2-pLALL-fw
Gal4-Sp2-pE-rev 
Gal4-Sp2-mE-rev 
Gal4-Sp2-mG-rev 
5'-AGA-TGA-CCA-TGG-CCG-CCA-CTG-CTG-CT-3' 
5'-GCC-TGG-ATC-CGC-ACC-TGT-CCA-TCA-TG-3' 
5'-TTG-AAA-GGA-TCC-GCT-GTT-GAA-GCT-GCA-GTG-AC-3' 
5'-TTG-AAA-GGA-TCC-CCT-ATC-AAA-CCC-GCT-CCT-CT-3' 
5'-TTG-AAA-GGA-TCC-CTG-ATC-AAC-AAA-GGG-AGC-CG-3' 
5'-TTG-AAA-GGA-TCC-ACC-CCG-TCA-ACA-TCT-GGT-CA-3' 
5'-TTG-AAA-GGA-TCC-AGT-ACG-ACT-ACC-ACC-CCT-GT-3' 
5'-TTG-AAA-GGA-TCC-CCG-CTC-AAC-AAC-CTG-GTG-AA-3' 
5'-TTG-AAA-GGA-TCC-CGT-ACA-CCT-TCT-GGT-GAG-GT-3' 
5'-TTG-AAA-GGA-TCC-GTG-CCT-GTC-ACC-ATC-ACC-AA-3' 
5'-AAC-TTT-GGA-TCC-GTC-CTG-GGT-TAG-AAC-GTC-TC-3' 
5'-TTG-AAA-CTC-GAG-GAG-CGA-TCCACA-GAT-GAG-CA-3' 
5'-AAC-TTT-GGA-TCC-GGC-TCC-CTT-TGT-TGA-TCA-GG-3' 
5'-TTG-AAA-GGA-TCC-CGC-TCA-ACA-ACC-TGG-TGA-AC-3' 
5'-AAC-TTT-AGA-TCT-GTC-CTG-GGT-TAG-AAC-GTC-TC-3' 
5'-TTG-AAA-GGA-TCC-CTG-TCA-GTC-CCA-GTG-ACT-AC-3' 
5'-TCC-TTT-CTA-GAT-CAG-CCC-ACT-GAT-AGT-CAG-G-3' 
5'-CCC-TTT-CTA-GAG-TAC-CTG-ACC-AGA-AGG-TGT-A-3' 
5'-CCC-TTT-CTA-GAT-GTT-CAC-CAG-GTT-GTT-GAG-C-3' 
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2.1.9.2 Oligonucleotides for Electrophoretic Mobility Shift Assays (EMSAs) 
 
Sp1-1-fw 
Sp1-1-rev 
Sp2-A-fw 
Sp2-A-rev 
Sp2-C-fw 
Sp2-C-rev 
Sp2-G-fw 
Sp2-G-rev 
Sp2-T-fw 
Sp2-T-rev 
GT-1-fw 
GT-1-rev 
CT-box-5 
CT-box-3 
WT-1-fw 
WT-1-rev 
Gal4-C 
Gal4-D 
5'-AGC-TCT-CCC-CGC-CCC-CCG-3' 
5'-TCG-ACG-GGG-GGC-GGG-GAG-3' 
5'-TCG-ACC-GTT-GGG-GCG-GAG-CTT-CAC-3' 
5'-TCG-AGT-GAA-GCT-CCG-CCC-CAA-CGG-3' 
5'-TCG-ACC-GTT-GGG-GCG-GCG-CTT-CAC-3' 
5'-TCG-AGT-GAA-GCG-CCG-CCC-CAA-CGG-3' 
5'-TCG-ACC-GTT-GGG-GCG-GGG-CTT-CAC-3' 
5'-TCG-AGT-GAA-GCC-CCG-CCC-CAA-CGG-3' 
5'-TCG-ACC-GTT-GGG-GCG-GTG-CTT-CAC-3' 
5'-TCG-AGT-GAA-GCA-CCG-CCC-CAA-CGG-3' 
5'-AGC-TTC-CGT-TGG-GGT-GTG-GCT-TCA-CG-3' 
5'-TCG-ACG-TGA-AGC-CAC-ACC-CCA-ACG-GA-3' 
5'-AGC-TGG-CGC-CTC-CCC-TGA-3' 
5'-TCG-ATC-AGG-GGA-GGC-GCC-3' 
5'-AGC-TTC-TCC-CTC-CCC-CTT-3' 
5'-TCG-AAA-GGG-GGA-GGG-AGA-3' 
5'-GCT-TAG-CGG-AGT-ACT-GTC-CTC-CGA-T-3' 
5'-GGG-ATC-GGA-GGA-CAG-TAC-TCC-GCT-A-3' 
 
Underlined nucleotides represent GC, GT and CT boxes as well as mutated versions 
of these boxes and the Gal4 binding site. Point mutations in the GC box sequence 
are depicted in red. 
 
 
2.1.9.3 Oligonucleotides for RT-PCR, Southern Blot probes and cosmid library 
screen (RZPD) 
 
MSp2-ES-RT-fw 
MSp2-ES-RT-rev 
Sp2-Ex5-RT-fw 
Sp2-Ex6-RT-rev 
Sp2-ES-a-SB-fw 
Sp2-ES-a-SB-rev 
5'-ATG-AGC-GAT-CCA-CAG-ATG-AGC-A-3' 
5'-ACT-TGA-CTT-CTG-GAC-AGG-AGC-T-3' 
5'-ATT-CAG-CTG-CCA-TTC-TCC-GA-3' 
5'-AGC-CCA-CTG-ATA-GTC-AGG-TT-3' 
5'-GCT-GGC-TCC-ACA-TCA-CTT-TG-3' 
5'-AGG-TGA-CGG-TTG-ATG-TGG-TT-3' 
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Sp2-Ex4-RZPD-fw 
Sp2-Ex4-RZPD-rev 
Cyclophillin-fw 
Cyclophillin-rev 
5'-CCG-TCA-ACA-TCT-GGT-CAT-AAG-C-3' 
5'-CTG-AAA-GTT-CTG-AGA-GGG-CTT-C-3' 
5'-TCA-CCA-TTT-CCG-ACT-GTG-GAC-3' 
5'-ACA-GGA-CAT-TGC-GAG-CAG-ATG-3' 
 
 
2.1.9.4 Oligonucleotides for loxP site generation and PCR amplification of Sp2 
genomic fragments 
 
Sp2-loxP1-fw 
 
Sp2-loxP1-rev 
 
Sp2-loxP2-fw 
 
Sp2-loxP2-rev 
 
Sp2-loxP3-fw 
 
Sp2-loxP3-rev 
 
MSp2-In1-fw 
MSp2-In1-rev 
 
MSp2-In2-fw 
MSp2-In2-rev 
MSp2-Ex4-fw 
 
MSp2-Ex4-rev 
5'-CTA-GAA-CTG-TGG-TCG-ACA-TAA-CTT-CGT-ATA-ATG-TAT-
GCT-ATA-CGA-AGT-TAT-GGT-AC-3' 
5'-CAT-AAC-TTC-GTA-TAG-CAT-ACA-TTA-TAC-GAA-GTT-ATG-
TCG-ACC-ACA-GTT-3' 
5'-GGC-CGC-ACT-GTG-CTC-GAG-ATA-ACT-TCG-TAT-AAT-
GTA-TGC-TAT-ACG-AAG-TTA-TGT-CGA-CAC-TGT-G-3' 
5'-TCG-ACA-CAG-TGT-CGA-CAT-AAC-TTC-GTA-TAG-CAT-ACA-
TTA-TAC-GAA-GTT-ATC-TCG-AGC-ACA-GTG-C-3' 
5'-GGC-CGC-ACT-GTG-GGA-TCC-ATA-ACT-TCG-TAT-AAT-
GTA-TGC-TAT-ACG-AAG-TTA-TC-3' 
5'-GGC-CGA-TAA-CTT-CGT-ATA-GCA-TAC-ATT-ATA-CGA-AGT-
TAT-GGA-TCC-CAC-AGT-GC-3' 
5'-ATT-ATA-GCG-GCC-GCG-TGT-CTG-TAA-TAT-C-3' 
5'-TGA-CTC-GGA-TCC-GCA-GGG-ATA-ACA-ACA-CAC-CCA-
GGT-3' 
5'-GAA-TGA-GAA-TTC-GAA-CTA-GAA-CC-3' 
5'-TGC-GAG-GAA-TTC-TTT-CTG-AAA-GA-3' 
5'-TAT-TAT-TGC-GGC-CGC-CGA-CAC-TAG-GCC-AGC-AGG-GC-
3' 
5'-CGG-CAC-TCG-AGT-CAT-TCT-TGC-TGT-TAT-ATA-TAC-TC-3' 
 
 
2.1.9.5. Oligonucleotides for mouse genotyping 
 
MSp2Ex/l3Seq3 
MSp2In2Seq4 
5'-CCC-TCT-CAG-AAC-TTT-CAG-ATC-3' 
5'-CTT-AGG-AGG-GAT-CTA-GAC-TAG-3' 
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Neo 5'-CAT-CGC-CTT-CTA-TCG-CCT-TCT-TGA-3' 
 
 
2.1.10 Plasmids 
 
2.1.10.1 Previously described plasmids 
 
pET3a-d: Plasmid for protein expression in E. coli BL21DE3 bacteria. One 
characteristic feature of the BL21DE3 strain is an IPTG-inducible T7 RNA 
polymerase; a-d represent different reading frames. For further details, see Studier et 
al. (1990). 
 
pPacHD: Drosophila expression plasmid (Bond and Davidson, 1986). 
 
pPacHD-Flag: Drosophila expression plasmid, containing a Flag/ HA epitope. 
 
pPacUbx: Drosophila expression plasmid, containing an Ubx leader sequence. 
Plasmid was obtained as a BamHI fragment of pPacSp1-DBD. 
 
pPac-Sp1: Plasmid for the expression of full-length Sp1 protein in Drosophila SL2 
cells. For detailed information, the reader is referred to Courey and Tjian (1988) and 
Pascal and Tjian (1991). 
 
pPac-Sp3FL-new: Plasmid for the expression of full-length Sp3 protein (containing 
both upstream AUGs) in Drosophila SL2 cells. 
 
pPacUbx-Sp1ZF: Plasmid for the expression of the Sp1 zinc finger region (DNA-
binding domain) in Drosophila SL2 cells. 
 
pSG424Gal4: Plasmid for the expression of the Gal4 DNA-binding domain in 
mammalian cells (HEK-293). Plasmid was obtained as a BamHI/XbaI fragment from 
pSG424Gal4-Sp1A. 
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pSG424Gal4-Sp1A: Mammalian expression plasmid encoding the approx. 186 
amino acid Sp1A fragment N-terminally fused to a Gal4 DNA binding domain 
(Southgate et al., unpublished). 
 
pCMVSport6: Mammalian expression plasmid. Also usable for in-vitro transcription/ 
translation. Invitrogen (Karlsruhe). 
 
pCMVSport6-mSp2cDNA: Plasmid for the expression of mouse full-length Sp2 
(aa1-606) in mammalian cells. The plasmid was obtained from the RZPD Deutsches 
Ressourcenzentrum für Genomforschung GmbH (Heidelberg), clone ID: 
IRAKp961P0541. Sp2 cDNA can be isolated as a SalI/NotI fragment. 
 
pN3: Mammalian expression plasmid. Plasmid was obtained as a SalI/ NotI fragment 
from pEGFP-N3. Clontech (USA: Palo Alto). 
 
pEGFP-C1: Enhanced green fluorescent protein (EGFP) expression plasmid to 
optically determine transfection efficiencies in mammalian cells. Clontech (USA: Palo 
Alto). 
 
p97b: B-galactosidase expression plasmid to normalize transfection efficiencies in 
Drosophila SL2 cells. For detailed information, the reader is referred to Di Nocera 
and Dawid (1983) as well as Hagen et al. (1994). 
 
pRSV-ß-Gal: B-galactosidase expression plasmid to normalize transfection 
efficiencies in mammalian cells. For detailed information, the reader is referred to 
Hagen et al. (1995). 
 
pGL3-Prom: Luciferase reporter plasmid to measure luciferase activity in Drosophila 
SL2 cells. The luciferase gene is driven by the Simian Virus 40 (SV40) promoter 
containing five Sp1 binding sites (GC boxes). For detailed information, the reader is 
referred to Dynan and Tjian (1983). Promega (USA: Madison). 
 
pBCAT-2: Plasmid for transfections in Drosophila SL2 cells expressing a 
chloramphenicol acetyl transferase (CAT) reporter gene driven by an artificial 
promoter containing two Sp1 binding sites of the HTLV promoter and an E1b-TATA 
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box. For detailed information, the reader is referred to Hagen et al. (1994) and Pascal 
and Tjian (1991). 
 
p(GC)2-CAT: Plasmid for transfections in Drosophila SL2 cells expressing a 
chloramphenicol acetyl transferase (CAT) reporter gene driven by an artificial 
promoter containing two GC boxes and the E1b-TATA box. 
 
pGAWG5E1b: Plasmid for transfections in mammalian cells expressing a Luciferase 
reporter gene driven by an artificial promoter containing five Gal4 binding sites and 
the E1b-TATA box. 
 
pPNT: Plasmid containing a pgk-driven neomycin resistance (Neo) and herpes 
simplex Thymidine Kinase (hsv-TK) gene (Tybulewicz et al., 1991; see also Mangold, 
diploma work, 1995). 
 
pGT1,8-IRES-ßGeo: Plasmid containing the En2-SA-IRES-LacZ-Neo-SVpA 
cassette, which can be isolated as a SalI fragment (Mountford and Skarnes, 
unpublished; see also Mangold, diploma work, 1995). Obtained from S. Philipsen 
(Rotterdam). En2: intron of the engrailed gene; SA: splice acceptor site; IRES: 
internal ribosomal entry site; LacZ: ß-galactosidase gene; Neo: neomycin resistance 
gene; SVpA: poly-adenylation signal derived from Simian Virus. 
 
 
2.1.10.2 Plasmids generated during this thesis work 
 
For those fragments, which have been amplified by PCR, the reader should also 
consult chapter 2.1.9 for the oligonucleotide sequences and chapter 2.2.2.2.3 for the 
resulting PCR fragments. 
 
 
2.1.10.2.1 Bacterial expression plasmids 
 
pET3d-mSp2: Plasmid for the expression of full-length mouse Sp2 in E. coli 
BL21DE3 bacteria. The Sp2 fragment was amplified by PCR with primer Sp2-Coli-
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Expr-fw and Sp2-Coli-Expr-rev, the first one containing a NcoI site, the second one 
containing a BamHI site. Sp2 fragment was subcloned into pET3d via NcoI/BamHI. 
 
 
2.1.10.2.2 Drosophila expression plasmids 
 
pPac-mSp2(1-606): Plasmid for the expression of mouse Sp2 (aa1-606) in 
Drosophila SL2 cells. Sp2 was subcloned into pPac as a SalI/NotI fragment with 
BamHI linkers obtained from pCMVSport6-mSp2cDNA. 
 
pPacUbx-mSp2(62-606): Plasmid for the expression of the N-terminal Sp2 deletion 
fragment Sp2 (aa62-606) in Drosophila SL2 cells. Sp2 fragment was amplified by 
PCR with primer Del1-1-Sp2-fw and Del1-Sp2-rev-sh, both containing a BamHI site, 
and subcloned into pPacUbx via BamHI. 
 
pPacUbx-mSp2(112-606): Plasmid for the expression of the N-terminal Sp2 deletion 
fragment Sp2 (aa112-606) in Drosophila SL2 cells. Sp2 fragment was amplified by 
PCR with primer Del1-2-Sp2-fw and Del1-Sp2-rev-sh, both containing a BamHI site, 
and subcloned into pPacUbx via BamHI. 
 
pPacUbx-mSp2(160-606): Plasmid for the expression of the N-terminal Sp2 deletion 
fragment Sp2 (aa160-606) in Drosophila SL2 cells. Sp2 fragment was amplified by 
PCR with primer Del1-3-Sp2-fw and Del1-Sp2-rev-sh, both containing a BamHI site, 
and subcloned into pPacUbx via BamHI. 
 
pPacUbx-mSp2(180-606): Plasmid for the expression of the N-terminal Sp2 deletion 
fragment Sp2 (aa180-606) in Drosophila SL2 cells. Sp2 fragment was amplified by 
PCR with primer Del1-4-Sp2-fw and Del1-Sp2-rev-sh, both containing a BamHI site, 
and subcloned into pPacUbx via BamHI. 
 
pPacUbx-mSp2(207-606): Plasmid for the expression of the N-terminal Sp2 deletion 
fragment Sp2 (aa207-606) in Drosophila SL2 cells. Sp2 fragment was amplified by 
PCR with primer Del2-Sp2-fw and Del1-Sp2-rev-sh, both containing a BamHI site, 
and subcloned into pPacUbx via BamHI. 
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pPacUbx-mSp2(349-606): Plasmid for the expression of the N-terminal Sp2 deletion 
fragment Sp2 (aa349-606) in Drosophila SL2 cells. Sp2 fragment was amplified by 
PCR with primer Del3-Sp2-fw and Del1-Sp2-rev-sh, both containing a BamHI site, 
and subcloned into pPacUbx via BamHI. 
 
pPacUbx-mSp2(441-606): Plasmid for the expression of the N-terminal Sp2 deletion 
fragment Sp2 (aa441-606) in Drosophila SL2 cells. Sp2 fragment was amplified by 
PCR with primer Del4-Sp2-fw and Del1-Sp2-rev-sh, both containing a BamHI site, 
and subcloned into pPacUbx via BamHI. 
 
pPacUbx-mSp2(478-606): Plasmid for the expression of the N-terminal Sp2 deletion 
fragment Sp2 (aa478-606), the DNA binding domain (Sp2 zinc finger region), in 
Drosophila SL2 cells. Sp2 fragment was subcloned as a PstI fragment of full-length 
mouse Sp2 cDNA with BamHI linker (Klenow filling) into pPacUbx via BamHI. 
 
pPacFlag/HA-mSp2(∆112-207): Drosophila expression plasmid encoding a Sp2 
deletion fragment lacking aa112-207. Both Sp2 fragments, Sp2 (aa1-111) and Sp2 
(aa208-606), were amplified by PCR. Primers for the amplification were Sp2FL-XhoI-
fw and Del1-2-BamHI-rev for Sp2 (aa1-111), Del2-BamHI-fw and Del1-BglII-rev-sh 
for Sp2 (aa208-606). Sp2 (aa1-111) was subcloned into pPacHD-Flag via 
XhoI/BamHI, Sp2 (aa208-606) via BamHI, leaving an non-functional BamHI/BglII site 
at the 3'-end of the fragment. 
 
 
2.1.10.2.3 Mammalian expression plasmids 
 
pN3-mSp2cDNA: Plasmid for the expression of mouse full-length Sp2 (aa1-606) in 
mammalian cells. Sp2 cDNA was subcloned into pN3 via SalI/NotI obtained from 
pCMVSport6-mSp2cDNA. 
 
pSG424Gal4-mSp2(6-471): Plasmid for the expression of the fused Gal4-Sp2 
deletion fragment Sp2 (aa6-471) in HEK-293 cells. Sp2 fragment was amplified by 
PCR with primer Gal4-Sp2-pLALL-fw and Gal4-Sp2-pE-rev, the first one containing a 
BamHI site, the second one a XbaI site. The Sp2 fragment was subcloned into 
pSG424Gal4 via BamHI/XbaI. 
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pSG424Gal4-mSp2(6-357): Plasmid for the expression of the fused Gal4-Sp2 
deletion fragment Sp2 (aa6-357) in HEK-293 cells. Sp2 fragment was amplified by 
PCR with primer Gal4-Sp2-pLALL-fw and Gal4-Sp2-mE-rev, the first one containing a 
BamHI site, the second one a XbaI site. The Sp2 fragment was subcloned into 
pSG424Gal4 via BamHI/XbaI. 
 
pSG424Gal4-mSp2(6-215): Plasmid for the expression of the fused Gal4-Sp2 
deletion fragment Sp2 (aa6-215) in HEK-293 cells. Sp2 fragment was amplified by 
PCR with primer Gal4-Sp2-pLALL-fw and Gal4-Sp2-mG-rev, the first one containing 
a BamHI site, the second one a XbaI site. The Sp2 fragment was subcloned into 
pSG424Gal4 via BamHI/XbaI. 
 
pSG424Gal4-mSp2(207-471): Plasmid for the expression of the fused Gal4-Sp2 
deletion fragment Sp2 (aa207-471) in HEK-293 cells. Sp2 fragment was amplified by 
PCR with primer Del2-BamHI-fw and Gal4-Sp2-pE-rev, the first one containing a 
BamHI site, the second one a XbaI site. The Sp2 fragment was subcloned into 
pSG424Gal4 via BamHI/XbaI. 
 
 
2.1.10.2.4 Knockout construct and pre-constructs 
 
pPNT-loxP1: Plasmid used to clone the conditional Sp2 knockout construct. First 
pre-construct. A XbaI-SalI-LoxP-KpnI fragment was synthesized by MWG AG 
Biotech (Ebersberg), hybridized and subcloned into the pPNT vector (see 2.1.10.1). 
 
pPNT-loxP2: Plasmid used to clone the conditional Sp2 knockout construct. Second 
pre-construct. A NotI-XhoI-LoxP-SalI-[XhoI] fragment was synthesized by MWG AG 
Biotech (Ebersberg), hybridized and subcloned into pPNT-loxP1. 
 
pPNT-Intron4: Plasmid used to clone the conditional Sp2 knockout construct. Third 
pre-construct. A ca. 1.8 kb Sp2 genomic fragment downstream of exon 4 (= intron 4; 
genomic DNA: nt32067-nt33907; see 6.2) was amplified by PCR with primer MSp2-
In2-fw and MSp2-In2-rev and subcloned into pPNT-loxP2 via EcoRI. 
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pPNT-Exon4: Plasmid used to clone the conditional Sp2 knockout construct. Fourth 
pre-construct. Sp2 exon 4 flanked by intronic regions (genomic DNA: nt30460-
nt32066; see 6.2) was amplified by PCR with primer MSp2-Ex4-fw and MSp2-Ex4-
rev, the first one containing a NotI, the second one a XhoI linker. The ca. 1.6 kb 
fragment was subcloned into pPNT-Intron5 via NotI/XhoI. 
 
pPNT-loxP3: Plasmid used to clone the conditional Sp2 knockout construct. Fifth 
pre-construct. A NotI-BamHII-LoxP-[NotI] fragment was synthesized by MWG AG 
Biotech (Ebersberg), hybridized and subcloned into pPNT-Exon4. 
 
pPNT-Intron3: Plasmid used to clone the conditional Sp2 knockout construct. Sixth 
pre-construct. A ca. 3.2 kb Sp2 genomic fragment upstream of exon 4 (= intron 3; 
genomic DNA: nt27217-nt30459; see 6.2) was amplified by PCR with primer MSp2-
In1-fw and MSp2-In1-rev, the first one containing a NotI, the second one a BamHI 
linker. The fragment was subcloned into pPNT-loxP3 via NotI/BamHI. 
 
pPNT-cSp2ko: Final construct to target the Sp2 gene in the mouse. A ca. 7.4 kb 
En2-SA-IRES-LacZ-Neo-SVpA fragment derived form pGT1,8-IRES-ßGeo was 
subcloned into pPNT-Intron4 via SalI. 
 
For further details concerning the generation of the final knockout construct and all 
pre-constructs, the reader is also referred to chapter 3.2.4. 
 
 
2.1.11 Cosmids 
 
To receive genomic fragments of murine Sp2, a 129/ola mouse cosmid library (library 
no. 121) was screened at the RZPD Deutsches Ressourcenzentrum für 
Genomforschung GmbH (Heidelberg) with a DNA probe against mouse Sp2 exon 4. 
The probe (called “Ex4-RZPD”) was amplified by PCR with primer MSp2-Ex4-RZPD-
fw and MSp2-Ex4-RZPD-rev (see 2.1.9.3). In total, 15 clones were identified and four 
of them verified by Southern Blot analysis. Clone number MPMGc121L17390Q2 was 
used to amplify the genomic fragments for the conditional knockout construct by 
PCR. Cosmids consist of a 8.7 kb Lawrist 7 vector (ampicillin resistance) usable in E. 
coli and a 38 kb genomic insert. 
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2.1.12 Bacterial strains 
 
Escherichia coli DH5α: Bacterial strain used for plasmid amplification. For detailed 
information, see Hanahan (1983). 
 
Escherichia coli BL21DE3: Bacterial strain used for protein overexpression. This 
strain constitutively expresses the Lac repressor. Moreover, expression of a T7 
polymerase gene is regulated by the IPTG-inducible Lac promoter. Consequently, 
target gene expression is regulated by an IPTG-induced T7 polymerase gene 
expression. In addition, the Lon and OmpT protease genes are absent in BL21DE3, 
thus leading to a decrease in protease activity. 
 
Escherichia coli 294-Cre: Bacterial strain expressing Cre recombinase, thus 
providing a simple assay to test for the recombination competence of constructs that 
are designed for use in Cre-mediated genomic manipulations. Cre recombinase 
expression is regulated by the λ-PR promoter and the temperature-sensitive cI857 
repressor. Recombination competence of loxP sites engineered into a plasmid can 
be tested by transformation into the 294-Cre strain and overnight growth at 37°C 
followed by restriction digestion checks of the plasmid DNA. For further details, the 
reader is referred to Buchholz et al. (1996). 
 
 
2.1.13 Cell lines 
 
Drosophila SL2 cells: Insect cells lacking Sp factors. For a detailed description, see 
Schneider (1972) and Suske (2000). 
 
Mouse embryonic fibroblasts (MEF): Wildtype cell line derived from day E13.5 
mouse embryos of Sp3 heterozygous crossings (Göllner; diploma work, 1998). 
 
Mouse embryonic stem cells (ES): Mouse embryonic stem cells used for Sp2 gene 
targeting derived from the ES cell line C88Bl/6 TdW and were cultured and handled 
by Nynke Gillemans at the Erasmus University of Rotterdam. 
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Human embryonic kidney 293 cells (HEK-293): Cell line derived from human 
embryonic kidney epithelial cells, transformed with adenovirus 5 DNA. 
 
HEK-293-pGAW5E1b cells: A HEK-293 cell line, which has been stabely transfected 
with plasmid pGAWG5E1b, thus constitutively expressing a Luciferase reporter gene 
regulated by an artificial promoter containing five Gal4 binding sites and an E1b-
TATA box. 
 
HeLa (Henrietta Lacks' cells): Cell line derived from human epithelial cells of a 
cervix adeno-carcinoma. HeLa cells are aneuploid and steroid hormone receptor 
negative. For Western Blot analyses or Electrophoretic Mobility Shift Assays 
(EMSAs), nuclear extracts of these cells were kindly provided by Alexandra 
Sapetschnig. 
 
Ishikawa cells: Cell line derived from human endometrial cells of an adeno-
carcinoma (Nishida et al., 1985). 
 
 
2.1.14 Mice 
 
The European house mouse Mus musculus, L. (Mammalia: Rodentia) was used as 
model organism for this thesis. To generate knockout mice, embryonic stem cells, 
derived from 129/ola mouse blastocysts, were transfected with the knockout 
construct, injected into blastocysts and the blastocysts implanted into pseudo-
pregnant foster mice (see also 2.2.4.5). For more detailed information, see Bishop et 
al. (1985). Additionally, all data concerning mouse strains and breeding are available 
at the mouse data bank of the Erasmus University of Rotterdam (EUR). 
 
 
2.1.15 Rabbits 
 
Two New Zealand White rabbits (rabbit no. 193 (“Zwick”) and no. 194 (“Zwack”); 
European wild rabbit Oryctolagus cuniculus, L. (Mammalia: Lagomorpha)) were used 
to generate polyclonal Sp2-specific antibodies. The detailed procedure of Sp2 
antibody generation is described in chapter 2.2.3.6. 
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2.2 Methods 
 
2.2.1 Radiation protection and biological safety 
 
Genetic engineering experiments were performed in accordance with the guidelines 
for genetic engineering (Gentechnikgesetz vom 16. Dezember 1993). Contaminated 
materials and solutions were collected separately and autoclaved. Experiments with 
radioactive substances, including waste disposal, followed the guidelines for radiation 
protection (Strahlenschutzverordnung vom 20. Juli 2001). 
 
 
2.2.2 Molecular biological methods 
 
2.2.2.1 RNA experiments 
 
To protect RNA from ribonucleases (RNases), all experiments were performed as 
sterile as possible: All solutions were freshly prepared, autoclaved and used only for 
RNA experiments. As water, fresh Braun’s aqua ad iniectabilia (Braun, Melsungen) or 
water treated with Diethylpyrocarbonat (DEPC-H2O) was used. Plastic tubes and 
pipette tips were used freshly and autoclaved; glass ware was cleaned with HCl 
(conc.), followed by 2 M NaOH and DEPC-H2O. For all experiments, vinyl gloves 
were used. Unless stated otherwise, all experiments were performed at 4°C. 
 
 
2.2.2.1.1 RNA isolation and purification 
 
To isolate RNA from mouse embryonic stem cells and embryonic or adult organs, 
two different methods were applied: 
 
RNeasy Mini Kit (Qiagen, Hilden) 
To isolate RNA from mouse embryonic stem cells, confluent cells were used. To 
isolate RNA from adult mouse organs, organs were frozen in liquid nitrogen 
immediately after mouse dissection. Organs were ground with a mortar on dry ice 
and dissolved in RNeasy Mini Kit RLT buffer (600 µl buffer per 30 mg pulverized 
organ). To remove insoluble tissue particles, the solution was shortly centrifuged and 
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the supernatant dissolved in the same volume of 70% ethanol. The further isolation 
procedure for embryonic stem cells and organs followed the RNeasy Mini Kit user 
manual (Qiagen, Hilden). For more detailed information, the reader is referred to the 
manual and/or to Göllner (PhD thesis, 2002), who performed the isolation. 
 
LiCl/ Urea protocol 
To isolate RNA from mouse embryonic organs, organs derived from day E18.5 
embryos were frozen in liquid nitrogen immediately after embryo dissection. Frozen 
organs were pulverized in 2-3 ml 3 M LiCl + 6 M urea by high pressure mortaring 
(Ultrathorax; Heidolph, Schwabach). The cell suspension was centrifuged at 4°C for 
25 min and the resulting pellet dissolved in 500 µl RB buffer + 500 µl phenol/ 
chloroform after washing with 3 M LiCl + 6 M urea for a second time. To facilitate 
dissolving, the solution was shaken at room temperature for 45 min. After 5 min of 
centrifugation, the water phase, containing the RNA, was dissolved in DEPC-H2O or 
precipitated in 3 volumes of ethanol + 1/10 volumes of 2 M sodium acetate pH 5.6 to 
store (in solution) at -20°C. 
 
RB buffer: 10 mM Tris pH 7.5; 1mM EDTA; 0.5 % SDS. 
 
 
2.2.2.1.2 RNA quantification 
 
RNA was quantified by UV photometry (Amersham Biosciences, Freiburg; or 
NanoDrop Technologies, USA: Wilmington). The UV absorption by nuclear acids 
were measured at a wavelength of λ = 260 nm. At this wavelength the side chains of 
the aromatic amino acids display maximal absorption. The absorption value allows to 
calculate RNA concentration of a solution (1 OD260 = 40 µg/ml). In addition, RNA was 
also quantified by agarose gel electrophoresis. 
 
 
2.2.2.1.3 Reverse transcriptase polymerase chain reaction (RT-PCR) 
 
Two different methods were applied to perform reverse transcriptase polymerase 
chain reactions (RT-PCR): 
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RT-PCR (standard protocol) 
To investigate Sp2 mRNA expression in mouse embryos, RNA from day E18.5 
mouse embryos were prepared (LiCl/ urea method). A SuperScriptII reverse 
transcriptase and a temperature stable DNA polymerase from Thermus aquaticus 
(Taq) (Invitrogen, Karlsruhe) were utilized for cDNA synthesis (RT) and amplification 
(PCR), respectively. The single reaction steps were as follows: 
 
DNase treatment: 
 
 
DEPC-H2O 
RNA (E18.5 embryos) 
10x DNase reaction buffer 
DNase (1 U/µl) (Promega, Mannheim) 
10 µl reaction 
ad 10 µl 
2 µg 
1 µl 
1 µl 
 
Reaction was performed at 37°C for 30 min. To stop the reaction, 1 µl of 25 mM 
EDTA was added to the reaction mix followed by 10 min incubation at 65°C and 
cooling down on ice. 
 
Reverse transcriptase: 
 
To denature RNA secondary structures, RNA mix (after DNase treatment) was 
incubated at 90°C for 5 min before preparing the reverse transcription reaction. 
Components of the reaction mix were obtained from Invitrogen (Karlsruhe). 
 
 
DEPC-H2O 
RNA mix (after DNase treatment) 
5x RT reaction buffer 
10 mM dNTP mix 
100 mM DTT 
Oligo dT (0.5 µg/µl) 
RNase inhibitor (5 U/µl) 
SuperScriptII RT (1 U/µl) 
20 µl reaction 
ad 20 µl 
8 µl 
4 µl 
1 µl 
2 µl 
1 µl 
1 µl 
1 µl 
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Reaction was performed at 42°C for 1 hour. After a 15 min incubation at 70°C and 
cooling-down at 4°C, 0.5 µl of RNase H (1 U/µl) were added to the reaction mix and 
incubated at 37°C for 30 min to remove RNA. Thus, the synthesized cDNA could be 
used for PCR amplification (reaction components: Invitrogen, Karlsruhe). 
 
Polymerase chain reaction (PCR): 
 
 
H2O (Braun, Melsungen) 
cDNA mix (after RT reaction) 
5'-Primer (see below) 
3'-Primer (see below) 
10x PCR reaction buffer 
10 mM dNTP mix 
50 mM MgCl2
DMSO (5%) 
Taq polymerase (1 U/µl) 
25 µl reaction 
ad 25 µl 
1 µl 
50 ng 
50 ng 
2.5 µl 
0.5 µl 
0.75 µl 
1.25 µl 
1 µl 
 
To detect Sp2 mRNA expression in day E18.5 mouse embryos, primers against exon 
5 and 6 (Sp2-Ex5-RT-fw; Sp2-Ex6-RT-rev) were used. As internal control for equal 
RNA amounts, primers against the cyclophillin gene (Cyclophillin-fw; Cyclophillin-rev) 
were utilized. Expected fragment lengths are: 228 bp for Sp2 and 130 bp for the 
cyclophilin gene. 
 
Reaction temperatures and times: 
 
1. primary denaturing 
2. denaturing 
3. primer annealing 
4. cDNA amplification 
5. 35 cycles (step 2-4) 
6. final extension 
7. cooling 
94°C 
94°C 
60°C 
72°C 
 
72°C 
4°C 
4 min 
30 sec 
30 sec 
30 sec 
 
7 min 
for ever 
 
To analyze the result, 10 µl of each reaction was loaded on an agarose gel. 
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Access RT-PCR System Kit (Promega, USA: Madison) 
To investigate Sp2 mRNA expression in mouse embryonic stem cells, 1 µg of RNA 
derived from Sp3 +/- ES cells were used for RT-PCR (RNA preparation followed the 
RNeasy Mini Kit (Qiagen, Hilden)). These cells represent Sp2 wildtype situation, and 
total RNA from these cells was kindly provided by Heike Göllner. RT-PCR was 
performed following the Access RT-PCR System Kit user manual (Promega, USA: 
Madison). A reverse transcriptase from Avian Myeloblastose Virus (AMV) and a 
temperature stable DNA polymerase from Thermus flavus (Tfl) were utilized. 
 
Reaction mix: 
 
H2O (Braun, Melsungen) 
5x Reaction buffer 
5'-Primer (MSp2-ES-RT-fw) 
3'-Primer (MSp2-ES-RT-rev) 
10 mM dNTP mix 
RNA (ES cells) 
50 µl reaction 
ad 50 µl 
10 µl 
50 pmol 
50 pmol 
1 µl 
1 µg 
 
To eliminate RNA secondary structures, the reaction mix was denatured at 95°C for 5 
min. After cooling down on ice, the reaction mix was completed by adding the 
following components: 
 
 
25 mM MgSO4
AMV Reverse transcriptase (5 U/µl) 
Tfl DNA polymerase (5 U/µl) 
50 µl reaction 
2 µl 
1 µl 
1 µl 
 
Reaction temperatures and times: 
 
Reverse transcription 
1. cDNA synthesis 
2. transcriptase inactivation 
Polymerase chain reaction (PCR) 
1. denaturing 
2. primer annealing 
 
48°C 
94°C 
 
94°C 
57°C 
 
45 min 
2 min 
 
30 sec 
30 sec 
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3. cDNA amplification 
4. 30 cycles (step 1-3) 
5. final extension 
6. cooling 
72°C 
 
68°C 
4°C 
30 sec 
 
7 min 
for ever 
 
To detect the expected Sp2 mRNA fragment (fragment length: 560 bp), 5 µl of each 
reaction were loaded on an agarose gel. 
 
 
2.2.2.1.4 Northern Blot analyses 
 
To detect Sp2 mRNA expression in mouse embryos, RNA from day E18.5 mouse 
embryos were prepared (LiCl/ urea method). 20 µg RNA were dissolved in 5 µl 
DEPC-H2O, added to 20 µl loading buffer, incubated at 65°C for 15 min and loaded 
with 5 µl Orange G (see 2.1.3) on a 1% denaturing formaldehyde agarose gel. To 
receive adequate separation of RNA, the gel was run in 1x MOPS at 20-30 V over 
night. After gel electrophoresis, the gel was stained with ethidiumbromide (1 µl 
ethidiumbromide (25 mg/ml) in 100 ml 1x MOPS) for 30 min, photographed under UV 
light and washed twice with 10x SSC for each 30 min. RNA was blotted in 10x SSC 
at 4°C over night to a Hyobond-N+ nylon membrane (Amersham Biosciences, 
Freiburg). For details the reader is referred to Braun (PhD thesis, 2001), e.g. After 
blotting, RNA was UV-crosslinked to the membrane (0.3 J/cm2) and the membrane 
washed with 3x SSC. The washed membrane was prehybridized at 42°C for 2 hours, 
followed by hybridization in a 6 ml hybridization mix at 42°C over night together with 
the radioactive labeled DNA probe (probe: Ex 3-6 NB; end concentration: 1-2 x 106 
cpm/ml, see also 2.2.2.2.5). The labeled probe was directed against exon 3-6 (cDNA: 
nt 71-1500; see 6.2) of murine Sp2 and obtained by BamHI/BglI digestion of pPac-
mSp2(1-606). Before autoradiography, membrane was washed twice with 2x SSC + 
0.1% SDS at room temperature for each 5 min, once at 50°C for 30 min and finally in 
0.1x SSC + 0.1% SDS at 60-65°C for 1-2 hours to reduce background radiation. 
Autoradiography was performed for 24 hours. 
 
Buffers and solutions: 
• Loading buffer: 375 µl deionized formamide; 75 µl 10x MOPS; 120 µl 37% 
formaldehyde in 50 µl DEPC-H2O. 
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• 10x MOPS pH 7.0: 0.4 M 3-N-Morpholinopropansulfonic acid (MOPS); 0.1 M 
sodium acetate; 0.01 M EDTA in DEPC-H2O. 
• Denaturing formaldehyde agarose gel (1%): 1.5 g agarose; 15 ml 10x MOPS; 
7.5 ml 37% formaldehyde in 127.5 ml DEPC-H2O. Agarose and water were 
autoclaved before adding MOPS and formaldehyde. 
• (Pre-) Hybridization mix: 500 ml formamide; 100 ml 100x Denhardts; 50 ml 1 M 
Tris pH 7.5; 10 ml 10 mg/ml denatured salmon sperm DNA; 90 g dextran sulfate 
(in 250 ml H2O (bidest.)); 58 g NaCl; 5 ml 20% SDS (filtered sterile); ad 1 l H2O 
(bidest.). In contrast to the prehybridization mix, the hybridization mix additionally 
contains the labeled DNA probe. 
 
 
2.2.2.2 DNA experiments 
 
All experimental steps were performed at 4°C, unless stated otherwise. Buffers, 
solutions and media were prepared with bidestilled water and autoclaved or filtered 
sterile before use. The following standard methods were performed as described by 
Ausubel et al. (1987) or Sambrook et al. (1989): 
 
• DNA digestion by restriction endonucleases, 
• DNA treatment with alkaline phosphatase, 
• Klenow filling of sticky DNA ends, 
• agarose gel electrophoresis, 
• DNA preparation from agarose gels, 
• ligation of DNA fragments, 
• ethanol or isopropanol precipitation, 
• phenol/ chloroform extraction, 
• DNA purification by cesium chloride ultra centrifugation. 
 
Purification of DNA from agarose gels or PCR fragments followed the QIAquick user 
manual (Qiagen, Hilden). 
 
Transformation of bacteria was carried out following two different protocols, either the 
heatshock protocol of Hanahan (1983) for standard transfections of E. coli DH5α 
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bacteria with plasmid DNA, or the CaCl2 method for mouse Sp2 protein expression in 
E. coli BL21DE3. For detailed information, see Stielow (diploma work, 2003). 
 
To test recombinase capacity of loxP sites in the conditional Sp2 knockout construct, 
E. coli 294-Cre bacteria were transformed with either the final knockout construct 
pPNT-cSp2ko (containing three loxP sites) or the precursor plasmid pPNT-loxP2 
(containing two loxP sites). Transformations were performed following Hanahan 
(1983). After incubation of transformed bacteria at 37°C over night, plasmid DNA was 
isolated, linearized by NotI or HindIII restriction digestion and analyzed by agarose 
gel electrophoresis. For further details, the reader is referred to 2.1.12 or Buchholz et 
al. (1996). 
 
 
2.2.2.2.1 DNA isolation and purification 
 
Isolation and purification of recombinant DNA from bacteria 
Analytical (small scale) and preparative (large scale) isolation of recombinant DNA 
from bacteria (E. coli) followed the NucleoBond® AX plasmid purification manual 
(Macherey and Nagel, Düren). The protocol for analytical DNA preparation was 
modified as described by Krüger (diploma work, 2002). 
 
Isolation and purification of mouse genomic DNA 
Yolk sac or mouse tail tip DNA was used for PCR genotyping of mouse embryos or 
new born mice, respectively. To isolate DNA, yolk sacs or tail tips were taken up in 
500 µl mouse mix buffer (MMB) with 10 µl proteinase K (10 mg/ml) and incubated for 
1-2 h or over night on a 55°C shaker. After 20 min of centrifugation, the pellet was 
removed and 300 µl isopropanol were added to the supernatant, followed by 30 min 
centrifugation to spin down the precipitated DNA. The DNA pellet was washed twice 
with 75% ethanol and finally dissolved in 100 µl 10/1 TE. For PCR genotyping, 1 µl of 
DNA was used per reaction. 
 
Mouse mix buffer (MMB): 50 ml 1 M Tris/HCl pH 7.5; 5 ml 0.5 M EDTA; 20 ml 5 M 
NaCl; 5 ml 2% (w/v) SDS ad 500 ml H2O (bidest.). 
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2.2.2.2.2 DNA quantification 
 
DNA was quantified by UV photometry (Amersham Pharmacia, Freiburg; or 
NanoDrop Technologies, USA: Wilmington). UV absorption by nuclear acids were 
measured at a wavelength of λ = 260 nm. At this wavelength the side chains of the 
aromatic amino acids display maximal absorption. The absorption value allows to 
calculate DNA concentration of a solution (double strand DNA: 1 OD260 = 50 µg/ml). 
In addition, DNA was also quantified by agarose gel electrophoresis. 
 
 
2.2.2.2.3 Polymerase chain reaction (PCR) 
 
Polymerase chain reaction (PCR) was used for: 
• amplification of Sp2 genomic fragments to generate a conditional knockout 
construct for the Sp2 gene in the mouse; 
• genotyping of mouse embryos; 
• generation of Sp2 DNA fragments for bacterial expression (E. coli BL21DE3); 
• generation of Sp2 deletion fragments; 
• generation of DNA probes to screen a cosmid library at the RZPD for Sp2 
genomic fragments (see also 2.1.11); 
• generation of DNA probes for Southern Blot analyses. 
 
Polymerase chain reaction (PCR) followed three different protocols: 
 
puRe Taq Ready To Go™ Kit (Amersham Biosciences, Freiburg) 
The Ready To Go™ system was used for the amplification of Sp2 genomic 
fragments, Sp2 DNA fragments for bacterial expression, DNA probes for cosmid 
screening as well as Southern Blot analyses. Per reaction, 50 pg of DNA, 15 pmol of 
each primer and H2O (Braun, Melsungen) ad 25 µl were added to the beads. For 
more detailed information, the reader is referred to the Ready To Go™ user manual. 
 
 
 
 
 
 45
Reaction temperatures and times: 
 
1. primary denaturing 
2. denaturing 
3. primer annealing 
4. DNA amplification 
5. 30 cycles (step 2-4) 
6. final extension 
7. cooling 
94°C 
94°C 
55-60°C* 
72°C 
 
72°C 
4°C 
4 min 
30 sec 
30 sec 
30 sec 
 
7 min 
for ever 
 
* Annealing temperatures vary from 55-60°C depending on primer length and the 
relation of G/C to A/T contents in the primers. The annealing temperature was 
determined by the following equation: Tm = 4 x (G+C) + 2 x (A+T). 
 
primer 
Sp2 genomic fragments: 
MSp2-In1-fw and -rev 
MSp2-In2-fw and -rev 
MSp2-Ex4-fw and -rev 
 
Sp2 DNA fragments:
Sp2-Coli-Expr-fw and -rev 
 
Sp2 DNA probes:
Sp2-ES-a-SB-fw and -rev 
Sp2-Ex4-RZPD-fw and -rev 
fragment 
 
genomic fragment 
genomic fragment 
genomic fragment 
 
 
bacterial expression 
 
 
ES Southern Blotting 
RZPD screening 
Tm
 
60°C 
60°C 
60°C 
 
 
60°C 
 
 
57°C 
57°C 
PCR fragment length
 
3.2 kb 
1.8 kb 
1.6 kb 
 
 
1.9 kb 
 
 
387 bp 
525 bp 
 
RZPD cosmid clone no. MPMGc121L17390Q2 (genomic fragments; ES cell 
Southern Blotting) or pCMVSport6-mSp2cDNA (bacterial expression; RZPD 
screening) was taken as DNA template. 
 
To analyze the result, 5-10 µl of each reaction were loaded on an agarose gel. 
Genomic fragments were completely sequenced to check exact amplification. 
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Invitrogen PCR Kit (Invitrogen, Karlsruhe) 
To genotype targeted Sp2 mouse embryos, PCR analyses were performed. All 
reaction components were used from Invitrogen (Karlsruhe). 
 
 
H2O (bidest.) 
DNA (isolated from yolk sacs or tail tips) 
5'-Primer (see below) 
3'-Primer (see below) 
10x PCR reaction buffer 
10 mM dNTP mix 
50 mM MgCl2
DMSO (5%) 
Taq polymerase (1 U/µl) 
25 µl reaction 
ad 25 µl 
1 µl 
50 ng 
50 ng 
2.5 µl 
0.5 µl 
0.75 µl 
1.25 µl 
1 µl 
 
Reaction temperatures and times were as indicated above. Primers annealed at 
55°C. The primers MSp2Ex/L3Seq3 and MSp2In2Seq4 allowed to detect Sp2 
wildtype allele (wt) by a 0.76 kb fragment. Primers Neo and MSp2In2Seq4 led to a 
0.9-1 kb fragment representing the targeted Sp2 locus (lzn). DNA templates derived 
from mouse embryonic yolk sacs or tail tips (see 2.2.2.2.1). To analyze the result, 5-
10 µl of each reaction were loaded on an agarose gel. 
 
 
Phusion™ Kit (Finnzymes Oy, Finland: Espoo) 
To generate Sp2 deletion mutants, the DNA fragments were amplified by PCR 
following the Phusion™ Kit user manual. The kit is based on a proof-reading DNA 
polymerase with an error rate of 4.4 x 10-7 (according to the manufacturer). For 
detailed information including the composition of the reaction mix, reaction times and 
temperatures, the reader is referred to the manual. Annealing temperatures of the 
primers were 58°C. Plasmid pPac-mSp2 served as DNA template (50 pg per 
reaction). 
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primer
Del1-1-Sp2-fw and Del1-Sp2-rev-sh 
Del1-2-Sp2-fw and Del1-Sp2-rev-sh 
Del1-3-Sp2-fw and Del1-Sp2-rev-sh 
Del1-4-Sp2-fw and Del1-Sp2-rev-sh 
Del2-Sp2-fw and Del1-Sp2-rev-sh 
Del3-Sp2-fw and Del1-Sp2-rev-sh 
Del4-Sp2-fw and Del1-Sp2-rev-sh 
 
Sp2FL-XhoI-fw and Del1-2-BamHI-rev 
Del2-BamHI-fw and Del1-BglII-rev-sh 
 
Gal4-Sp2-pLALL-fw and Gal4-Sp2-pE-rev 
Gal4-Sp2-pLALL-fw and Gal4-Sp2-mE-rev 
Gal4-Sp2-pLALL-fw and Gal4-Sp2-mG-rev 
Del2-BamHI-fw and Gal4-Sp2-pE-rev 
PCR fragment length 
1.89 kb 
1.74 kb 
1.60 kb 
1.54 kb 
1.48 kb 
1.05 kb 
0.78 kb 
 
0.37 kb 
1.45 kb 
 
1.39 kb 
1.06 kb 
0.63 kb 
0.79 kb 
 
To analyze the result, 5-10 µl of each reaction were loaded on an agarose gel. Sp2 
deletion fragments were completely sequenced to check exact amplification. 
 
 
2.2.2.2.4 Hybridization and purification of single-stranded oligonucleotides 
 
Hybridization of loxP site oligonucleotides 
To generate loxP sites, single-stranded loxP site oligonucleotides (see 2.1.9.4) were 
hybridized in equimolar amounts at 75°C for 20 min followed by cooling-down slowly 
to room temperature. 
 
Hybridization of oligonucleotides for Electrophoretic Mobility Shift Assays 
Equimolar amounts of single-stranded oligonucleotides (5-10 µg) were hybridized in 
10/1 TE ad 30 µl at 75°C for 20 min and slowly cooled down to room temperature 
over night. Hybridized oligonucleotides were separated from unhybridized ones by 
polyacrylamide-TBE gel electrophoresis on a 12% gel. After gel separation, the gel 
was transferred to a silica plate (Kieselgel 60 F254, Merck, Darmstadt) and the 
silhouette of the hybridized oligonucleotides was detected under UV light (λ = 254 
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nm). Oligonucleotides were cut out and eluted from the gel slices by grinding and 
incubation of the slices in each 500 µl 10/1 TE at 37°C and 250 rpm over night. 
Eluted DNA was separated from polyacrylamide by centrifugation over glass wool 
and purified by NAP-10 columns (Amersham Biosciences, Freiburg), followed by 
ethanol precipitation. Finally, the quantified DNA was radioactively labeled as 
described in 2.2.2.2.5 and used for Electrophoretic Mobility Shift Assays (EMSAs). 
 
Polyacrylamide-TBE gel (12%): 120 ml 5x TBE; 40 ml 30% acrylamide/ bisacrylamide 
(37.5 / 1); 40 ml H2O (bidest.); 1 ml 10% APS; 120 µl TEMED. Running buffer: 1x 
TBE. Electrophoresis: 80 V for 30 min; 130 V for 5-6 hours. 
 
 
2.2.2.2.5 Radioactive labeling of DNA 
 
Radioactive labeling of double-stranded oligonucleotides for EMSA 
To radioactively label double-stranded oligonucleotides for Electrophoretic Mobility 
Shift Assays (EMSAs), 5' sticky ends were filled by the Klenow fragment of the DNA 
polymerase I using the Megaprime DNA Labelling System (Amersham Biosciences, 
Freiburg). 
 
Reaction mix: 
 
oligonucleotides 
10x restriction enzyme buffer B (Roche, Mannheim) 
dATP (Megaprime Kit; Amersham Biosciences) 
dGTP (Megaprime Kit; Amersham Biosciences) 
dTTP (Megaprime Kit; Amersham Biosciences) 
[α-32P] dCTP (3000 Ci/ mmol) 
Klenow enzyme (1 U/µl) 
H2O (Braun, Melsungen) 
20 µl reaction 
20 ng 
2 µl 
1 µl 
1 µl 
1 µl 
2µl 
1 µl 
ad 20 µl 
 
The reaction was incubated at room temperature for 20 min, followed by phenol/ 
chloroform extraction. The extracted oligonucleotides were purified by ProbeQuant™ 
G-50 Micro Columns (Amersham Biosciences, Freiburg) and diluted to a 
concentration of 18000 cpm/µl (Scintillator; Beckman Coulter, Krefeld). 
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Oligonucleotides used for radioactive labeling and Electrophoretic Mobility Shift 
Assays are listed in 2.1.9.2. 
 
 
Radioactive labeling of single-stranded DNA 
The single-stranded DNA probe for Northern Blot analyses was labeled by the Nick 
Translation Kit of Amersham Biosciences (Freiburg): 100 ng DNA together with 4 µl 
dNTP mix (dCTP, dGTP and dTTP), 2 µl of fresh [α-32P] dATP (3000 Ci/mmol), 2 µl 
enzyme mix (1 U/µl) and H2O (bidest.) ad 20 µl were incubated at 37°C for 30 min. In 
contrast to that, single-stranded DNA probes for Southern Blot analyses were labeled 
following the Megaprime Kit of Amersham Biosciences (Freiburg). Here, 20 ng DNA 
together with 2.5 µl primer mix and 10/1 TE ad 14 µl were denatured at 100°C for 5 
min, followed by immediately cooling-down to 4°C. 4 µl of fresh [α-32P] dCTP (3000 
Ci/mmol), 5 µl of 5x buffer containing the other nucleotides and 2 µl Klenow enzyme 
(1 U/µl) were added to the reaction mix and incubated first at 37°C for 15 min, then at 
room temperature for at least 45 min. To remove free nucleotides, the reaction mixes 
were purified by ProbeQuant™ G-50 Micro Columns (Amersham Biosciences, 
Freiburg). 
 
Probes used for Northern (NB) and Southern Blot (SB) analyses were as follows: 
 
probe 
Ex 3-6 NB 
Ex4-RZPD 
ES-a-SB 
function 
NB probe against Sp2 exon 3-6 
SB probe against exon 4 to verify RZPD cosmids 
SB probe to detect targeted Sp2 allele in ES cells 
hybridization (see 6.2)
cDNA: nt 71-1500 
cDNA: nt 533-1057 
DNA: nt 34808-35195 
 
Oligonucleotides to amplify the probes are listed in 2.1.9.3. The Northern Blot probe 
against exon 3-6 (Ex 3-6 NB) was obtained by BamHI/BglI digestion of pPac-
mSp2(1-606). 
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2.2.2.2.6 Southern Blot analyses 
 
Southern Blot analyses (Southern, 1975) were performed to verify results obtained 
from screening a cosmid library at the RZPD Deutsches Ressourcenzentrum für 
Genomforschung GmbH (Heidelberg) for the Sp2 gene as well as to genotype 
targeted Sp2 embryonic stem cells and mouse embryos. For cosmid check, 1 µg of 
each cosmid DNA was digested with BglII, HhaI or EcoRI in a total volume of 20 µl. 
For mouse ES cell and embryo genotyping, 0.5 µg DNA were digested with SacI in a 
total volume of 50 µl. 10 µl (cosmid DNA) or 50 µl (ES cells, embryos) of each 
reaction mix were separated by agarose gel electrophoresis for 4-5 hours. After 
staining the gel for 30 min with ethidiumbromide (1 µl ethidiumbromide (10 mg/ml) in 
100 ml H2O), it was destained with H2O for 15 min and photographed under UV light. 
The gel was incubated in a denaturing solution for 30 min, neutralized for 30 min and 
blotted in 20x SSC over night to a Hyobond-N+ nylon membrane (Amersham 
Biosciences, Freiburg). For methodological details, the reader is referred to Krüger 
(diploma work, 2002), e.g. After blotting, DNA was UV-crosslinked to the membrane 
(0.3 J/cm2; Biometra Crosslinker) and the membrane incubated at 80°C for 1.5 hours. 
The membrane was shortly washed in 5x SSC and prehybridized at 42°C for 2 hours, 
followed by hybridization at 42°C for 4-5 hours (for cosmid clones) or over night (for 
mouse ES cell and embryo DNA) together with the denatured, radioactive labeled 
DNA probe (end concentration: 1-2 x 106 cpm/ml, see also 2.1.9.3 and 2.2.2.2.5). 
The labeled probes used for Southern Blot analyses are listed below. Previous to 
autoradiography, the membrane was washed twice with 2x SSC + 0.1% SDS at room 
temperature for each 1 min, once at 50°C for 30 min and finally in 0.1x SSC + 0.1% 
SDS at 60°C for 45 min to reduce background radiation. Autoradiography was 
performed by film exposure (Kodak, Stuttgart) to the membrane at -80°C over night. 
 
probe 
Ex4-RZPD 
ES-a-SB 
function 
SB probe against exon 4 to verify RZPD cosmids 
SB probe to detect targeted Sp2 allele in ES cells 
and mouse embryos 
hybridization (see 6.2) 
cDNA: nt 533-1057 
DNA: nt 34808-35195 
 
Resulting fragments after restriction endonuclease digestions are as follows: 
• Southern Blot analysis of RZPD cosmids: BglII: 5.8 kb; HhaI: 2.8 kb; EcoRI: 1.6 
kb; 
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• Southern Blot analysis of targeted Sp2 embryonic stem cells and mouse 
embryos: Sac I: 6.9 kb representing wildtype allele, 3.2 kb representing targeted 
allele. 
 
Solutions: 
• Denaturing solution: 0.5 M NaOH; 1.5 M NaCl in H2O (bidest.). 
• Neutralization solution pH 7.4: 1 M Tris; 1.5 M NaCl in H2O (bidest.). 
• Prehybridization solution: 5 ml formamide; 2.5 ml 20x SSC; 1 ml 50x 
Denhardts; 250 µl of 10 mg/ml denatured herring sperm DNA; 500 µl 1M sodium 
phosphate pH 6.4; 100 µl 10% SDS (filtered sterile); H2O (bidest.) ad 10 ml. 
• Hybridization solution: 5 ml formamide; 2 ml 20x SSC; 0.5 ml 50x Denhardts; 
100 µl of 10 mg/ml denatured herring sperm DNA; 200 µl 1 mM sodium 
phosphate pH 6.4; 100 µl 10% SDS (filtered sterile); 2 ml dextran sulfate; H2O 
(bidest.) ad 10 ml. 
 
 
2.2.3 Biochemical methods 
 
Unless stated otherwise, all experimental steps were performed at 4°C to prevent 
proteins from degradation. 
 
 
2.2.3.1 Recombinant Sp2 protein expression and purification from bacterial 
inclusion bodies 
 
Large-scale overexpressed proteins in bacteria accumulate in so-called insoluble 
inclusion bodies. To generate Sp2-specific polyclonal antibodies in rabbits, mouse 
Sp2 protein was expressed in four 1 l cultures of E. coli BL21DE3 bacteria and 
purified from bacterial inclusion bodies following a modified protocol from Nagai et al. 
(1985). Bacterial transformation by CaCl2 and IPTG-induced protein expression 
followed the protocols described in Stielow (diploma work, 2003). In the following 
description of inclusion body isolation and Sp2 protein purification from bacterial 
inclusion bodies, all amounts and volumes are referred to a 1 l culture. 
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Two hours after IPTG induction (0.5 mM IPTG), 1 l of cultured bacteria (E. coli 
BL21DE3) was harvested and spun down at 4000 rpm for 10 min. Bacterial pellets 
were resuspended in 40 ml resuspension buffer and incubated at 4°C for 30 min after 
adding 2.5 mg/ml lysozyme. To digest DNA, 10 µg/ml DNase I together with 1 mM 
MnCl2 and 10 mM MgCl2 were added and the suspension was incubated at room 
temperature on a head-over-tail rotator for 1 hour. After adding 100 ml washing buffer 
1, the suspension was centrifuged at 13000 rpm and 4°C for 12 min to pellet all 
insoluble components, like the inclusion bodies. The inclusion body pellet was 
dissolved in 20 ml washing buffer 1, centrifuged at 4000 rpm and 4°C for 12 min and 
resuspended in 20 ml washing buffer 2. The pellet was centrifuged again, washed up 
to 12 times in washing buffer 2 until the pellet did not decrease in size any more and 
dissolved in 2 ml 2x Laemmli protein loading buffer (see 2.1.2). To purify Sp2 protein 
from inclusion bodies, the suspension was incubated at 100°C for 10 min and 
separated by a discontinual, preparative SDS Polyacrylamide Gel Electrophoresis 
(10% SDS-PAGE; see also 2.2.3.4, 20x volume) at 80 V over night. To detect Sp2 
protein, the gel was stained with 300 mM CuCl2 up to 10 min and repeatedly washed 
in H2O. The Sp2 protein band was cut out from gel, washed three times in washing 
buffer 3 for each 10 min to remove copper ions, and incubated three times in elution 
buffer for each 10 min. Sp2 protein was eluted by electro-elution at 100 V for 6 hours 
in a gel chamber (dialysis tubes: Serva, Heidelberg) by changing the running buffer 
each 45 min. The protein solution was dialyzed against 0.5x PBS at room 
temperature for 5 hours changing buffer four times. To enrich proteins, the solution 
was lyophilized over night and the lyophilisate resuspended in 5-10 ml H2O (Braun, 
Melsungen). After determination of protein concentration by comparing increasing 
Sp2 volumes with a BSA standard of known concentration on a 10% SDS 
polyacrylamide gel, the purified Sp2 protein was used for rabbit immunization (see 
2.2.3.6). 
 
Buffers: 
• Resuspension buffer: 50 mM Tris/HCl pH 8.0; 25% (w/v) succrose; 1 mM 
EDTA. 
• Washing buffer 1: 1% (w/v) deoxycholate; 20 mM Tris/HCl pH 7.5; 2 mM EDTA; 
1.6% (v/v) NP-40; 200 mM NaCl. The components should be added in this order. 
• Washing buffer 2: 50 mM Tris/HCl pH 7.5; 150 mM NaCl; 0.5% (v/v) EDTA. 
• Washing buffer 3: 250 mM Tris/HCl pH 8.8; 250 mM EDTA. 
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• Elution buffer: 250 mM Tris/acetate pH 7.4; 1% (w/v) SDS; 100 mM DTT. 
• Running buffer: 50 mM Tris/acetate pH 7.4; 0.1% (w/v) SDS. 
 
 
2.2.3.2 Protein extraction from cells (nuclear extract preparation) 
 
Nuclear proteins derived from cultured cells were prepared for Western Blot analyses 
or Electrophoretic Mobility Shift Assays (EMSAs). 
 
To isolate nuclear proteins from cultured cells (6 cm culture plates), cells were 
washed twice in 1x PBS, harvested with a rubber spatula in 1.4 ml 1x PBS and spun 
down at 13000 rpm for 10 sec. Cell pellets were dissolved in 400 µl of hypotonic NE 
buffer B. After 10 min of incubation at 4°C, cells were spun down for 10 sec and the 
pellets containing the nuclei dissolved in 50 µl hypertonic NE buffer C. Nuclei were 
incubated in NE buffer C at 4°C for 20 min, spun down for 2 min, and the supernatant 
containing the nuclear proteins was split into aliquots. Protein concentration of the 
solutions was determined by Bradford assay (see below) and the aliquots were 
stored at -80°C until use. 
 
Buffers: 
• NE buffer B: 10 mM HEPES/KOH pH 7.9; 1.5 mM MgCl2; 10 mM KCl; 0.5 mM 
DTT; 0.2 mM PMSF; 1x PIC. 
• NE buffer C: 20 mM HEPES/KOH pH 7.9; 1.5 mM MgCl2; 420 mM NaCl; 0.2 mM 
EDTA; 25% Glycerol; 0.5 mM DTT; 0.2 mM PMSF; 1x PIC. 
 
 
2.2.3.3 Determination of protein concentrations 
 
Quantification after Bradford 
Photometric determination of protein concentrations after Bradford (1976) is based 
on a shift of the absorption maximum from λ = 465 nm to λ = 595 nm of Coomassie 
brilliant blue when binding to proteins. This shift can be detected photometrically at a 
wavelength of λ = 595 nm: the increase in extinction is proportional to the protein 
concentration of the measured solution. 5 µl of bovine serum albumin (BSA) in a 
concentration of 0.1 to 1.0 mg/ml were used to generate a standard curve. To 
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measure protein concentrations in a linear range, the measured sample volumes (1-5 
µl) where chosen in that way, that their extinction values did not exceeded OD = 1.0. 
Preparation of the staining solution and measuring procedure followed the 
instructions of the Biorad Protein Assay Kit (Biorad, München). 
 
Quantification after Lowry 
Protein concentrations of solutions containing SDS or other detergences could not be 
determined by Bradford quantification. In that case, a modified method of Lowry 
(1951), basis of the Biorad Detergent Compatible DC Kit (Biorad, München), was 
applied following the kit instructions. 20 µl of the BSA standards and extinction-
dependent sample volumes were used for photometric measurements at a 
wavelength of λ = 750 nm. 
 
 
2.2.3.4 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
Based on their molecular weights, proteins were separated by discontinual, 
denaturing SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) (Laemmli, 1970). 
Samples were denatured in 1 volume of 2x Laemmli protein loading buffer (see 2.1.2) 
at 100°C for 5 min before loading on a gel (Mini gel chambers; Biorad, München). 
Gel consists of two parts, one focussing the proteins (pH 6.8), the other one 
separating the proteins (pH 8.8). Percentage of the separating gel section ranged 
from 6-12% depending on the molecular weight of the proteins of interest. Proteins 
were focussed at 80 V until they reached the separating section, and separated at 
120V. After electrophoresis, proteins were stained (Coomassie Brilliant Blue; CuCl2) 
or analyzed in Western Blot. For deeper detailed information, the reader is referred to 
Stielow (diploma work, 2003). Protein staining by CuCl2 is described in 2.2.3.1. For 
Coomassie staining, the reader is referred to the Roti-Blue® user manual (Roth, 
Karlsruhe). 
 
Focussing gel (5%) 
 
H2O (Braun, Melsungen) 
30% acrylamide / bisacrylamide (37.5 / 1) 
focussing buffer (0.5 M Tris/HCl pH 6.8) 
 
end volume: 3 ml 
ad 3 ml 
500 µl 
760 µl 
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10 % sodium dodecyl sulfate (SDS) 
10% ammonium peroxo disulfate (APS) 
N'-tetramethylethylene diamine (TEMED) 
30 µl 
30 µl 
3 µl 
 
 
Separating gel (6-12%) 
 
H2O (Braun, Melsungen) 
30% acrylamide / bisacrylamide (37.5 / 1) 
separating buffer (1.5 M Tris/HCl pH 8.8) 
10 % sodium dodecyl sulfate (SDS) 
10% ammonium peroxodisulfate (APS) 
N'-tetramethylethylene diamine (TEMED) 
 
 
 
end volume: 7.5 ml 
ad 7.5 ml 
1.5 to 3.0 ml 
1.86 ml 
75 µl 
75 µl 
10 µl 
 
Solutions: 
• Running buffer: 25 mM Tris/HCl pH 8.3; 250 mM Glycine; 0.1% (w/v) SDS. 
• Molecular weight standards: Rainbow® marker (Amersham Biosciences, 
Freiburg); Prestained protein ladder (MPI Fermentas, St. Leon-Rot); Protein 
ladder (Biorad, München). 
 
 
2.2.3.5 Western Blot analyses 
 
To selectively detect proteins in protein solutions, Western Blot analyses were 
performed. For this, SDS-PAGE-separated proteins (2.2.3.4) were blotted to a 
polyvinylidene difluoride membrane (PVDF; Immobilon-P transfer membrane; 
Millipore, Eschborn) at 2.5 mA/cm2 for 75 min using a Biometra semi-dry blotting 
system (Biometra, Göttingen). For details, the reader is referred to Göllner (PhD 
thesis, 2002), e.g. The immobilized proteins were blocked in a blocking solution at 
4°C over night. Immune detection was performed with first and secondary antibodies 
listed below at room temperature for each one hour. Detection of the antibody-bound 
proteins was effected by the conjugation of the secondary antibody with horse 
reddish peroxidase (HRP) and the Enhanced Chemiluminescence Plus (ECL-Plus) 
system (Amersham Biosciences, Freiburg). To remove unspecifically bound 
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antibodies, thus reducing background signals, membrane was stringently washed 
after first and secondary antibody incubation for each 30 min in TBST. 
 
Antibody 
anti-Sp1; rabbit p.cl. antibody 
anti-Sp2; rabbit p.cl. antibody 
(no. 193, “Zwick”; 10 days after 1. boost) 
anti-Sp3; rabbit p.cl. antibody; sc-644 
anti-Gal4; rabbit p.cl. antibody; sc-577 
anti-rabbit; HRP-conj.; m.cl. sec. antib.; NA934V
dilutions for Western Blot analyses* 
1/3000 
unless stated otherwise 1/5000 
 
1/1000 
1/1000 
1/10000 
 
* = Antibodies were diluted in a 1% blocking solution. Membrane was incubated in 10 
ml antibody solution. 
 
Solutions:
• 1x TBS: 20 mM Tris/HCl pH 7.6; 137 mM NaCl in H2O (bidest.). 
• 1x TBST: 1x TBS; 0.1% (v/v) Tween 20. 
• 5% blocking solution: 20 mM Tris/HCl pH 7.6; 137 mM NaCl; 0.1% (v/v) Tween 
20; 5% (w/v) Difco™ Skim milk powder (BD, USA: Sparks). 
• Anode buffer 1: 0.3 M Tris/HCl pH 10.4; 10% (v/v) methanol. 
• Anode buffer 2: 25 mM Tris/HCl pH 10.4; 10% (v/v) methanol. 
• Cathode buffer: 25 mM Tris/HCl pH 9.4; 40 mM Glycine 10% (v/v) methanol. 
 
 
2.2.3.6 Rabbit immunization and generation of antiserum 
 
To generate polyclonal Sp2 antisera, two New Zealand White rabbits (no. 193, 
“Zwick” and no. 194, “Zwack”) were immunized with purified mouse Sp2 protein 
expressed in E. coli BL21DE3 bacteria (2.2.3.1). Per each immunization reaction, 1ml 
of protein solution (= 75 µg Sp2) together with 1 ml Freund's Adjuvant were 
subcutaneously injected into 3-4 different areas at the flank. In the first three 
immunization reactions the protein solution was mixed with complete Freund's 
Adjuvant (CFA; Sigma, München), all further immunizations were performed with 
incomplete Freund's Adjuvant (IFA; Sigma, München). In contrast to incomplete 
Freund's Adjuvant, complete adjuvant contains heat-inactivated, dried 
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Mycobacterium tuberculosis bacteria, which unspecifically stimulate the rabbit 
immune system. 
 
Immunization reactions were as follows: Day 1, 3 and 6 with each 75 µg Sp2 in CFA; 
day 36 (1. boost) and 70 (2. boost) with each 75 µg Sp2 in IFA. Before starting the 
first immunization reaction, 5 ml blood were taken from both rabbits for pre-immune 
serum extraction. As well, each 10 days after boost immunizations, 5 ml blood were 
taken to extract the Sp2 antiserum. Rabbit immunization was kindly performed by 
Bastian Stielow. 
 
To extract pre-immune or Sp2 antisera, blood coagulated at room temperature for 30 
min followed by 10 min centrifugation at 4000 rpm. The separated sera were 
transferred to fresh reaction tubes, mixed for conservation with 0.05% sodium azide 
and stored as aliquots at -20°C. Fresh aliquots were used for Western Blot analyses 
as well as immunostaining and Electrophoretic Mobility Shift Assays (EMSAs). 
 
 
2.2.3.7 Electrophoretic Mobility Shift Assay (EMSA) 
 
To investigate protein-DNA interactions, Electrophoretic Mobility Shift Assays (Fried 
and Crothers, 1981; Garner and Revzin, 1986) were performed. For this, nuclear 
extracts containing the protein of interest (either endogenous or overexpressed) were 
incubated with a radioactively labeled double-stranded oligonucleotide containing a 
specific sequence of a protein binding site. The oligonucleotides used to investigate 
Sp2-DNA interactions are listed in 2.1.9.2; the labeling protocol is described in 
2.2.2.2.5. Protein-bound oligonucleotides migrate slower in gel (shift) than unbound 
oligonucleotides. Additional incubation with an antibody directed against the protein 
of interest increases the slower migration of the protein-DNA complex (supershift). 
 
A reaction mix consisting of 0.2-10 µg nuclear extract, 1x BSB, 0.5 mg/ml BSA, 37.5 
ng/µl poly (dIdC), 4 mM DTT and 145 mM KCl in a total volume of 20 µl was 
incubated at 4°C for 10 min. After incubation, the labeled oligonucleotide (18000 
cpm) was added to the reaction mix and incubated at 4°C for 20 min. In case of 
supershift experiments, this incubation was reduced to 15 min followed by incubation 
with 1 µl antibody against the protein of interest (alternatively: pre-immune serum) at 
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4°C for 15 min. Protein-bound oligonucleotide was separated from unbound 
oligonucleotide by a 4% non-denaturing polyacrylamide gel (100 V for 30 min, 140 V 
for ca. 2.5 h). After electrophoresis, gel was transferred to a Whatman filter paper (3 
mm) and vacuum-dried at 80°C for 2 hours (Gel dryer; Biorad, München) followed by 
autoradiography at -80°C over night. 
 
Materials: 
• 5x Bandshift buffer BSB (GH): 62.5 mM HEPES pH 7.5; 31.25 mM MgCl2; 45% 
Glycerol; 25 µM ZnSO4; 0.25% NP-40. 
• 4% Polyacrylamide gel (PAA): 10 ml 40% acrylamide/bisacrylamide (40:1); 10 
ml 5x TBE; 80 ml H2O (Braun, Melsungen); 700 µl 10% APS; 70 µl TEMED. 
Running buffer: 0.5x TBE. 
 
 
2.2.4 Cellbiological methods and animal works 
 
2.2.4.1 Cell handling 
 
Cells were handled sterile. Frozen cells (liquid nitrogen) were transferred to 10 ml of 
the required culture medium, centrifuged at 1000 rpm for 5 min to remove DMSO, 
transferred again to 12 ml of fresh medium and plated for culturing (cell culture 
flasks; Greiner, Frickenhausen). Drosophila SL2 cells were cultured at 27°C, 
mammalian cells at 37°C in a 5% CO2-containing atmosphere. When reaching 80-
100% confluency, cells were split and used either for further culturing or were frozen 
for storage in 1.5 ml medium containing 10% DMSO, first at -80°C for two days, then 
in liquid nitrogen (Cryo Tube™ Vials; Nunc, Denmark: Roskilde). Splitting of 
Drosophila SL2 cells occurred after detaching cells from the culture plate by intensive 
slapping against the plate. Mammalian cells (MEF, HEK-293, Ishikawa) were 
detached from culture plate by 3 min trypsination (1 ml Trypsin/EDTA; Gibco, 
Karlsruhe) after washing with 1x PBS and removing the medium. Split cells were 
dissolved in 12 ml medium and plated again for culturing. Cells having been split for 
more than two times were frozen in liquid nitrogen for at least some weeks to 
recover. For mouse embryonic stem (ES) cell handling, see 2.2.4.5. 
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2.2.4.2 Cell immunostaining 
 
To investigate Sp2 subcellular localization, human embryonic kidney 293 cells (HEK-
293) were grown in a 24 well culture plate (Greiner, Frickenhausen) on 13 mm cover 
slips until 80-90% confluency, washed twice in 1x PBS and fixed at room temperature 
in a 4% paraformaldehyde (PFA) solution. After fixation cells were washed twice with 
PBS and permeabilized with 0.2% Triton X-100 (Serva, Heidelberg) in PBS for 25 
min. Permeabilized cells were washed again three times in 1x PBS, blocked in a 3% 
BSA blocking solution for 1 hour followed by first antibody and secondary antibody 
incubation each for one hour (150 µl per cover slip). To additionally reduce unspecific 
binding of the antibodies, cells were washed after each antibody incubation three 
times in 1x PBS each for 10 min. Mounting of cells to glass slides occurred with one 
drop of Vecta-shield mounting medium containing DAPI-4,6-diamino-2-phenylindole 
(Vector Laboratories, USA: Burlingame). Pictures were taken by a camera mounted 
on a Leica DMLB microscope (Leica, Bensheim) using filters for green (ex.: λ = 480 
nm; em.: λ = 520 nm) and red fluorescence (ex.: λ = 550 nm; em.: λ = 600 nm). 
 
antibody 
anti-Sp1; rabbit p.cl. antibody 
anti-Sp2; rabbit p.cl. antibody 
(no. 193, “Zwick”; 10 days after 1. boost) 
anti-Sp3; rabbit p.cl. antibody; sc-644 
anti-rabbit; FITC-conj.; m.cl. sec.; 111-095-003 
dilutions for immunostaining* 
1/1000 
1/1000 
 
1/1000 
1/300 
 
* = Antibodies were diluted in a 3% BSA blocking solution. Cells were incubated in 
400 µl antibody solution. 
 
3% BSA blocking solution: 3% BSA; 1x PBS; 0.05% (v/v) Tween; filter sterilized. 
 
 
2.2.4.3 Cell transfections 
 
To overexpress proteins in insect (Drosophila SL2) or mammalian cells (HEK-293), 
cells were transiently transfected with the respective expression plasmids listed in 
2.1.10 following three different protocols: 
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Transfection by FuGENE 6 (Roche, Mannheim) 
Standard transfections were performed by FuGENE 6 (Roche, Mannheim). 
Drosophila SL2 or HEK-293 cells (4 x 106 cells per 6 cm culture plate) were 
transfected with 1 µg of cesium-chloride-purified DNA in 5 µl FuGENE 6 reagent or 
with 1 µg of cesium-chloride-purified DNA in 3 µl FuGENE 6 reagent, respectively. 
For further details concerning the protocol, the reader is referred to the user manual. 
To analyze overexpressed proteins in Western Blot or Electrophoretic Mobility Shift 
Assays (EMSAs), cells were harvested for protein extraction 36 hours after 
transfection. 
 
Transfection by jetPEI™ (Biomol, Hamburg) 
To overexpress Gal4 fusion proteins in HEK-293 cells for transactivation assays 
measuring luciferase activity (Luc; see 2.2.4.4), cells were transiently transfected 
following the jetPEI™ transfection protocol (Biomol, Hamburg). Cesium-chloride-
purified DNA was used to enhance the transfection efficiency. Transfection mixes for 
4 x 106 cells per 6 cm culture plate were as follows: 
 
• HEK-293 cells: 1 µg Gal4 fusion plasmid, 3 µg luciferase reporter plasmid 
pGAWG5E1b and 0.5 µg control plasmid for transfection efficiency comparisons 
pRSV-ß-Gal in 9 µl jetPEI™. 
• HEK-293-pGAWG5E1b-(stable) cells: 1 µg Gal4 fusion plasmid and 0.5 µg control 
plasmid for transfection efficiency comparisons pRSV-ß-Gal in 3 µl jetPEI™. 
 
Cells were harvested for transactivation assays 48 hours after transfection. 
 
Transfection by Calcium-Phosphate 
To overexpress proteins in Drosophila SL2 cells for transactivation assays (Luc, CAT; 
see 2.2.4.4), cells were transiently transfected by the Calcium-phosphate method. 
Cesium-chloride-purified DNA was used to enhance the transfection efficiency. For 
both transactivation assays (Luc, CAT), the transfection procedure for 4 x 106 cells 
per 6 cm culture plate was as follows: 0.02-0.5 µg Sp expression plasmid, 4 µg 
luciferase (pGL3-Prom) or chloramphenicol acetyl transferase (pBCAT-2) reporter 
plasmid together with 2 µg p97b control plasmid for transfection efficiency 
comparisons were mixed with 250 µl sterile CaCl2 solution. The solution was added 
drop-wise within 30 sec to 250 µl 2x HeBS while continuously vortexing the HeBS 
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solution. Vortexing, i.e. supplying oxygen to the transfection mix, enables formation of 
calcium-DNA precipitates. After incubation at room temperature for 30 min, mix was 
distributed drop-wise and equally to the cells. Harvesting of cells for transactivation 
assays occurred 48 hours after transfection. 
 
Solutions: 
• CaCl2 solution: 250 mM CaCl2 in 1 mM HEPES pH 7.1; filter sterilized. 
• 250 ml 2x HeBS: 4 g NaCl; 0.175 g KCl; 0.125 g Na2HPO4; 0.5 g Dextrose; 2.5 g 
HEPES pH 7.1; filter sterilized. 
 
 
2.2.4.4 Transactivation assays 
 
Sp2 transactivation properties were investigated by measuring either Sp2-mediated 
luciferase (Luc) activity or chloramphenicol acetyl transferase (CAT) activity. To 
consider variations in transfection efficiency and to calculate relative Luc and CAT 
activity values, ß-galactosidase activity was determined supplementary. 
 
Chloramphenicol acetyl transferase activity assay (CAT assay) 
Investigation of Sp2 transactivation properties by measuring CAT activity was 
performed following the CAT ELISA instruction manual (Roche, Mannheim). 
Transfection procedure and amounts of transfected DNA are indicated in 2.2.4.3. 
 
Luciferase activity assay (Luc assay) 
To determine luciferase activity of transient transfected cells (6 cm culture plates), 
cells were washed twice in 1x PBS, harvested with a rubber spatula in 1.3 ml 1x PBS 
and spun down at 13000 rpm for 10 sec. Cell pellets were dissolved in 100 µl Luc 
resuspension buffer and frozen in liquid nitrogen followed by immediately re-thawing 
at 37°C. Freezing and re-thawing was repeated three times to lyze cells. After 
lyzation, cells were centrifuged at 4°C for 10 min and 50 µl of the supernatant were 
added to 360 µl luciferase buffer. Luciferase activity of the cell suspension was 
measured by light emission (10 sec measuring) by injecting 100 µl D-luciferin solution 
to each sample (AutoLumat LB953; Berthold Technologies, Bad Wildbad). 
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Solutions: 
• Luc resuspension buffer: 120 µl 100 mM Potassium phosphate; 1.2 µl 1 M DTT; 
1.08 ml H2O (Braun, Melsungen). 
• Luciferase buffer (per reaction): 180 µl 50 mM Glycylglycine pH 7.8; 5.4 µl 1 M 
Potassium phosphate pH 7.8; 5.4 µl 1 M MgSO4; 28.8 µl 50 mM EGTA; 7.2 µl 0.1 
M ATP; 3.6 µl 0.1 M DTT; 133.2 µl H2O (Braun, Melsungen). 
• Luciferin solution: 900 µl 1 mM D-Luciferin (Sigma, München); 2.25 ml 50 mM 
Glycylglycine; 9 µl 1 M DTT; 1.35 ml H2O (Braun, Melsungen). 
 
ß-Galactosidase activity assay (ß-Gal assay) 
To consider variations in transfection efficiency and to calculate relative Luc and CAT 
activity values, ß-galactosidase activity was determined (Hall et al., 1983). Cells 
treated as described for Luc and CAT assays were mixed with 250 µl buffer Z and 60 
µl O-Nitrophenyl-ß-D-galactopyranoside (ONPG) and incubated at 30°C until the 
solution became yellow. Depending on assay and cell line, volumes of added cells 
were as follows: 80 µl of cells derived from CAT assay preparation, 60 µl of cells 
derived from Luc assay preparation, whereas in both cases only 5 µl of HEK-293-
pGAWG5E1b-(stable) cells were used. Yellow staining of the solution is based on the 
enzymatic cleavage of ONPG to O-Nitrophenol by ß-galactosidase. To stop the 
enzymatic reaction, 100 µl 1 M Na2CO3 was added and the suspension was 
photometrically measured at λ = 420 nm (Emax Precision Microplate Reader; 
Molecular Devices, München). 
 
Solutions: 
• Buffer Z pH 7.0: 60 mM NaHPO4; 40 mM NaH2PO4; 10 mM KCl; 1 mM MgSO4; 
50 mM ß-Mercaptoethanol. 
• O-Nitrophenyl-ß-D-galactopyranoside (ONPG) pH 7.0: 4 mg/ml ONPG (Sigma, 
München) in 100 mM sodium phosphate buffer. 
 
 
2.2.4.5 Generation of Sp2-targeted mice and mouse handling 
 
Embryonic stem cell works 
To target the Sp2 gene, mouse embryonic stem cells (C88Bl/6 TdW; EUR 
Rotterdam) were grown in BRL-conditioned medium + 103 U/ml Leukaemia inhibitory 
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factor (LIF) on gelatinized (0.1% gelatin) culture plates (Greiner, Frickenhausen). To 
target embryonic stem (ES) cells with the conditional Sp2 knockout construct, cells 
(1x107 per 10 cm2 culture plate) were transfected with 15 µg 2x cesium-chloride-
purified and NotI-linearized DNA by electroporation (BioRad Gene Pulser; Biorad, 
München). After transfection, cells were cultured for ca. 10 days in a selection 
medium containing 200 µg/ml G418 (Gibco, Karlsruhe). Single clones were picked 
and cultured in selection medium until 60-70% confluency on 24-well plates (Greiner, 
Frickenhausen). Then, cells were split, grown again to 60-70% confluency and either 
stored until further use in ES cell medium + 10% DMSO at -70°C or used for DNA-
isolation. To isolate DNA, cells were lyzed in MMB buffer and proteinase K (10 
mg/ml) at 55°C over night, followed by phenol/ chloroform extraction and isopropanol 
(0.6 volumes) precipitation. DNA pellet was washed with 70% ethanol and dissolved 
in 50-75 µl 10/1 TE. For genotyping, 0.5 µg were digested by SacI in a total volume 
of 50 µl and analyzed by Southern Blotting and PCR (see 2.2.2.2.6 and 2.2.2.2.3, 
respectively). All ES cell works were kindly performed by Nynke Gillemans, Southern 
Blot analyses by Imme Krüger at the Erasmus University of Rotterdam. 
 
Media and buffers: 
• ES cell culture medium: 500 ml DMEM (high Gucose + Glutamine) (Gibco, 
Karlsruhe); 200 ml BRL conditioned medium; 50 ml FBS (suitable for embryonic 
stem cells); 5 ml non-essential amino acids; 5 ml 100x Penicillin/ Streptomycin 
(Cambrex, Belgium: Verviers); 0.9 ml ß-Mercaptoethanol (0.1 ml in 14 ml 
medium); 0.9 ml Leukaemia inhibitory factor (LIF of ESGRO) 106 U/ml (Gibco, 
Karlsruhe). 
• Mouse mix buffer (MMB): 50 ml 1 M Tris/HCl pH 7.5; 5 ml 0.5 M EDTA; 20 ml 5 
M NaCl; 5 ml 2% (w/v) SDS ad 500 ml H2O (bidest.). 
 
 
Blastocyst injection and implantation into foster mice 
Injection of targeted embryonic stem cells into blastocysts as well as blastocyst 
implantation into pseudo-pregnant mice was kindly performed by John Kong a Sang 
at the Erasmus University of Rotterdam. Mouse embryos were genotyped either by 
Southern Blot analysis with probe ES-a-SB (2.2.2.2.6 and 2.1.9.3) or by PCR with 
primers MSp2Ex/L3Seq3, MSp2In2Seq4 and Neo as described (2.2.2.2.3). 
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General mouse handling 
To avoid infections, mice were kept and handled as sterile as possible. Only up to 3 
mice were kept in a 22 x 16 cm cage. Mice were used for breeding when being 8-10 
weeks old. To guarantee sterility as well as the accordance with the legal 
requirements of animal protection (Tierschutzgesetz vom 25.05.1998) and gene 
technology (Gentechnikgesetz vom 16. Dezember 1993), mice were handled only by 
the personal of the mouse facilities. All data concerning mouse strains and breeding 
are available at the mouse data bank of the Erasmus University of Rotterdam (EUR). 
 
 
2.2.4.6 Body size and weight measurements and fixation of mouse embryos 
 
Body size and weight of mouse embryos (day E9.5, E12.5 and E18.5) were 
measured immediately after dissection. To determine the body size, the distance 
between top of the skull and tip base was measured. After measuring, embryos were 
fixed in 4% paraformaldehyde in PBS for 2 hours until over night under gentle stirring, 
washed twice in PBS for each 30-60 min and stored in 70% ethanol at 4°C until 
further procedure. Yolk sacs or tail tips were used for PCR genotyping (see 
2.2.2.2.3). To statistically evaluate measurement results, t-tests were performed. 
 
 
2.2.4.7 X-Gal and BluoGal staining of mouse embryos 
 
X-Gal and BluoGal staining of mouse embryos was performed by Dr. Sjaak Philipsen 
(Erasmus University of Rotterdam). 
 
X-Gal staining 
To investigate Sp2 expression in mouse embryos and to prove functional integration 
of the knockout construct into the mouse genome, X-Gal and BluoGal stainings 
based on LacZ expression in Sp2-targeted mice were performed with day E12.5 
embryos. Embryos were prepared and genotyped as described above followed by 30 
min fixation in 4% paraformaldehyde at 4°C while stirring gently. After fixation, 
embryos were washed three times in LacZ washing buffer for each 30 min, first at 
4°C then at room temperature, and stained in LacZ staining solution at 37°C over 
night in the dark while stirring gently. In case of precipitate formation, embryos were 
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shortly washed in DMSO after staining. Pictures were taken by a camera (JVC video 
camera KY-F55BE) mounted on a stereo microscope (Leica Wild M10). Embryos 
were stored until further use in 70% ethanol at 4°C. 
 
Solutions: 
• LacZ washing buffer: 0.2 M Sodium phosphate buffer pH 7.0; 2 mM MgCl2; 
0.02% NP-40; 0.01% Sodium desoxycholate (10% stem solution). 
• LacZ staining solution pH 7.3: 82.5 mg K3Fe(CN)6; 105 mg K4Fe(CN)6; 100 µl 
0.5 M EGTA in 50 ml LacZ washing buffer; 1 mg/ml 5-Bromo-4-chloro-3-indolyl-ß-
D-galactopyranoside (X-Gal solution in DMSO). 
 
BluoGal staining 
BluoGal staining of mouse embryos was performed in the same way as described for 
X-Gal staining. Instead of X-Gal, BluoGal was used at the same concentration. 
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3. Results 
 
3.1 Molecular characterization of the transcription factor Sp2 
 
3.1.1 Generation of rabbit polyclonal Sp2-specific antibodies 
 
When initiating this thesis work, no Sp2-specific antibodies were available. For this, 
Sp2-specific polyclonal antibodies were generated by expressing Sp2 protein in E. 
coli BL21DE3, followed by immunizing two New Zealand White rabbits (no. 193, 
“Zwick” and no. 194, “Zwack”) with SDS-PAGE-purified Sp2 protein (see 2.2.3.1 and 
2.2.3.6). The specificity of the obtained antiserum was tested by Western Blot 
analysis (2.2.3.5). 
 
 
3.1.1.1 Expression of Sp2 protein in E. coli BL21DE3 bacteria 
 
Mouse Sp2 protein was expressed by pET3d-mSp2 in two 1 l cultures of E. coli 
BL21DE3 bacteria. In both cultures IPTG-induced Sp2 expression was detectable 
after 2 hours of induction. 
 
Fig. 3.1.1.1. Expression of mouse Sp2 protein in two 1 l cultures of E. coli BL21DE3. 1 ml of 
each culture (culture 1 and 2) before (-) and after (+) IPTG induction was analyzed for Sp2 
expression. Bacterial pellets were resuspended in 2x Laemmli protein loading buffer and 10 µl of each 
protein solution separated by 10% SDS-PAGE. M, Rainbow® marker. Coomassie staining. 
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3.1.1.2 Isolation of inclusion bodies containing recombinant Sp2 protein 
 
Mouse Sp2 protein expressed in E. coli BL21DE3 accumulates in inclusion bodies. 
Inclusion bodies of two IPTG-induced 1 l cultures were isolated according to Nagai et 
al. (1985; see also 2.2.3.1) and an aliquot of each culture was analyzed by SDS-
PAGE. Sp2 protein could be detected in both inclusion body aliquots (Fig. 3.1.1.2). 
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Fig. 3.1.1.2. Purified inclusion bodies containing recombinant Sp2 protein. Inclusion body pellets 
derived from two 1 l E. coli BL21DE3 cultures were resuspended in equal volumes of 2x Laemmli 
protein loading buffer. 10 µl of each inclusion body solution were separated by 10% SDS-PAGE (lane 
4 and 7). As controls, 10 µl of protein solution derived from each non-induced (-) and induced bacteria 
culture (+) were loaded (lane 2, 3, 5 and 6). M, Rainbow® marker (lane 1). Coomassie staining. 
 
 
3.1.1.3 Immunization of rabbits 
 
Mouse Sp2 protein was purified from inclusion bodies by preparative SDS-PAGE, 
lyophilized and dissolved in H2O as described in 2.2.3.1. Protein concentration was 
determined by comparing increasing Sp2 volumes with increasing amounts of a BSA 
standard of known concentration by SDS-PAGE, resulting in a Sp2 protein 
concentration of approximately 100 ng/µl and a total amount of 500 µg of 
recombinant mouse Sp2 protein. 
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Fig. 3.1.1.3. Rough quantification of purified recombinant mouse Sp2 protein. Quantification of 
recombinant mouse Sp2 protein after purification by preparative SDS-PAGE and lyophilization. 
Increasing Sp2 volumes (1-5 µl; lanes 2-4) compared with increasing BSA amounts (1-5 µg; lanes 5-
7), each dissolved in equal volumes of 2x Laemmli protein loading buffer. M, Protein-Ladder (MBI 
Fermentas, St. Leon-Rot) (lane 1). Coomassie staining. 10% SDS-PAGE. 
 
As the total amount of recombinant Sp2 protein was insufficient for rabbit 
immunization, expression of mouse Sp2 protein in E. coli BL21DE3 was repeated 
under the same conditions as described resulting in additional 250 µg of Sp2 protein 
(data not shown), thus leading to a final amount of 750 µg recombinant mouse Sp2 
protein. To generate Sp2-specific polyclonal antibodies, two rabbits were immunized 
with each 75 µg of recombinant Sp2 per immunization reaction (see 2.2.3.6). 
 
 
3.1.1.4 Characterization of Sp2-specific rabbit antisera 
 
Antiserum taken 10 days after the first boost (see 2.2.3.6) was analyzed in Western 
Blot for Sp2 specificity. In addition, pre-immune serum that has been obtained before 
initiating immunization, was used as a control for antiserum specificity. As depicted in 
Fig. 3.1.1.4, Sp2 antiserum but not the pre-immune serum (both derived from rabbit 
no. 193, “Zwick”) specifically detects recombinant Sp2 protein in Western Blot without 
cross reactivity towards recombinant Sp1 or Sp3 protein. This specificity could be 
confirmed by Western Blot analysis of nuclear extracts (Drosophila SL2, HEK-293 
cells) containing overexpressed mouse Sp2 protein as well as by Electrophoretic 
Mobility Shift Assays (EMSAs) (see 3.1.5). 
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Fig. 3.1.1.4. Analysis of Sp2-specific rabbit antisera. Western Blot analysis. Decreasing amounts 
of recombinant mouse Sp2 protein (50-1 ng) were separated through 10% SDS-PAGE, blotted to a 
PVDF membrane and incubated with Sp2-specific antiserum (lane 2-7). Antiserum was obtained from 
immunized rabbit no. 193 (“Zwick”), 10 days after the first boost. As control, rabbit pre-immune serum 
was used (Pre; lane 1). To analyze antiserum cross reactivity towards other Sp factors, 10 ng of each 
recombinant Sp1 and Sp3 protein were incubated with the antiserum (lane 8-9). Pre-immune and 
antiserum were diluted 1:5000. 
 
 
3.1.2 Endogenous Sp2 protein expression 
 
When initiating this thesis, no data about endogenous Sp2 expression were available 
(see 1.4). To study Sp2 protein expression, Western Blot analyses were performed 
using various cell lines as well as adult mouse tissues. 
 
 
3.1.2.1 Endogenous Sp2 protein expression in various cell lines 
 
To study endogenous Sp2 protein expression in cells, nuclear extracts derived from 
two mouse (mouse embryonic fibroblasts (MEF); mouse embryonic stem cells (ES 
cells)) and two human (human embryonic kidney cells (HEK-293); Ishikawa cells) cell 
lines were investigated by Western Blot analysis. As depicted in Fig. 3.1.2.1, Sp2 
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protein is detectable in all four cell lines by two distinct bands of approximately 75 
kDa. Whether these two bands reflect two translationally controlled Sp2 isoforms, 
alternative splice variants or different posttranslational modifications, has to be 
clarified. The Sp2-specific antiserum not only detects endogenous mouse Sp2 but 
also human Sp2. This can be explained by the high sequence homology between 
mouse and human Sp2 protein (see 3.2.1). 
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Fig. 3.1.2.1. Endogenous Sp2 protein expression in various cell lines. Western Blot analysis. 28 
µg nuclear protein extracts of MEF (lane 3), undifferenciated mouse ES (lane 4), Ishikawa (lane 5) 
and HEK-293 cells (lane 6) were separated through 10% SDS-PAGE, blotted to a PVDF membrane 
and incubated with Sp2-specific antiserum. 20 ng recombinant Sp2 protein were used as positive 
control (lane 7). To control specificity, 28 µg nuclear protein extracts from undifferenciated mouse ES 
(lane 1) and Ishikawa cells (lane 2) were incubated with rabbit pre-immune serum (Pre). Pre-immune 
and Sp2 antiserum (rabbit no. 193; “Zwick“) were diluted 1:5000. 
 
 
3.1.2.2 Endogenous Sp2 protein expression in adult mouse tissues 
 
To determine Sp2 expression pattern in the adult mouse, total cell extracts from adult 
mouse organs of a Sp2 wildtype mouse were analyzed in Western Blot. The extracts 
were kindly provided by Grigore Rischitor and prepared as described in Rischitor 
(PhD thesis, 2005). Although Sp2 expression signals were weak, Sp2 protein is 
present in all tested organs, however with a certain variation of the expression level 
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(Fig. 3.1.2.2). Whereas high expression levels could be detected for liver, kidney and 
heart, the expression values of lung and muscles were comparably low. 
Nevertheless, also in the adult mouse, Sp2 is at least widely expressed and not 
restricted to a subset of organs or body regions. 
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Fig. 3.1.2.2. Endogenous Sp2 protein expression in adult mouse tissues. Western Blot analysis. 
Each 30 µg protein derived from total cell extracts of different adult mouse organs were separated 
through 10% SDS-PAGE as indicated above, blotted to a PVDF membrane and incubated with Sp2-
specific antiserum (lane 1-8). 20 ng recombinant Sp2 protein were used as positive control (lane 9). 
Sp2 antiserum (rabbit no. 193; “Zwick”) was diluted 1:5000. 
 
 
3.1.3 Subcellular localization of Sp2 protein 
 
To obtain information concerning the subcellular localization of endogenous Sp2, 
immunofluorescence analysis of Sp2 protein in HEK-293 cells was performed. 
Endogenous Sp2 is expressed exclusively in the nucleus, thus displaying the same 
subcellular localization as Sp1 and Sp3 (Fig. 3.1.3). 
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Fig. 3.1.3. Subcellular localization of Sp2 protein in HEK-293 cells. Detection of Sp1, Sp2 and Sp3 
protein by α-Sp1 (1:3000), α-Sp2 rabbit no. 193 “Zwick” (1:5000) or α-Sp3 sc-644 (1:1000) and a 
FITC-conjugated secondary antibody (1:300) as indicated. Nuclei are DAPI-stained. 
Immunofluorescence microscope pictures. 
 
 
3.1.4 Transactivation properties of Sp2 protein overexpressed in SL2 cells 
 
An important aspect of transcription factor function is its ability to regulate gene 
expression. To investigate Sp2 transactivation properties, reporter assays were 
performed in Drosophila SL2 cells. As described in 2.2.4.3-4, 4 µg of a luciferase 
(pGL3-Prom) or CAT reporter plasmid (pBCAT-2) were transiently co-transfected 
along with 2 µg of a Sp-independent ß-galactosidase expression plasmid (p97b) and 
0.02-0.5 µg of each Sp1, Sp2 or both, Sp1 + Sp2 expression constructs (Fig. 3.1.4). 
In the reporter plasmid pGL3-Prom a luciferase gene is driven by the Simian Virus 40 
(SV40) promoter containing five Sp1 binding sites (GC boxes), whereas in the 
pBCAT-2 plasmid an artificial promoter harbouring two Sp1 binding sites of the HTLV 
promoter and an E1b-TATA box regulates CAT gene expression. The ß-
galactosidase expression plasmid p97b was used to compare transfection 
efficiencies. 
 
As depicted in Fig. 3.1.4, Sp1 (0.5 µg) strongly activates both promoters (SV40: 84 
fold; BCAT-2: 21 fold activation). However, on both promoters, Sp2 activation values 
did not exceed the values derived from the empty plasmid (pPacHD). Moreover, Sp2 
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had no effect on Sp1 activity (and vice versa) under these conditions. Only for the 
BCAT-2 promoter, a slight decrease of Sp1 activity from 11 fold to 4 fold activity was 
detectable in the case of Sp1 and Sp2 co-transfection (Fig. 3.1.4.B, column 2 and 6). 
However, this can be a normal variation. 
 
Fig. 3.1.4. Transactivation properties of full-length Sp2 protein overexpressed in SL2 cells. 
Drosophila SL2 cells were transiently co-transfected with 4 µg of pGL3-Prom (A) or pBCAT-2 reporter 
(B), 2 µg p97b ß-galactosidase expression plasmid and 0.02 or 0.5 µg pPac-Sp1 and/or pPac-
mSp2(1-606) as indicated. As negative control, the empty plasmid pPacHD was co-transfected with 
the reporter constructs (A, B; column 1). Transfection was performed by the Calcium-phosphate 
method. Cells were harvested 48 hours after transfection. A. Luciferase activity assay. B. 
Chloramphenicol acetyl transferase (CAT) activity assay. 
 
 
3.1.5 DNA binding capacity of Sp2 protein 
 
As transcription factor Sp2 did not activate the GC/GT-box-driven luciferase and CAT 
reporter genes, we next investigated whether Sp2 protein binds to these sequences. 
The interaction between transcription factors and DNA is a complex and often 
regulated process, crucial for the activation capability of the transcription factors (see 
1.1-3). When initiating this thesis work, no detailed report concerning Sp2-DNA 
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interactions was available (apart from the few data of Kingsley and Winoto, 1992). 
However, based on the high sequence homology of the DNA-binding domain (zinc 
finger region) within the individual Sp family members (see 1.4), Sp2 binding to the 
classical GC boxes, was expected. 
 
To study Sp2 DNA binding properties, Electrophoretic Mobility Shift Assays (EMSAs) 
were performed using overexpressed and endogenous Sp2 protein derived from 
insect or mammalian cell lines. The binding capacity towards various oligonucleotides 
harbouring different potential Sp2 binding sites like GC, GT or CT boxes as well GC 
box mutants (see 2.1.9.2) was investigated. In addition to full-length Sp2 protein 
(3.1.5.1-4), the DNA binding capacity of different Sp2 deletion mutants was analyzed 
(3.1.5.5-7). 
 
 
3.1.5.1 GC box binding capacity of full-length Sp2 protein overexpressed in 
Drosophila SL2 cells 
 
To investigate Sp2 GC-box-binding capacity, full-length Sp2 protein was 
overexpressed in SL2 cells (FuGENE 6 transfection) and nuclear extracts were 
incubated with a GC box oligonucleotide as described (Sp2-G; see 2.1.9.2) and 
analyzed by Electrophoretic Mobility Shift Assay (EMSA). Nuclear extracts derived 
from Sp1- and mock- transfected SL2 cells were used as positive and negative 
controls, respectively. As depicted in Fig. 3.1.5.1, no interaction between 
overexpressed Sp2 protein and the DNA is visible although Sp2 protein is detectable 
in Western Blot. Thus, Sp2 incapability to activate reporter gene expression in 
transactivation assays (see 3.1.4) can be explained by the lack of DNA binding. 
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Fig. 3.1.5.1. GC box binding capacity of full-length Sp2 protein overexpressed in Drosophila 
SL2 cells. A. Electrophoretic Mobility Shift Assay (EMSA). 4% native PAA gel. 5 µg nuclear extract of 
either Sp1- (pPac-Sp1; lane 1), mock- (pPacHD; lane 3) or Sp2-transfected (pPac-mSp2(1-106); lane 
4) SL2 cells were incubated with the 32P-labeled GC box oligonucleotide Sp2-G (GC box sequence: 
GGGGCGGGG; see also 2.1.9.2). (•), unspecific signal. FuGENE 6 transfection. B. Western Blot 
analysis to detect Sp2 protein expression in the transfected SL2 cells. 10 µg of SL2 nuclear extracts 
were separated through 10% SDS-PAGE as indicated, blotted to a PVDF membrane and incubated 
with Sp2-specific antiserum (rabbit no. 193; “Zwick“); dilution 1:5000. 30 ng recombinant Sp2 protein 
were used as positive control (lane 6), 30 ng recombinant Sp1 protein as negative control (lane 5). 
 
 
3.1.5.2 GC box binding capacity of endogenous Sp2 protein (MEF, HEK-293 and 
HeLa cells) 
 
To exclude artifacts from Drosophila SL2 cell expression, nuclear extracts from MEF, 
HEK-293 and HeLa cells were used to investigate DNA binding properties of 
endogenous Sp2 protein. Extracts were incubated with the GC box oligonucleotide 
Sp2-G (GC box sequence: GGGGCGGGG; see also 2.1.9.2) and analyzed by 
Electrophoretic Mobility Shift Assay (EMSA). As in the case of SL2-overexpressed 
Sp2 protein, no DNA interaction could be detected in supershift assays, although Sp2 
protein was detectable in Western Blot (Fig. 3.1.5.2). 
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A 
 
Fig. 3.1.5.2. Potential GC box binding activity of endogenous Sp2 in various cell lines. A. 
Electrophoretic Mobility Shift Assays (EMSAs). 4% native PAA gel. Nuclear extracts derived from MEF 
(each 2 µg; lane 1-5), HEK-293 (each 8 µg; lane 6-8) or HeLa cells (each 5 µg; lane 9-13) were 
incubated with the 32P-labeled GC box oligonucleotide Sp2-G in presence (+) or absence (-) of 
antibodies/-sera against Sp1-3 or pre-immune serum (Pre) as indicated. To see that the Sp2-specific 
antiserum (rabbit no. 193; “Zwick”) is able to recognize Sp2 protein in EMSA, the reader is referred to 
Fig. 3.1.5.6.D. B. Western Blot analysis to monitor Sp2 expression in the respective cells. MEF (15 µg; 
lane 1), HEK-293 (20 µg; lane 2) and HeLa (20 µg; lane 3) nuclear extracts were separated through 
10% SDS-PAGE as indicated, blotted to a PVDF membrane and incubated with Sp2-specific 
antiserum (rabbit no. 193; “Zwick“); dilution 1:5000. 10 ng recombinant Sp2 protein were used as 
positive control (lane 4). 
 
As visible in Fig. 3.1.5.2.A, the presence of other Sp family members (like Sp1 and 
Sp3) binding with high affinity to the GC box oligonucleotide, extremely impede a 
potential Sp2 detection. To prevent from this, all further experiments were performed 
with Sp2 protein, mainly overexpressed in Drosophila SL2 cells, which are 
characterized by the lack of endogenous Sp factors (Suske, 2000). 
 
 
 
Sp2 
MEF HEK-293 HeLa 
α-Sp1 
Pre - - - + - - + - - - + - - 
- + - - + - - + - - - + - 
α-Sp2 - + - - - - - - + - - - + 
- + - - - + - - - + - + - α-Sp3 
Sp1 
Sp3 
1 2 3 4 5 6 7 8 9 10 11 12 13
B 
1 2 3 4 
M
E
F 
H
E
K
-2
93
 
H
eL
a 
re
c.
 S
p2
 
48
54
75
100
130
180
kDa
supershifts 
 77
3.1.5.3 Binding capacity of SL2-overexpressed full-length Sp2 protein towards 
GT and CT boxes 
 
As described in chapter 1.3, the DNA-binding domain (zinc finger region) is highly 
conserved among the individual members of the Sp/XKLF super-family. However, 
Sp2 displays a slightly altered amino acid sequence in the first zinc finger (chapter 
1.4). For this, Kingsley and Winoto (1992) claimed a higher binding affinity of Sp2 
protein towards GT than GC boxes. To consider this, Sp2 DNA binding capacity was 
investigated using GT (GGGGTGTGG) as well as CT box (CGCCTCCCC or 
TCCCTCCCC) oligonucleotides (see also 2.1.9.2). However, SL2-overexpressed 
Sp2 protein did neither bind to the GT nor to the CT box oligonucleotides (Fig. 
3.1.5.3.A). 
A 
Sp1 mock Sp2 
 
Fig. 3.1.5.3. Binding capacity of SL2-overexpressed, full-length Sp2 protein towards GT and CT 
boxes. A. Left: Electrophoretic Mobility Shift Assay (EMSA). 4% native PAA gel. 4 µg nuclear extract 
of either Sp1- (pPac-Sp1; lane 1-4), mock- (pPacHD; lane 6-8) or Sp2-transfected (pPac-mSp2(1-
106); lane 9-12) SL2 cells were incubated with either a 32P-labeled CT box (CT, WT-1), GT box (GT-1) 
or GC box (Sp1-1) oligonucleotide as indicated (for detailed oligonucleotide sequences, see 2.1.9.2). 
(•), unspecific signal. FuGENE 6 transfection. Right: Sequences of the DNA binding motifs inside the 
CT, WT, Sp1-1 and GT-1 oligonucleotides. B. Western Blot analysis to detect Sp2 protein expression 
in the transfected SL2 cells. 10 µg of SL2 nuclear extracts were separated through 10% SDS-PAGE 
as indicated, blotted to a PVDF membrane and incubated with Sp2-specific antiserum (rabbit no. 193; 
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“Zwick”); dilution 1:5000. 20 ng of recombinant Sp1 (lane 4) or Sp2 (lane 5) protein were used as 
negative and positive control, respectively. 
 
 
3.1.5.4 Binding capacity of SL2-overexpressed full-length Sp2 protein towards 
GC box variants 
 
To further consider the H→L substitution in the first zinc finger of Sp2, mutated GC 
box oligonucleotides were designed (2.1.9.2) following the so-called zinc finger code 
(see 1.3 and Fig. 3.1.5.4.A). To investigate Sp2 DNA binding capacity, nuclear 
extracts derived from SL2 cells were incubated with these mutated GC box 
oligonucleotides and analyzed in EMSA. As depicted in Fig 3.1.5.4.B, in contrast to 
overexpressed Sp1, Sp2 protein did not bind to any of the tested oligonucleotides. 
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Fig. 3.1.5.4. Binding capacity of SL2-overexpressed full-length Sp2 protein towards GC box 
variants. A. Scheme of GC box oligonucleotide mutants. Following the so-called zinc finger code (see 
1.3), three amino acids of each zinc finger enable the specific contact between a zinc finger and the 
SL2 
B 
1 2 3 4 
Sp1 Sp2 mock
Sp2-A 
Sp2-T 
Sp2-G 
Sp2-C 
5 7 8 9 10 11 12 
Sp1 
•
GT-1 
Sp1-1 
+ + +
+ + +
+ + +
++ + 
+++
+ +
ZF 3 ZF 2 ZF 1 Sp1 zinc 
finger   K H R R R H  A H K   
L Sp2 
DNA G G G  G G G  3’ 
5’ G C G  (GC box)  C G C  C C C  C C C  
A GC box T variants C
re
c.
 S
p2
 
C 
m
oc
k 
Sp
2 
6 13 14 16 17 15 
Sp2 
1 2 3 4 
100
kDa
130
75
54
48
180
Sp
1 
 79
DNA by contacting each one nucleotide of the DNA sequence. Considering the H→L substitution in 
the first zinc finger of the Sp2 protein, GC box oligonucleotides were designed exhibiting a mutation 
(depicted in red) of the corresponding second G nucleotide. B. Electrophoretic Mobility Shift Assay 
(EMSA). 4% native PAA gel. Nuclear extract of either Sp1- (each 5 µg; pPac-Sp1; lane 1-6), Sp2- 
(each 10 µg; pPac-mSp2(1-106); lane 7-12) or mock-transfected (each 10 µg; pPacHD; lane 13-17) 
SL2 cells were incubated with either a 32P-labeled GC box (Sp1-1 or Sp2-G), a GT box (GT-1) or one 
of three mutated GC box oligonucleotides (Sp2-A, -C, -T) as indicated (for oligonucleotide sequences, 
see 2.1.9.2 or Fig. 3.1.5.3.A). (•), unspecific signals. FuGENE 6 transfection. C. Western Blot analysis 
to detect Sp2 expression in SL2 cells. 10 µg of SL2 nuclear extracts were separated through 10% 
SDS-PAGE as indicated, blotted to a PVDF membrane and incubated with Sp2-specific antiserum 
(rabbit no. 193; “Zwick”); dilution 1:5000. 30 ng recombinant Sp2 protein were used as positive control 
(lane 4). 
 
 
3.1.5.5 DNA binding capacity of the Sp2 DNA-binding domain overexpressed in 
SL2 cells 
 
Electrophoretic Mobility Shift Assays (EMSAs) were performed using nuclear extracts 
from SL2 cells that were transiently transfected with the zinc finger domain of Sp2 
only. As depicted in Fig. 3.1.5.5, the Sp2 zinc finger fragment Sp2 (aa478-606) is 
able to bind to the classical GC box as well as GC box variants with similar affinity. 
The binding affinity towards the GT box oligonucleotide, however, appears to be 
lower. This suggests that sequences inside the Sp2 protein carry an inhibitory 
function and somehow prevent Sp2 from binding to DNA. Thus, the H→L substitution 
in the first zinc finger of Sp2 seems to have no influence on Sp2 DNA binding 
capacity. 
 
 
 80
Sp1-ZF Sp (aa476-606) mock 
 
Fig. 3.1.5.5. DNA binding capacity of the Sp2 DNA-binding domain overexpressed in SL2 cells. 
Electrophoretic Mobility Shift Assay (EMSA). 4% native PAA gel. 5 µg nuclear extract derived from 
SL2 cells, which have been transfected (FuGENE 6) with an empty vector (pPacHD; lane 7-12) or an 
expression plasmid for the zinc finger region of either Sp1 (pPacUbx-Sp1ZF; lane 1-6) or Sp2 
(pPacUbx-mSp2(478-606); lane 13-18), were incubated with different 32P-labeled oligonucleotides as 
indicated (for oligonucleotide sequences, see 2.1.9.2 or Fig. 3.1.5.3-4.A). (•), unspecific signals. 
 
 
3.1.5.6 DNA binding capacity of SL2-overexpressed N-terminal Sp2 protein 
deletion mutants 
 
To identify putative sequences that prevent full-length Sp2 protein from binding to 
DNA, a series of N-terminal Sp2 deletion mutants were generated (Fig. 3.1.5.6.A; 
see also 2.1.10.2.2) and tested for GC box binding by Electrophoretic Mobility Shift 
Assay (EMSA). As depicted in Fig. 3.1.5.6.B, all Sp2 truncations lacking the first 179 
N-terminal amino acids are able to bind to the GC box oligonucleotide. However, the 
intensity of the DNA binding signal decreased with the length of the Sp2 fragments. 
No or only a very weak signal was detected for the deletion fragment Sp2 (aa160-
606), lacking the first 159 N-terminal amino acids. As all fragments, which the 
antibody is able to detect, display similar expression levels in Western Blot (Fig. 
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3.1.5.6.C), the weak or absent signal has to be interpreted as a reduction or total loss 
of the DNA binding capability. 
  
 
Fig. 3.1.5.6. DNA binding capacity of SL2-overexpressed N-terminal Sp2 deletion mutants. A. 
Schematic drawing of N-terminal Sp2 deletion mutants (see also 2.1.10.2.2). Numbers in brackets 
represent start and end amino acid of the protein fragments. Glutamine-rich putative transactivation 
domains are depicted in red, zinc fingers in black, serine/threonine-rich regions in yellow. (+/-) 
represents an area of charged amino acids. Sp2 (∆112-207) is fused to a Flag/HA tag (depicted in 
grey) derived from the plasmid pPacHD-Flag; all other fragments are fused to an Ubx leader 
sequence derived from the plasmid pPacUbx. Green ellipse point out the N-terminal amino acids 
being present in the Sp2 deletions exhibiting no DNA binding capacity in EMSA experiments. B. 
Electrophoretic Mobility Shift Assay (EMSA). 4% native PAA gel. 5 µg nuclear extract derived from 
SL2 cells, which have been transfected with either Sp1 (pPac-Sp1; lane 1), mock (pPacHD; lane 2) or 
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one of the Sp2 constructs (lane 3-10), were incubated with the 32P-labeled GC box oligonucleotide 
Sp2-G and loaded on the gel as indicated. FuGENE 6 transfection. C. Western Blot analysis to detect 
expression of the N-terminal Sp2 deletions in SL2 cells. 10 µg SL2 nuclear extract were separated 
through 8% SDS-PAGE as indicated, blotted to a PVDF membrane and incubated with Sp2-specific 
antiserum (rabbit no. 193; “Zwick”), dilution 1:5000. Sp2 deletion fragments starting with amino acid 
349, 441 or 478 were not detected by the antiserum. D. Electrophoretic Mobility Shift Assay (EMSA) 
with 5 µg of SL2 nuclear extract expressing the N-terminal deletion mutant Sp2 (aa 207-606) to 
demonstrate functionality of the Sp2-specific antiserum (rabbit no. 193; “Zwick”) in EMSA. Pre, pre-
immune serum. 4% native PAA gel. 
 
To investigate whether only a part of the N-terminal 179 amino acid is responsible for 
the loss of DNA binding capacity, amino acids 112 to 207 were deleted and the Sp2 
deletion protein (Sp2 (∆112-207)) tested for DNA binding by Electrophoretic Mobility 
Shift Assay (EMSA). However, the deletion fragment also was unable to bind to the 
GC box oligonucleotide. (Fig. 3.1.5.6.B). This result indicates that the entire N 
terminus from amino acid 1-179 contains sequences that prevent SL2-overexpressed 
Sp2 from binding. 
 
 
3.1.5.7 DNA binding capacity of Gal4-fused C-terminal Sp2 deletion mutants 
overexpressed in HEK-293 cells 
 
Based on the result that the N-terminal amino acids 1-179 influence the DNA binding 
capacity of Sp2, we investigated whether the N terminus also inhibits Sp2-DNA 
interactions when being N-terminally fused to a heterologous Gal4 DNA-binding 
domain. For this, C-terminal truncated Sp2 protein fragments were generated lacking 
the zinc finger region and further C-terminal parts of the protein. In addition, one Sp2 
fragment (= Gal4-Sp2 (aa207-471)) was generated lacking both, zinc finger domain 
and the N-terminal region around domain A (Fig. 3.1.5.7.A; see also 1.4 and 
2.1.10.2.3). All four Sp2 fragments were fused at the N terminus to a Gal4 DNA-
binding domain. The Gal4-Sp2 fusion constructs were overexpressed in HEK-293 
cells and tested for DNA binding capacity in Electrophoretic Mobility Shift Assays 
(EMSAs). As depicted in Fig. 3.1.5.7.B, a diffuse signal in the range of the gel slots 
was observed for Gal4-Sp2 (aa6-471), Gal4-Sp2 (aa6-357) and Gal4-Sp2 (aa6-215). 
In contrast to that, no binding signal was obtained for the Gal4-Sp2 (aa207-471) 
fusion fragment, although it lacks the first 207 amino acids, which seem to influence 
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Sp2 DNA binding capacity in the N-terminal Sp2 deletion mutants (see 3.1.5.6). 
However, all fragments exhibit similar expression levels in Western Blot 
(Fig.3.1.5.7.C). 
 
Fig. 3.1.5.7. DNA binding capacity of Gal4-Sp2 fusions overexpressed in HEK-293 cells. A. 
Schematic drawing of Gal4-fused C-terminal Sp2 deletion mutants (see also 2.1.10.2.3). Numbers in 
brackets represent start and end amino acid of the protein fragments. Glutamine-rich domains are 
depicted in red, serine/threonine-rich regions in yellow. (+/-) represents an area of charged amino 
acids. Instead of possessing the zinc finger region, the Sp2 truncations are fused at the N terminus to 
a Gal4 DNA-binding domain derived from pSG424Gal4, depicted in blue. Green ellipse point out the 
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N-terminal amino acids being present in the Sp2 deletion fragments described in 3.1.5.6, which 
exhibited no DNA binding in EMSAs. B. Electrophoretic Mobility Shift Assay (EMSA). 4% native PAA 
gel. Each 2 µg nuclear extract derived from HEK-293 cells, which have been transfected by FuGENE 
6 with each one of the constructs described in (A), were incubated with a 32P-labeled Gal4 binding site 
oligonucleotide and loaded on the gel as indicated. To investigate Gal4-Sp2 (aa207-471) DNA binding 
capacity, EMSA was performed in duplicates with two different nuclear extract preparations containing 
overexpressed Gal4-Sp2 (aa207-471). C. Western Blot analysis to detect expression of the Gal4-
fused Sp2 deletions in HEK-293 cells. HEK-293 nuclear extracts (10 µg) were separated by 8% SDS-
PAGE as indicated, blotted to a PVDF membrane and incubated with an anti-Gal4-DBD antibody 
(USA: St. Cruz; no. sc-577), dilution 1:1000. (∗) The comparably short Gal4-DBD (aa1-145) fragment 
could not be detected as it ran out from gel. 
 
These results suggest that the 179 N-terminal amino acids also impair “correct” 
interaction between the Gal4 DNA-binding domain and the corresponding DNA 
sequence. Thus, the impairment of DNA binding by the Sp2 N terminus appears to 
be independent of the position of the DNA-binding domain (zinc finger → C terminus; 
Gal4-DBD → N terminus). Moreover, the lack of any binding activity in the Gal4-Sp2 
(aa207-471) mutant indicates that also sequences between amino acid 207-471 are 
involved in the DNA binding inhibition.  
 
 
3.1.6 Transactivation properties of Sp2 deletion mutants displaying DNA 
binding capacity 
 
3.1.6.1 Transactivation properties of N-terminal Sp2 deletion mutants 
overexpressed in SL2 cells 
 
Based on the findings that Sp2 deletion fragments lacking the first 179 N-terminal 
amino acids are able to bind DNA in Electrophoretic Mobility Shift Assays (EMSAs) 
(see 3.1.5.6), transactivation assays with these Sp2 deletion mutants were 
performed. Sp2 (aa180-606) and Sp2 (aa207-606), both binding to GC box 
oligonucleotides in EMSA, as well as Sp2 (∆112-207) lacking amino acids 112-207 
were tested for their capability to activate reporter gene expression. In addition, 
control experiments with full-length Sp1 and Sp2 or an empty vector (pPacHD) were 
performed. As reporters, plasmid pGL3-Prom (containing a luciferase gene driven by 
the SV40 promoter) and p(GC)2-CAT (containing a CAT gene driven by an artificial 
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promoter consisting of two GC boxes and the E1b-TATA box) were used. The ß-
galactosidase expression plasmid p97b served to compare transfection efficiencies. 
 
As depicted in Fig. 3.1.6.1.B-C, activation values of all tested Sp2 deletion fragments 
are comparable to the values obtained from mock transfections (pPacHD). Although 
binding to DNA, the Sp2 deletion fragments Sp2 (aa180-606) and Sp2 (aa207-606) 
lacking the glutamine-rich domain A did not activate reporter gene expression in 
these assays. In contrast to that, Sp1 strongly activated luciferase and CAT 
expression (SV40: 33 fold; (GC)2-CAT: 308 fold activation). Possible reasons for 
inactivity will be discussed in chapter 4.2. 
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Fig. 3.1.6.1. Transactivation properties of N-terminal Sp2 deletion mutants in SL2 cells. A. 
Schematic drawing of N-terminal Sp2 deletion mutants used for transactivation analysis (see also 
2.1.10.2.2 and Fig. 3.1.5.6.A). Numbers in brackets represent start and end amino acid of the protein 
fragments. B-C. Drosophila SL2 cells were transiently transfected with 4 µg of either pGL3-Prom (B) 
or p(GC)2-CAT reporter (C), 2 µg p97b ß-galactosidase expression plasmid and 0.5 µg of either 
pPacHD (column 1), pPac-Sp1 (column 2), pPac-mSp2(1-606) (column 3), pPac-mSp2(180-606) 
(column 4), pPac-mSp2(207-606) (column 5) or pPac-mSp2(∆112-207) (column 6), as indicated. 
Transfection was performed by the Calcium-phosphate method. Cells were harvested for 
transactivation assays 48 hours after transfection. B. Luciferase activity assay. C. Chloramphenicol 
acetyl transferase (CAT) activity assay. 
 
 
3.1.6.2 Transactivation properties of Gal4-Sp2 deletion mutants overexpressed 
in HEK-293 cells 
 
Transactivation properties of the Gal4-fused C-terminal Sp2 deletion proteins, at 
least three of them exhibiting a diffuse DNA binding signal in Electrophoretic Mobility 
Shift Assays (EMSAs) (see 3.1.5.7), were investigated by luciferase reporter assays. 
In addition, control experiments with plasmids expressing either only the Gal4 DNA-
binding domain (pSG424Gal4) or a Gal4-fused Sp1-A fragment (pSG424Gal4-Sp1A) 
were performed. As reporter plasmid, pGAWG5E1b, which contains a luciferase 
gene driven by an artificial promoter consisting of five Gal4 binding sites and the E1b-
TATA box, was used. HEK-293 cells were either transiently or stabely transfected 
with the reporter construct and co-transfected with the ß-galactosidase expression 
plasmid pRSV-ß-Gal (to standardize transfection efficiencies) and the Gal4-fused 
expression plasmids. 
 
As depicted in Fig. 3.1.6.2, the three Gal4-Sp2 fragments containing the N-terminal 
amino acids 1-179 did not activate reporter gene expression. No differences were 
detected between cells being transiently or stabely transfected with the reporter 
construct. Investigation of the fusion fragment Gal4-Sp2 (aa207-471) displaying no 
DNA interactions resulted in a 7.3 fold activation in the stabely transfected cells. 
However, no activation was detected in transiently transfected cells, supposing that 
the 7.3 fold activation reflects the normal variation. In contrast to the Gal4-Sp2 
fragments, Sp1 displays 21-53 fold luciferase activity in all experiments. 
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In summary, no Sp2-mediated activation of reporter gene expression could be 
detected in these experiments. Possible reasons for Sp2 inactivity will be discussed 
in chapter 4.2. 
A 
 
Fig. 3.1.6.2. Transactivation properties of Gal4-Sp2 deletion mutants in HEK-293 cells. A. Left: 
Schematic drawing of Gal4-fused C-terminal Sp2 deletion mutants (see also 2.1.10.2.3). Numbers in 
brackets represent start and end amino acid of the protein fragment. Right: Schematic drawing of the 
artificial G5E1b promoter and the luciferase reporter gene in the plasmid pGAWG5E1b. B-E. 
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Luciferase activity assays. HEK-293 cells were either transiently or stabely (3 µg) transfected with a 
luciferase reporter (pGAWG5E1b) and co-transfected with 0.5 µg ß-galactosidase expression plasmid 
(pRSV-ß-Gal) and 1 µg of each Gal4 expression construct, as indicated. Transient transfections were 
performed by the jetPEI™ method (Biomol, Hamburg). Cells were harvested for reporter assays 48 
hours after transfection. B+D. HEK-293 cells, transiently transfected with the luciferase reporter 
plasmid pGAWG5E1b. C+E. HEK-293 cells, stabely transfected with the luciferase reporter plasmid 
pGAWG5E1b (HEK-293-pGAWG5E1b cells). 
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3.2 Generation of Sp2 gene targeted mice 
 
3.2.1 Sp2 gene structure 
 
To design a knockout vector for Sp2 gene targeting in the mouse, the exon-intron 
structure of the Sp2 gene had to be identified. For this, genomic Sp2 DNA sequence 
derived from the Celera data base (Celera access. no.: mCG 13240) was aligned 
with different Sp2 cDNA sequences present in the data base of the National Center 
for Biotechnology Information (NCBI). Exon-intron transitions were identified by the 
splice donor and acceptor site nucleotides GT/(GC) and AG. For this alignment, 
mouse (NCBI access. no.: BC021759 and NM_030220) as well as human cDNA 
sequences (NCBI access. no.: BC016680 and D28588) were used. 
A 
•••
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Fig. 3.2.1. Sp2 gene structure. A. Sp2 exon identification. Mouse genomic Sp2 DNA sequences 
(Celera data base; access. no.: mCG 13240) were aligned with different Sp2 cDNA sequences (NCBI 
data base) as indicated. Exons are numbered and coloured as described in B. Dots represent AUGs 
being in frame in the exons 1, 2, 3 and the two upstream exons (E); vertical lines represent stop 
codons. (Sequence of exon 8 is incomplete in the cDNA sequence NM_030220 (dotted line)). B. 
Exon-intron structure of Sp1-4 (modified after Krüger (diploma work, 2002)). Size of murine and 
human Sp2 gene exons (black numbers) and introns (grey numbers) are indicated. As the 
transcription start site in the first exon was not determined experimentally, only a minimal size could 
be calculated. The size of the last exon was determined until the start of the poly-adenylation 
sequence. As exon 2 is absent in the mouse cDNA sequences, size values could not be determined 
(= ?). Exon colour code: Red exon encodes the two glutamine-rich putative transactivation domains 
(A+B), yellow and orange exons code for the N-terminal protein region, blue exons for the region 
between glutamine-rich domains and zinc finger region, and green exons encode the C-terminal 
protein region including the zinc finger domain. The existence of the dashed exon 2 in mouse has to 
be proven. (∗) represents the codons for the Sp box. 
 
As depicted in Fig. 3.2.1.A, the murine and human Sp2 gene consists of at least 7 
exons (exon 1 and 3-8). Exons 3-8 are present in all analyzed cDNAs, whereas exon 
1 is only present in the Sp2 cDNAs no. BC021759 (mouse) and BC016680 (human) 
but not in NM_030220 (mouse) and D28588 (human). By sequence comparisons of 
Sp2 exon 1 with the first exon of Sp1, Sp3 and Sp4, a consensus sequence of ATG-
AG/CC-G at the 3'-end of the exon could be identified (Krüger, diploma work, 2002). 
As the transcription start site in exon 1 is not known, only a minimal size could be 
calculated (see Fig. 3.2.1.B). Nevertheless, Sp2 mRNA and thus Sp2 protein is 
longer than originally described (Kingsley and Winoto, 1992). 
 
Alignment of human Sp2 cDNA no. D28588 (but not BC016680) with mouse Sp2 
genomic DNA (Celera access. no.: mCG 13240) supports the existence of a potential 
second exon around nt 16520-16660 (genomic Sp2 DNA) which is absent in the 
published mouse cDNAs. Probably this exon is a target of alternative splicing in 
mouse, which has to be proven experimentally. In addition, two potential upstream 
exons with unknown function (genomic Sp2 DNA: nt 10000-10106; nt 11368-11542) 
could be identified by sequence alignment of mouse Sp2 genomic DNA with cDNA 
no. NM_030220 (mouse). 
 
Regarding translation, mouse (BC021759) and human (BC016680) Sp2 mRNA 
exhibit a relatively large number of putative translation start sites (in-frame AUGs) at 
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the 5'-region. The first start site, which not results in an uncompleted translation 
product, is located at the 3'-end of exon 1 (cDNA no. BC021759: nt 32 and 
BC016680, nt 31), according to the situation in Sp1, Sp3 and Sp4 (see above and 
Krüger; diploma work, 2002). This AUG is directly flanked downstream by two AUGs 
in exon 3 (e.g., cDNA no. BC021759: nt 47 and 53). The two putative upstream 
exons also contain three in-frame AUGs, however followed by two stop codons after 
43 amino acids regarding the first AUG (see Fig. 3.2.1.A). 
 
As depicted in Fig. 3.2.1.B, Sp2 displays a similar exon-intron structure as Sp1, Sp3 
and Sp4: Exon 4 encodes the glutamine-rich putative transactivation domains and 
the characteristic Sp box (see 1.4), exons upstream of exon 4 for the N-terminal part 
of the protein, exon 7 for the first two and exon 8 for the third zinc finger as well as for 
the short region C-terminal to the third zinc finger. In contrast to Sp1, Sp3 and Sp4, 
the region between putative transactivation and DNA-binding domain is encoded by 
two exons, exon 5 and 6, the latter encoding the buttonhead box (see 1.4). It has to 
be emphasized that Sp2 (like Sp1, Sp3 and Sp4) exhibits not one but two glutamine-
rich putative transactivation domains. This inconsistency towards previous results 
(e.g., Kingsley and Winoto, 1992) correlates with the finding that the Sp2 N-terminus 
is longer than previously described. 
 
As depicted in Tab. 3.2.1, Sp2 displays high sequence identity on the protein as well 
as on the RNA level between mouse and human. Moreover, the overall identity 
between Sp2 and Sp1, Sp3 and Sp4 protein sequences is at least 24% and is mainly 
based on the highly conserved zinc finger domain. 
 
cDNA alignment 
BC021759 (mouse) x BC016680 (human) 
protein alignment 
BC021759 protein (mouse) x BC016680 protein (human) 
BC021759 protein (mouse) x Sp1 protein sequence (mouse) 
BC021759 protein (mouse) x Sp3 protein sequence (human) 
BC021759 protein (mouse) x Sp4 protein sequence (mouse) 
Identity [%] 
ca. 82% 
 
ca. 94% 
ca. 24% * 
ca. 25% * 
ca. 28% * 
 
Tab. 3.2.1. Sequence identity [%] between murine and human Sp2 cDNA and protein as well as 
between Sp1-4 protein. DNA-Strider analysis. (∗) Identity mainly based on the highly conserved zinc 
finger sequences. 
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Based on the high conservation of exon 3-8 in all analyzed cDNAs and on exon 1 
homology between Sp 1-4, all experiments in this work requiring cDNA were 
performed by using mouse cDNA no. BC021759. The cDNA sequence together with 
the mouse Sp2 genomic DNA sequence is attached in 6.2. For all other cDNA 
sequences, the reader is referred to the NCBI data base. 
 
 
3.2.2 Strategy to target the Sp2 gene in the mouse 
 
Based on the analysis of the Sp2 gene structure (see 3.2.1), a knockout vector was 
designed to target the Sp2 gene in mouse for the investigation of Sp2 function in 
vivo. This vector exhibits the option for the generation of both, a constitutive and a 
conditional Sp2 knockout (Fig. 3.2.2.A). 
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Fig. 3.2.2. Strategy to target the Sp2 gene in the mouse. A. Scheme of the Sp2 protein, wildtype 
locus and targeting vector. Zinc fingers of the DNA binding domain are depicted as black beams, 
glutamine-rich domains A and B as well as exon 4 encoding these domains are depicted in red. The 
floxed exon 4 as well as the floxed SA-IRES-LacZ-Neo-SVpA sequence replace exon 4 after 
homologous recombination. The LacZ-Neo gene is driven by the endogenous Sp2 promoter. Genomic 
fragments (intron 3 and 4), necessary for the homologous recombination, are indicated. The negative 
hsv-TK selection gene driven by a pgk promoter is located downstream of the homologous 
sequences. Triangles represent loxP sites enabling Cre-driven recombination. SA, splice acceptor 
site; IRES, internal ribosomal entry site; LacZ, gene encoding ß-galactosidase; Neo, neomycin 
resistance gene encoding aminoglycoside phosphotransferase; SVpA, poly-adenylation site derived 
from Simian Virus; pgk, phosphoglycerate kinase promoter; hsv-TK, gene encoding the herpes 
simplex virus Thymidine Kinase. For further details concerning the targeting vector, the reader is also 
referred to chapter 3.2.4-5. B. RT-PCR with RNA derived from undifferenciated mouse ES cells to 
prove Sp2 gene expression. 5 µl of each RT-PCR reaction were loaded on a 1.8% agarose gel. 
Primers MSp2-ES-RT-fw and -rev were used to detect Sp2 mRNA (560 bp fragment; lane 2). Primers 
against the myc gene were used as positive control (pc; 273 bp fragment; lane 3); the negative control 
reaction was performed without RNA (nc; lane 4). M, pBR-322 marker after HinfI digestion (lane 1). C. 
Scheme of RT-PCR strategy. Sp2 mRNA; exons 1-8 are indicated following the colour code of 3.2.1. 
Arrows represent primer MSp2-ES-RT-fw (= fw) and MSp2-ES-RT-rev (= rev) used to amplify Sp2 
cDNA by PCR resulting in a 560 bp RT-PCR fragment (black beam). D. Mouse crossing scheme. Mice 
being heterozygous for the entire targeting vector (lzn/wt) were received from ES cell transfection, 
blastocyst injection and crossing of the resulting chimeric mice (see 1.5). The heterozygous mice then 
were crossed to homozygosity (lzn/lzn), exhibiting a functional knockout (see 3.2.8-9). 
 
The knockout construct consists of a floxed exon 4, which encodes the two 
glutamine-rich domains A and B, flanked by two genomic regions (in the following 
named intron 3 and 4), necessary for the homologous recombination. Exon 4 has 
already been successfully used to generate the Sp3 knockout (Bouwman et al., 
2000) and, for this, seems to be appropriate to target also Sp2. 
 
Inside the homologous region, downstream of exon 4, a floxed selection cassette 
was inserted. The cassette consists of a promoter-less LacZ-Neo fusion gene (LacZ 
encodes ß-galactosidase, Neo encodes the aminoglycoside phosphotransferase 
leading to neomycin resistance, thus enabling positive selection of the targeted 
embryonic stem cells), an internal ribosomal entry site (IRES) as well as a splice 
acceptor site (SA) upstream of the LacZ-Neo fusion gene, and a poly-adenylation 
sequence derived from the Simian Virus (SVpA) downstream of the LacZ-Neo fusion 
gene. 
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As the Sp2 gene is expressed in mouse embryonic stem (ES) cells (see Fig. 3.2.2.B), 
the LacZ-Neo gene could be set under the control of the endogenous Sp2 promoter. 
This has the advantage of an increased selection efficiency. Moreover, it opens the 
possibility of Sp2 expression studies by LacZ stainings (X-Gal, BluoGal) in the 
targeted animals (see 2.2.4.7). 
 
The SA, SVpA and IRES elements inside the cassette are required for the 
transcriptional and translational control of the Sp2, LacZ and Neo gene. In the 
knockout mice, Sp2 exons 1-4 will be fused to the LacZ-Neo gene by the splice 
acceptor site (SA) during transcription. The poly-adenylation signal (SVpA) 
downstream of the Neo gene will stop transcription of this fusion product. Thus, Sp2 
exons 5-8 should not be transcribed in the targeted animals. The IRES sequence 
enables an independent translation of the LacZ-Neo transcript, which allows to 
perform LacZ-based expression studies as well as positive selection by neomycin 
resistance. 
 
Unlike the SA-IRES-LacZ-Neo cassette, the hsv-TK (herpes simplex virus Thymidine 
Kinase) gene, regulated by the phosphoglycerate kinase promoter (pgk), is located 
downstream of the homologous sequences, thus serving as negative selection 
marker (see 1.5). 
 
As described in chapter 1.5, mouse embryonic stem (ES) cells were transfected with 
the targeting vector and selected by the two selection markers (Neo, hsv-TK). 
Positively selected ES cell were injected into blastocysts and chimeric mice, followed 
by mice being heterozygous (lzn/wt) for the entire construct, were generated. These 
mice were crossed to homozygosity (lzn/lzn) leading to a functional knockout (Fig. 
3.2.2.D; see also 3.2.8-9). 
 
Due to the floxed exon 4, the targeting vector also enables the generation of 
constitutive or conditional Sp2 knockout mice based on Cre-driven exon 4 deletion 
(see 1.5). 
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3.2.3 Screening for Sp2 genomic DNA 
 
To receive genomic fragments of the murine Sp2 gene, a 129/ola mouse cosmid 
library at the RZPD Deutsches Ressourcenzentrum für Genomforschung GmbH 
(Heidelberg) was screened with a DNA probe against exon 4. The probe was 
amplified by PCR with primer MSp2-Ex4-RZPD-fw and MSp2-Ex4-RZPD-rev (see 
2.1.9.3). In total, 15 clones were identified and four of them scrutinized by Southern 
Blot analysis. Clone number MPMGc121L17390Q2 positively tested by Southern 
Blotting was utilized for PCR amplification of the genomic fragments exon 4, intron 3 
and intron 4 (targeting construct). 
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Fig. 3.2.3. Screening for Sp2 genomic DNA. A. Scheme of the Southern Blot strategy. A 129/ola 
mouse cosmid library was screened with a 525 bp DNA probe against exon 4 at the RZPD Deutsches 
Ressourcenzentrum für Genomforschung GmbH (Heidelberg). The identified cosmid clones were 
digested with either BglII, HhaI or EcoRI as indicated and hybridized with the labeled probe (Southern 
Blot). Clones containing exon 4 exhibit a 5.8 kb fragment for BglII, a 2.8 kb fragment for HhaI and a 
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1.6 kb fragment for EcoRI digestion. B. Southern Blot analysis of cosmid clones no. 
MPMGc121N1886Q2 (lane 1), MPMGc121L17390Q2 (lane 2), MPMGc121G055Q2 (lane 3), 
MPMGc121G23244Q2 (lane 4). The probe (Ex4-RZPD) was amplified by PCR with primer Sp2-Ex4-
RZPD-fw and Sp2-Ex4-RZPD-rev (see 2.2.2.2.3). 
 
 
3.2.4 Generation of the Sp2 knockout construct 
 
To target the Sp2 gene in mouse, a knockout construct was designed displaying the 
option for the generation of both, a constitutive and a conditional Sp2 knockout (see 
3.2.2). The starting vector for the Sp2 knockout was the pPNT plasmid (Fig. 3.2.4.A), 
containing a pgk-driven neomycin resistance (Neo) and herpes simplex Thymidine 
Kinase gene (hsv-TK) (Tybulewicz et al., 1991; see also Mangold, diploma work, 
1995). The PCR-amplified and sequenced Sp2 genomic fragments intron 3, intron 4 
and exon 4 (see 2.2.2.2.3 and Fig 3.2.4.B) as well as the three hybridized loxP sites 
(see 2.2.2.2.4) were subcloned into pPNT as described above (2.1.10.2.4) and 
depicted in Fig. 3.2.4.C. As a final cloning step, the pgk-driven neomycin resistance 
gene (Neo) of the pPNT plasmid was replaced by the En2-SA-IRES-LacZ-Neo-SVpA 
fragment (see 3.2.2) derived from plasmid pGT1,8-IRES-ßGeo (Mountford and 
Skarnes, unpublished; see also Mangold, diploma work, 1995) (Fig. 3.2.4.A). To 
verify correct integration of the subcloned fragments, characteristic restriction 
digestions were performed and the constructs sequenced (data not shown). A 
scheme of the final Sp2 knockout construct pPNT-cSp2ko as well as all pre-
constructs including fragment lengths are depicted in Fig. 3.2.4.C. 
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Fig. 3.2.4. Generation of the Sp2 knockout construct. A. Scheme of the starting plasmid pPNT 
(Tybulewicz et al., 1991) and the plasmid pGT1,8-IRES-ßGeo harbouring the En2-SA-IRES-LacZ-
Neo-SVpA fragment (Mountford and Skarnes, unpublished). B. PCR-amplified genomic fragments 
intron 3 (lane 2+3), intron 4 (lane 4+5) and exon 4 (lane 6+7). M, Lambda 1 marker after EcoRI and 
HindIII digestion (lane 1). 1% agarose gel. C. Scheme of the final Sp2 knockout construct (pPNT-
cSp2ko) and all pre-constructs after NotI linearization. Triangles represent loxP sites. For details, the 
reader is referred to 2.1.10.2.4. 
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3.2.5 Functional analysis of Cre-driven loxP site recombinase capacity 
 
To investigate whether the loxP sites present in the Sp2 knockout construct are 
functional, i.e. whether Cre recombinase is able to delete DNA sequences flanked by 
the loxP sites, a functionality assay in E. coli 294-Cre was performed as described in 
2.2.2.2. For this purpose, the final Sp2 knockout construct pPNT-cSp2ko and the pre-
construct pPNT-IoxP2 were used. Sp2 knockout construct pPNT-cSp2ko contains 
three loxP sites flanking exon 4 and the En2-SA-IRES-LacZ-Neo-SVpA cassette (in 
total 9 kb). Pre-construct pPNT-loxP2 harbours two loxP sites flanking the pgk-driven 
neomycin resistance gene (1.8 kb). Both fragments should be deleted due to Cre 
recombinase expression after transformation into E. coli 294-Cre bacteria. As 
depicted in Fig. 3.2.5, loxP-flanked DNA sequences of both constructs are 
successfully deleted by Cre recombinase, i.e. all three loxP sites are functional. 
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A DH5α Cre pPNT-loxP2 
 
Fig. 3.2.5. Functional analysis of Cre-driven loxP site recombinase capacity. A. E. coli DH5α and 
E. coli 294-Cre bacteria were transformed with either pPNT-loxP2 or the control plasmid pPNT. 
Plasmids were HindIII-digested and separated through a 0.6% agarose gel as indicated. As controls, 
undigested plasmids were loaded. Scheme represents situation before (above) and after Cre 
recombination (below) of pPNT-loxP2 in E. coli 294-Cre. Cre recombination leads to the deletion of 
the floxed Neo cassette (not visible in gel; depicted in brackets) resulting in a remaining 5.4 kb 
plasmid, visible in gel (lane 9). However, when transforming E. coli DH5α with pPNT-loxP2, a ca. 7.2 
kb fragment is expected after linearization (lane 7). In contrast to this, no Cre-driven recombination is 
observed for the loxP-less control plasmid pPNT (lane 5+3). M, Lambda 1 marker after EcoRI and 
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HindIII digestion (lane 1). B. The same experiment, described in (A), was performed with the final Sp2 
knockout construct pPNT-cSp2ko and the loxP-less control plasmid pPNT. Instead of HindIII digestion 
plasmids were linearized by NotI. Expected pPNT-cSp2ko fragment sizes visible in gel are 10.2 kb for 
successful Cre recombination (lane 9) and ca. 19.2 kb without Cre recombination (lane 8). In contrast 
to this, no Cre-driven recombination is observed for the loxP-less control plasmid pPNT (lane 5+4). 
Samples were loaded as indicated. M, Lambda 1 marker after EcoRI and HindIII digestion (lane 1). M1 
pPac-cSp2ko after BamHI digestion (lane 10). 0.4% agarose gel. 
 
 
3.2.6 Sp2 gene targeting in mouse embryonic stem cells 
 
Mouse embryonic stem (ES) cells were transfected with the conditional Sp2 knockout 
construct and selected for homologous recombination as described (2.2.4.5). Positive 
selected clones were tested by Southern Blotting (2.2.2.2.6) for homologous 
integration of the knockout construct (lzn/wt; see also 3.2.2 and 1.5) and used for 
blastocyst injections. Fig. 3.2.6 depicts strategy and results of ES cell genotyping by 
Southern Blot analysis. 
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Fig. 3.2.6. Sp2 gene targeting in mouse embryonic stem cells. A. Southern Blot strategy for ES 
cell genotyping. Wildtype (wt) and targeted (lzn) Sp2 alleles are depicted. A 387 bp probe hybridizes 
with an intronic region downstream of exon 4 (= intron 4). SacI (S) digestion of Sp2 heterozygous ES 
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cell DNA (lzn/wt) should result in a 6.9 kb fragment representing the wildtype allele (wt) and a 3.2 kb 
fragment representing the targeted Sp2 allele exhibiting homologous integration of the conditional Sp2 
knockout construct (lzn). B. Southern Blot analysis of 19 targeted ES cell clones after SacI (S) 
digestion. The 387 bp probe (ES-a-SB) was obtained by PCR amplification using primer Sp2-ES-a-
SB-fw and Sp2-ES-a-SB-rev (2.2.2.2.3). 
 
 
3.2.7 Genotyping of constitutive Sp2 lzn/lzn knockout mice 
 
Targeted embryonic stem (ES) cells were injected into blastocysts and implanted into 
pseudo-pregnant foster mice as described above (1.5 and 2.2.4.5) resulting in 
chimeric mice. Chimeric mice were crossed to heterozygosity (see 1.5 and 3.2.2). 
Sp2 heterozygous mice display one wildtype allele (wt) and one targeted allele (lzn) 
having replaced exon 4 by the conditional Sp2 knockout construct (floxed exon 4 + 
floxed En2-SA-IRES-LacZ-Neo-SVpA cassette). These mice were crossed to 
homozygosity (lzn/lzn) and genotyped by PCR (see 2.2.2.2.3). Fig. 3.2.7 depicts an 
example of genotyped mouse embryos. 
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Fig. 3.2.7. Genotyping of targeted hetero- and homozygous Sp2 mice. A. Scheme of the PCR 
strategy. Annealing region of the three used primers and resulting PCR fragments are depicted for 
wildtype (wt) and targeted Sp2 allele (lzn). Primers MSp2Ex/L3Seq3 (c) and MSp2In2Seq4 (b) allow 
the detection of the Sp2 wildtype allele (0.76 kb fragment), primers Neo (a) and MSp2In2Seq4 (b) the 
detection of the targeted Sp2 locus (1 kb fragment). B. PCR with DNA templates derived from mouse 
embryo tail tips (see 2.2.2.2.1) and primers indicated above demonstrating wt/wt (lane 2), lzn/lzn (lane 
3) and lzn/wt (lane 4) situation. Detailed PCR conditions are described in 2.2.2.2.3. M, Lambda 1 
marker after EcoRI and HindIII digestion (lane 1). 1% agarose gel. 
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3.2.8 Sp2 expression in targeted Sp2 lzn/lzn knockout mice 
 
PCR genotyping (3.2.7) demonstrated the correct targeting of the Sp2 gene in the 
mouse. To verify that the homozygous integration of the construct leads to a 
functional constitutive Sp2 knockout, Sp2 expression in the lzn/lzn mice was 
examined by Northern Blot analysis (3.2.8.1) and RT-PCR (3.2.8.2). Moreover, to 
study Sp2 protein expression during embryonic development, ß-galactosidase activity 
measurements were performed by LacZ stainings (X-Gal, BluoGal) of day E12.5 
mouse embryos (3.2.8.3). 
 
 
3.2.8.1 Detection of a Sp2-lzn fusion mRNA in the targeted mice 
 
To investigate whether the Sp2 knockout strategy leads to the loss of a functional 
Sp2 transcript, Northern Blot analyses were performed with total RNA from 
homozygous (lzn/lzn), heterozygous (lzn/wt) as well as from wildtype (wt/wt) mouse 
embryos (day E18.5). As depicted in Fig. 3.2.8.1, the expected Sp2 transcript of ca. 
2.5-3 kb was detected in wildtype (wt/wt) and a ca. 6-8 kb transcript representing the 
fusion mRNA of the Sp2 exons 1-4 with the IRES-LacZ-Neo-SVpA cassette in 
homozygous (lzn/lzn) embryos. According to this, both transcripts are detectable in 
heterozygous embryos (lzn/wt). 
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Fig. 3.2.8.1. Detection of a Sp2-lzn fusion mRNA in Sp2-targeted mice. Northern Blot analysis. 20 
µg of total RNA from day E18.5 embryos isolated by the LiCl/urea method (see 2.2.2.1.1) were 
separated through a 1% denaturing formaldehyde agarose gel, transferred to a nylon membrane and 
hybridized with a radioactive labeled probe against exon 3-6 (Ex 3-6 NB; see 2.2.2.1.4). 28S and 18S 
rRNA signals on the gel demonstrate comparable RNA loading amounts in all investigated samples. 
Wt, wildtype Sp2 allele; lzn, targeted Sp2 allele. 
 
 
3.2.8.2 Absence of exon 5-8 in the targeted mice 
 
The existence of a Sp2-LacZ-Neo fusion transcript requires to prove the absence of 
exons downstream of the LacZ-Neo cassette (exon 5-8) in this transcript. For this, an 
RT-PCR experiment was performed with RNA derived from fetal liver and brain (day 
E18.5) using primers against exon 5 and 6 (see 2.2.2.1.3). In wildtype but not lzn/lzn 
embryos these primers should anneal within exon 5 and 6, thus resulting in a 228 bp 
PCR fragment. As expected, Fig. 3.2.8.2 demonstrates the presence of exon 5 and 6 
sequences in the wildtype (wt/wt) but not in the targeted (lzn/lzn) fetal transcript. 
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Consistently, a weak 228 bp signal appears with RNA from heterozygous embryos 
(lzn/wt). 
A fw 
 
Fig. 3.2.8.2. Absence of exon 5-8 in the targeted lzn/lzn mice. A. Scheme of RT-PCR strategy. 
Wildtype Sp2 mRNA (wt) and targeted Sp2-lzn fusion mRNA (lzn) are depicted. Exons 1-8 are 
indicated following the colour code of 3.2.1. Arrows represent primer Sp2-Ex5-RT-fw (= fw) and Sp2-
Ex6-RT-rev (= rev) that should amplify exon 5 and 6 in the Sp2 wildtype (wt) but not in the targeted 
(lzn) RNA, resulting in a 228 bp RT-PCR fragment (black beam). B. RT-PCR with RNA obtained from 
liver (Li) and brain (Br) of lzn/lzn (lanes 2-9), lzn/wt (lanes 10-17) and wt/wt (lanes 18-25) mouse 
embryos (day E18.5) using primer Sp2-Ex5-RT-fw and Sp2-Ex6-RT-rev (for detailed information, see 
2.2.2.1.3). As internal reaction control (pc), primers Cyclophillin-fw and -rev directed against 
sequences of the cyclophillin gene were used resulting in a ca. 100 bp fragment. Each reaction was 
performed in duplicates. M, Lambda 1 marker after PstI digestion (lane 1). 1.6% agarose gel. 
 
 
3.2.8.3 Endogenous Sp2 expression in mouse embryos 
 
To determine Sp2 expression pattern during embryogenesis, ß-galactosidase activity 
in day E12.5 mouse embryos was investigated by X-Gal and BluoGal staining of 
lzn/lzn, lzn/wt and wt/wt embryos (see 2.2.4.7). Lzn/lzn embryos are characterized by 
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integration of the conditional knockout construct at the Sp2 locus of both alleles (see 
1.5 and 3.2.2), thus exhibiting the ß-galactosidase gene (LacZ) under the control of 
the endogenous Sp2 promoter. If the Sp2 promoter is active in these embryos, the 
LacZ gene is expressed and ß-galactosidase activity can be detected by X-Gal or 
BluoGal stainings of the embryos. Thus, all blue-stained embryonic tissues or body 
regions display Sp2 expression. On the other hand, lzn/wt embryos exhibit 
homologous integration of the conditional Sp2 knockout construct only on one allele. 
For this, a weaker ß-galactosidase activity should be observed. In contrast to that, no 
activity should be detected in homozygous wildtype (wt/wt) embryos. Fig. 3.2.8.3 
demonstrates that Sp2 is widely expressed in day E12.5 embryos. Moreover, the 
intensity of X-Gal and BluoGal staining is lower in the heterozygous lzn/wt and 
absent in the wt/wt embryos, as expected. 
A 
 
Fig. 3.2.8.3. LacZ expression in day E12.5 mouse embryos. Lateral view of day E12.5 mouse 
embryos. Blue colour represents ß-galactosidase activity, i.e. Sp2 expression in the corresponding 
tissue or body region. Wt, wild type Sp2 locus; lzn, targeted Sp2 allele. A. X-Gal staining. B. BluoGal 
staining. 
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3.2.9 Preliminary characterization of targeted Sp2 lzn/lzn mice 
 
Two aspects were investigated to characterize Sp2 lzn/lzn knockout mice being 
available at the end of the thesis period: viability (3.2.9.1) and the occurrence of 
growth abnormalities during embryonic development (3.2.9.2). 
 
 
3.2.9.1 Post- and pre-natal viability of targeted Sp2 lzn/lzn mice 
 
Heterozygous Sp2 (lzn/wt) knockout mice are viable, reproduce normal and display 
no obvious phenotype after birth. Also no obvious abnormalities during embryonic 
development were detectable. In contrast to this, homozygous Sp2 lzn/lzn knockout 
mice exhibit a strongly reduced viability: only 1 out of 73 born mice are lzn/lzn (Tab. 
3.2.9.1). This embryo died during the first weeks after birth (Nynke Gillemans, 
personal communication). To find out whether homozygous Sp2 lzn/lzn knockout 
mice already die during embryonic development, embryos of three different 
developmental time points (E18.5, E12.5 and E9.5) were analyzed. As depicted in 
Tab. 3.2.9.1, Sp2 lzn/lzn embryos exhibit a normal Mendelian distribution at all three 
time points. Thus far, no dramatic effect of Sp2 protein deficiency on viability is 
visible in these animals. However, Sp2 lzn/lzn embryos at day E18.5 slightly deviate 
from the Mendelian distribution but probably due to the low number of analyzed 
samples. 
 
 Sp2 lzn/lzn Sp2 lzn/wt Sp2 wt/wt total number
born 
day E18.5 
day E12.5 
day E9.5 
 
expected 
distribution 
1 (1.4%) 
10 (18.5%) 
14 (24.6%) 
7 (24.1%) 
 
 
25% 
52 (71.2%) 
31 (57.4%) 
31 (54.4%) 
15 (51.7%) 
 
 
50% 
20 (27.4%) 
13 (24.1%) 
12 (21.1%) 
7 (24.1%) 
 
 
25% 
73 
54 
57 
29 
 
 
 
 
Tab. 3.2.9.1. Post- and pre-natal viability of targeted Sp2 lzn/lzn mice. Genotype distribution in [n] 
and [%] of either new-born Sp2 mice or day E18.5, E12.5 and E9.5 embryos. Mouse genotyping was 
performed as described in 3.2.7 and 2.2.2.2.3. Wt, wildtype Sp2 allele; lzn, targeted Sp2 allele. 
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3.2.9.2 Reduced growth in day E18.5 Sp2 lzn/lzn embryos 
 
Consistent with the findings, that Sp2 deficiency influences viability of new-born and 
probably also day E18.5 embryos, a significant reduction in body size and weight of 
day E18.5 Sp2 knockout (lzn/lzn) embryos compared to wildtype (wt/wt) and 
heterozygous (lzn/wt) embryos is detectable, however with a strong variation (Fig. 
3.2.9.2.A-B). This reduction is associated with a developmental retardation, at least 
in some of the lzn/lzn embryos (see Fig. 3.2.9.2.B). In addition, the body size at 
earlier developmental time points (E12.5 and E9.5) was determined. However, no 
statistically significant differences between knockout and wildtype or heterozygous 
embryos were observed (Fig. 3.2.9.2.A+C). This favours the conclusion that Sp2 
deficiency effects normal mouse development in later embryonic stages (at least 
E18.5). However, the mechanisms leading to this Sp2-based abnormal development 
have to be explored. 
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Fig. 3.2.9.2. Growth reduction in day E18.5 Sp2 lzn/lzn embryos. A. Weight [mg] and size 
distribution [mm] in day E18.5 mouse embryos as well as size distribution in E12.5 and E9.5 mouse 
embryos. Wt, wildtype Sp2 allele; lzn, targeted Sp2 allele. N, number of analyzed embryos per each 
developmental time point. B. Example of wildtype (wt/wt) and Sp2-targeted (lzn/lzn) mouse embryos 
of embryonic day E18.5. Lateral view. C. Examples of wildtype (wt/wt) and Sp2-targeted (lzn/lzn) 
mouse embryos of embryonic day E9.5. Lateral view. 
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4. Discussion 
 
4.1 Structure comparisons between Sp2 and the glutamine-rich family 
members Sp1, Sp3 and Sp4 
 
Many data exist supporting the fundamental importance of the glutamine-rich Sp 
family members Sp1, Sp3 and Sp4 in a diverse set of biological processes (Philipsen 
and Suske, 1999; Bouwman and Philipsen, 2002). However, until now, such 
information lacks for the transcription factor Sp2, which represents the less 
conserved member of the glutamine-rich Sp subgroup. The studies reported herein 
were conducted to initiate the characterization of structural and functional properties 
of the transcription factor Sp2 on the molecular as well as on the physiological level. 
 
Concerning the gene and protein structure, our analyses demonstrate high 
similarities between transcription factor Sp2 and the glutamine-rich family members 
Sp1, Sp3 and Sp4. The Sp2 gene is characterized by a similar exon-intron structure 
as it is described for these factors. The two most downstream exons of the Sp2 gene 
(exon 7 and 8; see Fig. 3.2.1.B) encode the characteristic DNA-binding domain, a 
large central exon (exon 4) codes for the two glutamine-rich and serine/threonine-rich 
domains, and the exons upstream of exon 4 encode the N terminal part of the 
protein. 
 
Specific for the Sp2 gene is the existence of two exons (exon 5 and 6; see Fig. 
3.2.1.B) encoding the protein region between domain B and the DNA-binding 
domain. In Sp1, Sp3 and Sp4 this region is encoded by only one exon. Whereas 
exon 6 encodes the so-called Btd box (see 1.4 and 3.2.1) and displays homology 
towards the corresponding exon in the remaining glutamine-rich Sp members (Sp1, 
Sp4: exon 4; Sp3: exon 5; see Fig. 3.2.1.B), the evolution and function of exon 5 has 
to be clarified. However, it is conspicuous that the length of exon 5 plus exon 4 
together (the latter encoding domain A and B and being smaller in size as the 
corresponding gene in Sp1, Sp3 and Sp4) is comparable with the length of the exon 
encoding domain A and B in Sp1, Sp3 and Sp4. Supposing Sp2 as the evolutionary 
most basal factor among the glutamine-rich Sp factors (Kolell and Crawford, 2002; 
Suske, 1999), it might be that the large exon coding for the transactivation domains 
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in Sp1, Sp3 and Sp4 evolved from two individual exons. Whether Sp2 exon 5 
displays specialized function, has to be explored. 
 
Also specific for the Sp2 gene is one exon, which is present in the human cDNA 
upstream of exon 3 but not in the published mouse cDNA sequences. Whether this 
exon exists in mouse and whether it is target of alternative splicing has to be 
determined. The occurrence of alternative splicing of the third exon in Sp3 (Krüger, 
diploma work, 2002) could be a hint that such an event is also expectable for Sp2. 
 
In addition, two potential exons upstream to exons 1 (the latter harbouring the 
translation start codon; see Fig. 3.2.1.A) were identified in Sp2 by alignment with the 
mouse cDNA NM_030220. Although these exons also contain several AUG codons, 
the reading frames are closed by stop codons. Moreover, they are not present in the 
other Sp2 cDNAs. Thus, it remains to be clarified whether these are “real” exons. 
 
Apart from these structural differences on the gene level, the similarities in the exon-
intron structure as well as the corresponding functional protein domains support the 
relationship between Sp2 and the glutamine-rich family members Sp1, Sp3 and Sp4. 
On protein level, Sp1-4 share several functional domains like the aforementioned 
highly conserved DNA binding domain, a stretch of 81 amino acids forming three 
C2H2 zinc fingers, and the glutamine- and serine/threonine-rich regions. Contrary to 
previous reports (e.g. Kingsley and Winoto, 1992; Bouwman and Philipsen, 1992), 
Sp2 protein also possesses two glutamine-rich domains (domain A and B) and two 
serine/threonine-rich regions. 
 
Different to the glutamine-rich Sp factors is the lack of the D domain in Sp2, a region 
located C-terminally to the zinc fingers. In Sp1, domain D together with the two 
transactivation domains A and B are required for a synergistic transcription activation 
by binding to multiple sites (Pascal and Tjian, 1991). In theory, this function should 
be absent in Sp2. However, its ability to form multimers via the glutamine-rich B 
domain like in Sp1 (Pascal and Tjian, 1991) should be present. As a result of the 
absence of the D domain, the Sp2 protein is shorter in size as Sp1, Sp3 and Sp4. 
This again supports its evolutionary most distant position within the glutamine-rich Sp 
subgroup. 
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To summarize the analysis of the mouse Sp2 gene and protein structure, it is to 
retain that Sp2 protein shares many of the characteristic structural features with the 
related glutamine-rich Sp family members Sp1, Sp3 and Sp4 like DNA binding and 
glutamine-rich domains. However, as described above, also differences are observed 
when comparing protein and gene structure. Nevertheless, the assumption that Sp2 
should not be recognized as a member of the Sp family, which is favoured by Kolell 
and Crawford (2002) based on the H→L substitution in the first zinc finger and the 
assumed absence of domain A, can be excluded. Whether and how the structural 
distinctions influence the functional specificity of Sp2 has to be unravelled. The 
results of the functional in vitro and in vivo studies presented in this thesis work 
suggest that these structural differences indeed affect Sp2 function (as it will be 
discussed in the following chapters). 
 
 
4.2 Regulation of Sp2 DNA binding capacity and transactivation properties 
 
When initiating this thesis work, no functional data about the transcription factor Sp2 
were available. To analyze Sp2 function, the ability of Sp2 to activate reporter gene 
expression was investigated. Based on the structural similarities towards the other 
glutamine-rich family members (zinc finger domain, glutamine-rich regions, etc.) and 
the results from expression and subcellular localization studies, a similar binding 
affinity towards the classical Sp1 binding site (GC box) was expected. Therefore, 
reporter constructs were used, in which the expression of the reporter gene was 
controlled by a promoter containing Sp1 binding sites. However, no Sp2-driven 
activation was detectable. 
 
Investigation of the Sp2 capacity to bind to GC-box-containing DNA sequences 
resulted in the finding that full-length Sp2 protein –although highly expressed– is 
unable to bind to the classical Sp1 binding site. Also when using DNA sequences 
harbouring other binding motifs, full-length Sp2 failed to bind. However, when 
analyzing N-terminally truncated Sp2 protein fragments, it turned out that those 
fragments lacking the first 179 N-terminal amino acids are able to bind DNA (GC 
boxes). This led to the assumption that the N terminus somehow is involved in the 
regulation of Sp2 DNA binding capacity and that the exchange of a critical amino acid 
in the first zinc finger does not influence sequence specificity as it was previously 
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postulated (e.g. Kingsley and Winoto,1992; Moorefield, 2004). Yet, although binding 
DNA, the N-terminal Sp2 deletions did not activate reporter gene expression. 
 
Unexpected results were obtained, when C-terminally truncated, zinc-finger-less Sp2 
deletion mutants were fused at the N terminus to a Gal4 DNA-binding domain. Those 
Sp2 fragments containing the first 179 N-terminal amino acids were able to bind the 
Gal4 DNA-binding site but exhibited an extremely retarded migration in gel 
electrophoresis (see Fig. 3.1.5.7.B). However, when analyzing a Gal4-Sp2 fusion 
protein fragment lacking these amino acids, no binding signal for this fragment was 
detectable. In addition, compared to a Gal4-Sp1 control, the Gal4-Sp2 deletions did 
not activate reporter gene expression. 
 
These results suggest that a putative regulatory function is not only restricted to the 
N-terminal part of the Sp2 protein but also involves a region located around the B 
domain. Assuming this, three questions arise that should be discussed: (1) What is 
the general nature of the regulating mechanism; (2) why are the Gal4-Sp2 fusions 
containing the N-terminus as well as the region around the B domain (e.g. fragment 
Gal4-Sp2 (aa6-471)) still able to bind DNA; and (3) why does a N-terminal deletion of 
the first 206 amino acids (fragment Sp2 (aa207-606)) rescue from binding inhibition 
but not when the same Sp2 fragment is fused at the N terminus to a Gal4 DNA-
binding domain (fragment Gal4-Sp2 (aa207-471))? 
 
Regarding the general mechanisms regulating Sp2 DNA binding activity, several 
putative alternatives are imaginable, including regulation by posttranslational 
modification and/or protein-protein interactions, either inhibiting or activating the DNA 
binding capacity. As data bank research for known protein modification or interaction 
motifs in the Sp2 sequence did not reveal any helpful information, the further 
discussion is rather speculative. 
 
Regulation of protein activity by posttranslational modifications is a well-known 
mechanism and examples can be found within the Sp family members. Transcription 
factor Sp1 activity, e.g., is regulated by phosphorylation and glycosylation. 
Depending on cell type and stimuli, phosphorylation of Sp1 protein can either 
increase (e.g. Merchant et al., 1999; Rohlff et al., 1997), decrease (e.g. Armstrong et 
al., 1997; Borellini et al., 1990; Leggett et al., 1995), or not affect (Jackson et al., 
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1990) Sp1 DNA binding activity. Reduced O-GlcNAcylation of Sp1 protein is reported 
to result in a decreased Sp1 binding activity (Han and Kudlow, 1997). However, other 
reports correlate increased O-GlcNAcylation of Sp1 protein with a positive (Han and 
Kudlow, 1997; Du et al., 2000) or negative (Yang et al., 2001) regulation of Sp1 
activity. 
 
Another possibility of regulating Sp factor activity by posttranslational modification is 
the inhibition of Sp3 transactivity by SUMO. SUMO regulates Sp3 transactivation 
capacity by attaching to a critical lysine residue within an inhibitory domain (Dennig et 
al., 1996; Sapetschnig et al., 2002). Based on its functional variety (reviewed in 
Seeler and Dejean, 2003), it is conceivable that SUMO also regulates DNA binding 
specificity of transcription factors. However, no classical SUMO site is present in the 
Sp2 protein. 
 
Whether and how Sp2 DNA binding capacity is regulated by posttranslational 
modifications has to be explored. Western Blot analyses of endogenous Sp2 
expression in various cell lines resulted in two differently migrating protein species 
detected by the Sp2-specific antiserum (see Fig. 3.1.2.1-2). Apart from reflecting the 
existence of alternative splice variants or translationally controlled protein isoforms, 
this might also be a hint for posttranslational modifications. It is conceivable, that a 
modification influences protein conformation and by this enables the interaction of 
Sp2 protein with the DNA. On the other hand, it is possible that a modification like 
e.g. glycosylation somehow masks the zinc finger domain thus preventing Sp2 from 
binding. However, it is difficult to explain, why the deletion fragment Sp2 (aa207-606) 
is able to bind DNA whereas the same construct N-terminally fused to a Gal4 DNA-
binding domain is unable to interact. 
 
Another putative mechanism regulating Sp2 DNA binding capacity would be based 
on protein-protein interactions. An interacting protein could either function as 
activator or inhibitor of Sp2-DNA interaction. Our results obtained from DNA binding 
studies with N-terminal truncated Sp2 protein fragments would suggest the existence 
of an inhibitory protein binding within the first 179 N-terminal amino acids of Sp2 
protein. This inhibitor could prevent Sp2 from binding to DNA by conformational 
changes and/or by masking the zinc finger domain. As described above, our results 
obtained from the Gal4-Sp2 studies, however, indicate that also a region around the 
 115
B domain is involved in the regulation process. Moreover, the fact that Sp2 DNA 
binding inhibition occurs as well in insect (Drosophila SL2) and mammalian (HEK-
293) cells favours the existence of a protein that is highly abundant. 
 
During the period of this thesis work, Horowitz and co-workers published results on 
transactivation and DNA binding properties of Sp2 (Moorefield et al., 2004). 
Consistent with our findings, they observed that SL2-overexpressed Sp2 protein does 
not or at the most very weakly activate the Hamster DHFR promoter. According to 
this, Sp2 protein that has been overexpressed by recombinant baculoviruses in Sf9 
insect cells did only bind to these sequences when being used in a 20-50 fold excess 
compared to Sp1- or Sp3-containing extracts. Also when using several GC-rich 
oligonucleotide variants, Sp2-DNA interactions remained comparably low. In addition, 
Sp2 protein was observed to be expressed in many human and mouse cell lines. 
However, no or only low binding affinity was apparent in extracts prepared from these 
cells. When incubating recombinant Sp2 protein derived from baculovirus-infected 
Sf9 cells with increasing amounts of the mammalian cell extracts before analyzing its 
DNA binding activity, the weak interactions between DNA and the recombinant Sp2 
protein could be totally blocked. Western Blot analyses of the extract mixes 
demonstrated that the loss of DNA binding capacity was not due to Sp2 protein 
degradation. From this, Horowitz and co-workers concluded that Sp2 DNA binding 
activity is inhibited by one or more proteins in mammalian cells, thus supporting our 
results. By protein-protein binding assays, two interacting proteins were identified, a 
84 kDa protein (p84) specifically binding to the glutamine-rich domains of Sp2 and a 
74 kDa protein (p74) also binding to the transactivation domains of Sp1 and Sp3. 
Whereas p84 function is unclear, p74 is reported to decrease the transactivation 
capacity of at least Sp1 (Murata et al., 1994). Whether p74 also negatively influence 
the Sp2 DNA binding capacity and whether it functionally interacts with p84, has to 
be explored. Moreover, Horowitz and co-workers could not prove whether p84 
inhibits Sp2-DNA interactions. 
 
Besides the regulation by one or two inhibitory proteins binding to two distinct sites 
within the Sp2 protein, it is also conceivable that one protein contacts Sp2 by two or 
more binding sites, e.g. within the first 179 N-terminal amino acids as well as the N-
terminal part of the B domain. As depicted in Fig. 4.2, the DNA binding incapability of 
Sp2 fragments containing the first 179 N-terminal amino acids on the one hand and 
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the ability for DNA interactions of those fragments lacking these amino acids on the 
other hand thus would be explainable. Assuming one contact sequence being located 
around the B domain, it could be suggested that a small percentage of the fragments 
Sp2 (aa180-606) (not depicted here) and Sp2 (aa207-606), which contain parts of 
the sequence, still interact with the inhibitor. This would explain the gradual effect 
observed in gelelectrophoresis for these fragments in comparison to the fragments 
completely lacking the N-terminal part of domain B (see Fig. 3.1.5.6). 
 
Fig. 4.2. Hypothetical regulation model of Sp2-DNA interactions. A. This model suggests the 
existence of an inhibitory protein (depicted in green) regulating Sp2-DNA interactions. The inhibitor 
contacts Sp2 through two putative binding sites located at the N-terminal parts of domain A and B. 
Probably due to conformational changes and/or masking of the zinc finger domain, this prevents Sp2 
from contacting the DNA. In the case of Gal4-Sp2 (aa207-471), the inhibitor protein binds to the N-
terminal region of the B domain of each individual Gal4-Sp2 molecule dimerized through the Gal4 
DNA-binding domain. These interactions mask the Gal4-DNA binding sites thus leading to DNA 
binding incapability. Dotted lines represent putative interactions between two inhibitor molecules. B. In 
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the fragment Sp2 (aa207-606), the inhibitor is unable to bind (indicated as red cross) due to the lack of 
the second binding site. This can not be compensated by either a second inhibitor molecule or the 
Gal4 DNA-binding domain like in the corresponding Gal4 fusion fragment. The interaction with the 
dimerized Gal4-Sp2 (aa6-471) fragments should not influence their DNA binding capacity but results 
in a reduced mobility of the fragments during gelelectrophoresis due to the interaction with the two 
inhibitor proteins. A-B. Green ellipse point out the N-terminal amino acids being present in the Sp2 
deletion mutants exhibiting no DNA binding capacity in EMSA experiments (see 3.1.5.6). 
 
Whereas GC boxes can be bound by transcription factor monomers, the Gal4 binding 
sites require dimerization, which occurs through the Gal4 DNA-binding domain. 
Assuming an inhibitory protein, which also contacts sequences of the B domain, it 
can be postulated for the Gal4-Sp2 (aa207-471) fragment that the inhibitor binds to 
the N-terminal region of the B domains of each fusion fragment. This could either 
impede the dimerization process due to steric reasons or could mask the dimerized 
Gal4 DNA-binding domains and prevent them from interacting with the DNA. As the 
unfused fragment Sp2 (aa207-606) appears not to interact with the inhibitory protein, 
it could be assumed that a Gal4-Sp2 (aa207-606) monomer would also be unable for 
this interaction. Only when being dimerized this interaction should be possible. Thus, 
the inhibitor should not prevent from dimerization but impede Gal4-DNA interactions 
by masking the Gal4 DNA-binding domain. 
 
Regarding the situation for those Gal4-Sp2 fusions including the first 179 N-terminal 
amino acids (e.g. Gal4-Sp2 (aa6-471)): Assuming an inhibitor, which binds within the 
first 179 N-terminal amino acids as well as the N-terminal part of the B domain, such 
an effect as described for Gal4-Sp2 (aa207-471) should not be expected. Here, the 
Gal4 DNA-binding domain should remain unmasked because both transactivation 
domains of Sp2 (A and B) are accessible for the inhibitor. In addition, the ability of 
these Sp2 fragments to bind to DNA although interacting with the inhibitor could also 
explain the reduced mobility observed in gelelectrophoresis (see Fig. 3.1.5.7). 
 
In addition to the Sp2-DNA interaction studies with unfused or Gal4-fused truncated 
Sp2 protein fragments, transactivation assays were performed using those fragments 
being able to bind to the GC boxes. However, although binding to DNA, these 
fragments were unable to activate reporter gene expression on different GC-box-
containing promoters. 
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This could be explained by the lack of one transactivation domain in the analyzed 
protein fragments Sp2 (aa180-606), Sp2 (aa207-606), Gal4-Sp2 (aa6-215), Gal4-
Sp2 (aa207-606) or the occupancy of the transactivation domains in the Gal4-fused 
Sp2 fragments including the first 179 N-terminal amino acids (Gal4-Sp2 (aa6-471), 
Gal4-Sp2 (aa6-357)). However, it is reported for Sp1 that one activation domain is 
sufficient for transactivation (Courey and Tjian, 1988). This would favour a repressing 
function of transcription factor Sp2 in the regulation of gene expression. 
 
During the period of this thesis work, Phan et al. (2004) postulated a repressive 
function of transcription factor Sp2 on the expression of the carcinoembryonic 
antigen-related cell adhesion molecule 1 (CEACAM1) in prostate cancer cells. A 
repressive function of Sp2 would support the results presented here in this thesis. 
Their statement was based on the detection of an increased Sp2 expression level 
along with a decreased CEACAM1 expression in prostate cancer cells. Sp2 
expression was detected by using the Sp2-specific Santa Cruz antibody no. sc-643 
(Santa Cruz Biotechnology; USA: Santa Cruz). When trying to detect recombinant 
Sp2 protein by the related Sp2-specific Santa Cruz antibody no. sc-17814 during this 
thesis work, we observed that the antibody does not detect the recombinant protein 
(data not shown). In addition, when analyzing Sp2 protein expression in mouse 
tissues, the antibody detected a protein, which is smaller in size than expected for 
Sp2. This could also be observed for the expression data presented by Phan et al. 
(2004). From this, it can be concluded that the Santa Cruz antibody no. sc-643 might 
also be unable to detect the Sp2 protein. Therefore, the results of Phan et al. have to 
be interpreted cautiously. 
 
In summary, our data suggest a regulation of the Sp2-DNA interaction capacity and 
by that its function as regulator of gene expression. Although exhibiting structural 
similarities like the highly conserved DNA-binding domain, the individual glutamine-
rich Sp family members display a high functional specificity as demonstrated by the 
different knockout phenotypes. The functional specificity is achieved e.g. by 
differences in expression pattern or posttranslational modifications (Bouwman and 
Philipsen, 2002). The regulation of Sp2-DNA interaction capacity probably represents 
a further mechanism leading to this functional specificity. 
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Further steps in analyzing the mechanisms of Sp-DNA binding and transactivation 
regulation could be the attempt to narrow down the putative inhibitor binding sites by 
generating further deletion mutants. In addition, a yeast-two-hybrid screen for 
proteins interacting with the putative binding regions could be a valuable approach. 
On the other hand, the investigation of Sp2 posttranslational modifications should be 
performed. Moreover, a focus should also be directed on the analysis of Sp2-DNA 
interactions in vivo by ChIP assays. 
 
 
4.3 Sp2 is essential for normal mouse development 
 
To unravel the biological function of Sp2, Sp2-targeted mice were generated. These 
mice are characterized by the insertion of a LacZ-Neo cassette downstream of exon 
4, which encodes the two glutamine-rich domains A and B. The insertion results in a 
fusion transcript consisting of the Sp2 exons 1-4 and the LacZ-Neo mRNA. RT-PCR 
experiments demonstrated that the exons 5-8 are absent in the Sp2-LacZ-Neo (Sp2-
lzn) fusion transcript. It is expected that translation of the Sp2-lzn transcript leads to 
an non-functional Sp2 protein fragment. However, Western Blot analyses of Sp2-
targeted and wildtype mouse tissue extracts (day E18.5) did not allow to distinguish 
between the targeted and the wildtype Sp2 protein (data not shown). From this, it has 
to be concluded that the translated Sp2-lzn transcript includes IRES and LacZ 
sequences at the C terminus, thus being similar in size as wildtype Sp2 protein. To 
confirm that the LacZ-Neo insertion reflects Sp2 deficiency and to determine putative 
differences between the Sp2 lzn/lzn and a Sp2 -/- phenotype, the generation of Sp2 
knockout mice based on exon 4 deletion by crossing Sp2 lzn/lzn with Cre 
recombinase-expressing mice is in progress. 
 
Regarding the Sp2 lzn/lzn phenotype: Whereas heterozygous Sp2-targeted mice 
(Sp2 lzn/wt) do not differ from wildtype animals, homozygous targeted mice (Sp2 
lzn/lzn) display a clear phenotype: only one out of 73 born mice was lzn/lzn. This 
animal died within the first weeks after birth. To find out whether Sp2 lzn/lzn mice 
already die during embryonic development, mouse embryos of day E18.5, E12.5 and 
E9.5 were investigated. Whereas embryos appear normal until day E12.5, Sp2 
lzn/lzn embryos at day E18.5 display a significant reduction in body size and weight, 
however with a strong variation. This favours the conclusion that the mutation of the 
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Sp2 gene effects normal mouse development at least at later embryonic stages. As 
Sp2-targeted mice were only available at the end of this thesis work, a detailed 
analysis of the mechanisms leading to the abnormal development could not be 
performed. For this, further studies are required. 
As discussed above, Sp2 is closely related to the glutamine-rich Sp family members 
Sp1, Sp3 and Sp4, all of them recognizing the same DNA elements. However, the 
essential biological functions appear to be different. Whereas Sp1 mutant embryos 
are already severely retarded in the early development and die around day E10.5 of 
gestation (Marin et al., 1997), Sp3-deficient mice develop normal until birth but die a 
few minutes post-natum due to respiratory failure (Bouwman et al, 2000). In addition, 
they are characterized by abnormalities in tooth and bone development (Bouwman et 
al., 2000; Göllner et al, 2001b) and an impaired hematopoiesis (Van Loo et al., 
2003). Disruption of the Sp4 gene revealed that Sp4 also is important for early post-
natal survival since approximately two-thirds of the Sp4-deficient mice die within the 
first weeks after birth for unknown reasons (Göllner et al., 2001a). Surviving mice are 
growth retarded and either exhibit a pronounced delay in sexual maturation (females) 
or an abnormal reproduction behaviour (males). 
 
Although displaying different phenotypes, overlapping functions of the individual Sp 
family members might exist in vivo. This is supported e.g. by the observation that 
Sp3 mRNA is up-regulated in Sp4-deficient mice suggesting a functional 
compensation of Sp4 deficiency by increased Sp3 levels (Göllner et al., 2001a). The 
existence of a certain functional redundancy within the glutamine-rich Sp family 
members could explain why loss of Sp2 does not visibly affect the early mouse 
development (at least until day E12.5). 
 
Another possible explanation for this is based on the assumption that the interaction 
between transcription factor Sp2 and its corresponding DNA binding site in a 
promoter is a regulated process (see 4.2). Although widely expressed in mammals, 
Sp2 thus might control the expression of only a well defined set of genes at certain 
developmental time points or under distinct cellular or environmental conditions 
depending on the nature of the regulating mechanism. This functional specificity 
could be a reason why the effect of Sp2-deficiency is not visible at the early stages of 
development and not in all of the day E18.5 embryos. 
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To elucidate the reasons for the abnormal development of the targeted animals, a 
detailed histological analysis of the E18.5 Sp2 lzn/lzn embryos is required. As well, 
day E16.5 and E14.5 embryos should be examined to determine whether an 
influence of Sp2 deficiency is also observed at this stage of development. 
Additionally, as mentioned before, the generation of Sp2 knockout mice based on the 
complete deletion of exon 4 and the comparison with the lzn/lzn phenotype should be 
performed. Moreover, as the deletion of transcription factor Sp2 leads to lethality, the 
generation of tissue- or time-point-specific conditional knockout mice is necessary to 
unravel precisely its role in adult mice. Thus far, our results demonstrate that the loss 
of transcription factor Sp2 has an tremendous effect on the normal development and 
viability of the mouse. 
 
In addition to the experiments proposed above, two other approaches should be 
performed in future: On the one hand, the occurrence or influence of redundancy in 
the Sp2 mouse phenotype due to the further individual Sp family members should be 
investigated by the generation of double or compound Sp knockouts. On the other 
hand, a second aim should be the identification of Sp2 target genes by the 
microarray technique. 
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6. Appendix 
 
6.1 Abbreviation index 
 
Additionally to the usual SI and IUPAC units, the following shortcuts were used: 
 
A 
APS 
ATP 
bp 
BSA 
C 
°C 
CAT 
cDNA 
cpm 
dATP 
dCTP 
Del 
DEPC 
DMEM 
DMSO 
DNA 
dNTP 
DTT 
EDTA 
EGTA 
ES cells 
FBS 
Fig. 
fw 
G 
G418 
HA 
HEPES 
Adenosin 
Ammonium peroxodisulfate 
Adenosin triphosphate 
base pairs 
Bovine serum albumine 
Cytidin 
degree Celsius 
Chloramphenicol acetyl transferase 
complementary DNA 
counts per minute 
desoxy Adenosin triphosphate 
desoxy Cytidin triphosphate 
deletion 
Diethylpyrocarbonate 
Dulbecco’s modified Eagle’s medium 
Dimethylsulfoxide 
Desoxy ribonucleic acid 
desoxy nucleotide triphosphate 
Dithiothreitol 
Ethylenediamine-tetraacetic acid 
Ethyleneglycol-tetraacetic acid 
embryonic stem cells 
Fetal bovine serum 
Figure 
forward 
Guanosin 
Neomycin analogon G418 
Haemaglutinine 
4-(2-Hydroxyethylene)-1-Piperazineethansulfonate 
 135
hsv-TK 
HTLV 
IPTG 
kb 
kDa 
Luc 
lzn 
mRNA 
Neo 
nt 
OD 
PAA 
PAGE 
PBS 
PCR 
pgk 
PMSF 
PVDF 
RNA 
rev 
RNase 
rpm 
SDS 
SSC 
SV40 
T 
TBE 
TE 
TEMED 
Tris 
U 
V 
v/v 
wt 
w/v 
herpes simplex virus Thymidine Kinase 
Human T-cell Lymphotrophic Virus 
Isopropyl-ß-D-galactoside 
kilo base pairs 
kilo Dalton 
Luciferase 
LacZ-Neo (targeted Sp2 allele) 
messenger RNA 
Neomycin resistance gene 
nucleotide 
optical density 
Polyacrylamide 
Polyacrylamide Gel Electrophoresis 
Phosphate buffered saline 
Polymerase chain reaction 
phosphoglycerate kinase promoter 
Phenylmethylsulfonylfluoride 
Polyvinylidendifluoride 
Ribonucleic acid 
reverse 
ribonuclease 
revolutions per minute 
Sodium dodecyl sulfate 
SDS sodium citrate buffer 
Simian Virus 40 
Thymidine 
Tris borate EDTA buffer 
Tris EDTA buffer 
Tetramethylethylendiamin 
Tris-hydroxy-methyl-amino-methane 
Unit (enzyme activity) 
Volt 
volume per volume 
wildtype 
weight per volume 
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6.2 Mouse Sp2 genomic DNA and cDNA sequences 
 
Mouse Sp2 genomic DNA sequence; Celera access. no. 
mCG13240 
 
Exon identification via alignment of the genomic Celera mouse Sp2 DNA 
sequence with two mouse (NCBI access. no. BC021759 and NM_030220) 
and two human (NCBI access. no. BC016680 and D28588) Sp2 cDNA 
sequences. 
 
 
9001   ATGAAGACCT GAGTTCATAT CTCCAGTACC CATGTCAAAA ACAGTGTGCA CATTCATAAC 
9061   CCAGGTTCGG GGAAGGTGGA GACAGAAGGG TTTACTGGCC CCAGTCTAGC TGAATCTGCA 
9121   GGTTCTGGTT CAATGAGAGA CTGAGGACAA CTATCGCCTT CTTATGACCA TATGCACACA 
9181   CATGTGCTTG TACCAGAACT CACANNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN 
9241   NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN 
9301   NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN 
9361   NNNNNNNNNN NNNNNNNNNA TGTCTTCGGC GCTCAGCGCT TACACTGTCC CCTGGCTAAG 
9421   CCTTCCTTAA CTAAGGCCCT CTGTCCTCAG AACTGCAGGT GGTTTGGACC AAGTCCTGAG 
9481   TCTTCCCTGC ATTGAGGTGA TGGCTGCCAG GCAGAGCGGG ATGGGCAGTA AGTATGTGGG 
9541   TCTGGGTACA GAGGAAAGGA CAGGAGTGCC GTCCTACAAA TTATGCTATC ATCAATTCAC 
9601   TGTGACCTCA GCCAACTCCA GCACCTTCTC GAGCCTTGGT TTCCCCTGGT CATAAAATAT 
9661   GGGGTTAATT GTCCCTCCTA GGGAAGCTGG GAGGGTTAAT TGGGCAATGG CTCTGAAGAG 
9721   AAGGAGATCT ATAAATACAA GGGATCATTA GAGGGTATTT CACAGCCGTT TTGTGGCCCC 
9781   GATGGTATTA TTAATATGAT TATTGTTATT GTTATCGCCA CCATCACCCA CTTCCCGAGT 
9841   CTCTGCCAGC TGGGTCCTGC TTCCAGGTGA AGGAGCTCTG CCAACAGCCT CTGTGACCCT 
9901   CCACCCTCAG GAGTGTCGGG GACCCCTCAG GAGGTTATTT CATTGTGGCA TTACAGAGGG 
9961   GGTCAAGAGC TTTAAGGGGA GGGGGTGAGG GGACGTGCCA TGCTTGCTTA GTGAGGGCTA 
10021  AAGGCTTTTA GTCCAGGGAT GACCCTGGTC TGCTGTGGGA AGCCTGGACT CGAGAAGCCT 
10081  GATGGCTCCA TGGAAATGTG CTCATGGTGA GGAGAGGGCC AGCAGGAGTT TGAGGGGATG 
10141  GTGTTTTCTG GGACGCTGAG GGACGGGCAG ATGGGGATGT GCTCTCTTGA GGAGGCAAAT 
10201  GGCTCTTCTT AAAGGAATCT CTTTGTAGGG GTCCTAGGAT TCTTAAGGCC TGGGGATGAA 
10261  GGACGGCCTA GGCTGGCCAA TAGTAGGCCC AGAATATCCA CCAGGTTATC TGTGTTTCCT 
10321  CCTTTGGGCA TGTAAAACCA CGGTCAGGGG CTTCTGAAAT GCCTTGGGTG CCCTCTGGCG 
10381  GCAACACGTG AGTGCTACAG AGGACCAACA CCTGCCCAGA GAGCACCTCC TCCTGCCCTC 
10441  GGCGAGAAGG AAGAACCTAC CAGAGGGATG GCTGGAATGT CCTTGCTGGG AGATTCTGTG 
10501  GCAGTTGGCC AGCAGCCATC CACCTGGCCA GGAAGGCCAA GGGTAGAGGG AGCTGTGGGG 
10561  TCACAGCAAG GGACGGAAGT GGTATCCCTG GGTTTGCAAC ACGGGCAGTT GGTGGCTGTA 
10621  TGTGTGCACC AGGATGCACA GTGTGGGGAG CTAGAACATA TGAGGGAATC CACCTTTGGC 
10681  GTTCCTGGAT GGTTCACCCA AACCAAGGGT TTTCCCATCA AGCCACTGTC GGGGTTTATG 
10741  CATCAGGGCA TCAGGGATGT ATGGGAGGGT CTTCTCCATA GGTGGAGAGA GAATGAAGAA 
10801  AGAAAACCAG AGGAGGAAAA GGAAGAGGCA GAGGCCATGG GGAGATCCTA AGGCAAAAGT 
10861  GAGCATCCTC AGAAGGCTGA GGGGGCTGTA ATGGTTTGAA GAATTAGCCT GTCAAACTTG 
10921  GGCCATAGGA GGGAGTGTGA CCCGGTGTGG AGGCCAAGGC TGCCTGCCCT TAGACAAAGG 
10981  CAGTCAGGAC ATGCTTCTAG ACCAAGAGCA ATGTTGAGCC TTGTGGATCT TTCTATATCT 
11041  TCCTGGGGAC AGAGACCATG ACTCCGTGTG TCTCCTTCAG TGTGCTCAGC ACCCTTGGGG 
11101  ACTCTGGATA GACAAGGGCA GCCACATGCA GAAGAGAACA GAGAGGGCTG GGAAGCAGGG 
11161  AGAGCCCAGA AGGGCTTCAC AGGAAGCTGA AGCCAGGGAA GCAATAGAGC GGACATGGAG 
11221  CAAGCTGAGC CCGAGTGAGA AGTGCTCAAA GGACCGCCAA CAGCTGTGCG CCTGCCAGCG 
11281  GCACTGTGCC GGTAGTGGAG GGCGCGCGGT GGAGGTCAAG GTAAACATGG ACCATACGTG 
11341  GTGGAGAACG AGTAACTTTG CACACTAGAA ATGGGGACAG AGTGGAAACG TGGACTAGGA 
11401  GGAGGCTCAA AGCAGCTGGA GGCAGCACCG ACAGAACTTG CTTCCAGACC CACCAGGGAC 
11461  AAGATGGCGC TGTGACGTGG GTGATGTGGG CAGACACAGC TGGAACCGCC TAGCCACCTT 
11521  TGCTCTTCAA ACACCACTGC AGGTAGGGTG GAACAAGGAG CTCTTCAGGG ATGGAGAGGC 
11581  AGGAGTGGGT TGGCTCAGGG CCTTTGGTGA AGGAATGCTT TGTTTACATC TGCCTTGCTT 
11641  ACACATGGAT TACCTGAGGG TCTTCTTCAT ATAGGTGCTC GGCTCCATCC TAGGGACTGA 
11701  CATCCTGGGA TGAGACAGGA GCCCAACTTC AGAACTGGTG AAAGGCCGTC TGCTGAGTCT 
11761  GACGTATAGT CAGGACTCTG ATGTGGTTAG AGCACTTGCT TTTTGTGCAC GAGGCTCTGG 
11821  GTTCAATCCC CAGTATAGGA ATCAGGCATA GTGGAACCTG CTGCCTAGTC TCTTGGAAAT 
11881  GGAGACCTGT GAGAAAAAAA CAGTTGTGCG GTGGTCTGAG GGGGCTTATG AATGAACTTG 
11941  AAAGACTCAT CGGTAGGGTA GGGAATGTGG TTCAGTGGAC CCTGGTTCAG CAAGCATGAG 
12001  GCCCCAGATT CAATGCCCAG TACAAGGGGC AAACAAGCAA ACACAAAGGG TCCCTGTTTT 
12061  TGTCTGTGCC TTTAATAACC TAAAAACAAA ACAAACGTAC ACCCCTTTAA TCCCAGCACT 
12121  CAGAAGGCAG AGGCAGGTGG ATTTCTGTGA CTATGAGACC AGCTTGGTGT ACAGAGTGAG 
12181  TCTACAGGGC TACACAGAGA AACCCTGCCT GGAGAAACGA AAAAAAAAAC CAGATAGCCA 
12241  AAACCCAAAA ACAAACAAAC AAACTGACAG GCTTTAAAAG GGCTGAACCA TTCATTTTAA 
12301  AACTATTGGT ACCAGTTGGG TCTGGTGGCC CATGCCTGAG AGCCTAGCAC TTGGGAGGTA 
12361  GAGGCAGGAA GATCATGAGT TCTGGGCAAG CCTGGGCTAT TTGAGACCCT GTCCTAAAAA 
12421  CAACTAACCA CCCAATCACT ACTACTGGTG AATCCTAGGT TTTCTCACTG TCCCCCACCC 
12481  ACACTTTTCA TGTGTTCTTC ATGAGAGGGC CTCTGGGAAG GACAGAGTTA GCTACCTCCA 
12541  GCTTTGTCCT AGAAGAGGTT TCCACCCAGC AGGATAGTCA GCCCCACCTC CCCACCAAAA 
12601  CCCCTGCACC CTAATGTACC TGAGTCACTG AATCCGGGCG GAGCCCTTGG CTACACAGCA 
12661  AAGCAAGCCA AACTGGAAAC TGGCCCTGGG AACAGAATGT ATGGGCTAAA CAAGTCTTAT 
12721  GCAGATGTAG GAGTATGCAA AGTCATTCTT GAACTCCGAA TCCATTTCCT GATCATCTCG 
12781  GATAGAAGGC CCAGTTCTTC CACTGTAGCT CAGTCCCTTA GGGCAGCCAT GAGGGAGAAT 
12841  GGGGCTCAGT GGTAGAGACT GCCTCCGATG TGGGAGGTCC TGGCCTTGAT TCCCTAGCCC 
12901  TGAAACAAAC AGAAGTGAAA GAGTGGGAGA AGGGAGTCCT TCATGTAAGC CAGTGACAGA 
12961  CCAGGGCAGC CAGCACAAGC AAGGCGAAGC TTGACTGGGC AGGAGTGAAG AGAACAGATT 
13021  TTGTAGGACA AAGGAAAGGC TTACCTAAGA AGAAAGGGAA CTCCTATGTG TTTAGGGACT 
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13081  GTGACACCTT TCCTTGAGAG AAAAGACTAG GGAAGCAAAG AAAGGTGGGG AAAGGCATGA 
13141  AAGACAAGAG CATGGAGGGT ATGTGTGCGT GTGTGTGTGT GTGTGTGTGT GTGTGTGTTT 
13201  GTGTGTGTAA GGGTGAAGGA CCCAGTTTAA GCAGAAAGCT TTGATTTTAT AAAGGACATA 
13261  GAGTCCCAAT GAAGGAACGG TGCGTGGGCA CACATGTGCA CACGGACGCC AGAGCAGGAC 
13321  ATACACTGGG TCCTGCTCTG TTGCTGTGTC TCACAAAGCC TGGAGCTAGG TTGGCCACTG 
13381  GCAGACTCCA GCCATCCTCC GGTCTCCGCC CTGACCTCAC ATGTGAGAGG TGGGGTTACA 
13441  GAGGCTGAAC TCCAGCTTTT CACACGGGCT CTGAACTCAG GCCTCTTGTG TTTGAACAGC 
13501  AAGTGACATC TTCCCAGCCC CAAGTGAAGG ATTCTAGCTC CAGAACTGAT AGCATCTGAT 
13561  GTTTGGTGTT TCAAAACCTA ACCAGAGAGA GGTAGACTGG TAATTCCAAA TTACTACACT 
13621  CTAAGCATTT GGCTCTTTAT TGTTTATTTA TTTATTTTTT TGTTTGTGGT TTGTGGTGTG 
13681  TGTGTGTGTG TGTGTGTGTG TGTGGTTTTT GTTTTAGACA GGGTTTCTCT GTGTAGTCCT 
13741  GGCTGTCCTG GAACTTTCAC TGTAGACCAG GCTGGACTCA AAGTCAGAGA TCTGCCAGCC 
13801  TCTGCCTCCC TGCTGCTGGG ATTGAAGGCC TGGGCCACTG CCACCCAGCT TGGCTCTATA 
13861  TTTTGTTATC ACTTTATCTC AGCAACCTTT TCTTCGAAGT GACAGGAAGA AGGAGGAGGA 
13921  AGATAGAAGA GGCGAAGAGA AAATGTAATG AGAGCTGGGG AACAGCTCGA CGATACAGTT 
13981  CATGCTTAGT GTTTATACAG TTCATGCTTA GTGTTGGGGA CTTGATCCTC AGCAAATAAG 
14041  ACCCCAGCAG GGATGTATGT GTCTCATCTA CCTGCGATCA ATGTCTCTCA AATGTTGATT 
14101  TGGGAAGCTT TGTTACATGT TCTTATAAGT TAATTTACTG GATGTAAAAC ATTTTTTTCT 
14161  CACTGTGGGT TAAAACAACA AAACAAAACC AACCAGGAAG GGTGGTACTA TGAGGTGGAT 
14221  GTGTGAGTGC TCTGGCTTCA ACAAGAGTCT AAGGGTCCAC TGCAGATGGG GTGTGGGGTT 
14281  TCCTACCCAC GCAGGTCTCA AGCCAGCGTG AATTCCCTCT GAGTGCTACG TACAGCTTGC 
14341  CTAAGTTAGT CGTTCGCAGA GGGCCTGGAA GAGAAAGCTA AACCTACCTG TGGTGCCTGT 
14401  CAAGCACGGC CCCTCATACA GGAGGAGATG AAGCAGAGAC CAAGCAGGGT CGCTAGGATG 
14461  CCAGCGTGCA ATTCTGCCCA CCTGAGGCGC AGGCTAAAAT GCAGATTCTA GGCACACACA 
14521  CCCCGCCCCC CGGGAAATAG CAAATGTAAC TAGGGACGAC CCTAGGGATC TGCTTTTGAT 
14581  AAAGGCTCAA ACACGCCTGT CTGAAGCTGA GAGGATCAGG GAAGCTCTGC GAAACATTGG 
14641  TGAAGATTAG CAGGGGCTTG AGATGACATA ATGACAATTC CCTCTAGGAA GTGCCAGGTA 
14701  ACCCAACTCC TGCCAGGTCG TCGACTCTCG AGAGGCGATG GATGGCGGGC GAGGGCCTGA 
14761  GGTGAAGGCG ATGCGCTCAC TGGGGGCCGG GCACCGCGTA TCCGACAGCT ACACTTGAGA 
14821  CTCACCATGC CAGACTGTAT TGAGAGATGT ATAAGCTCTT TACGGGGCAT TTCACAGTAG 
14881  CACTTCTGAT TGGCTTTAGG GCAGATCTAT CACTTATCTG CTGGGTTAGA GGTGGGTGGA 
14941  AGGTCAATTA CGACCAATAC AAAAACACTT CTCGGCTAAG CCCCTCCTCA CCCAGCTTCC 
15001  TGTTGCTGTC CATCAACCTC CTAGCAGGCG GGACTTTGCC TCCCGCCAGT TGGCTAAAGG 
15061  ATACGTCGTT CATTCCCCCG TTGATTTCCG GTTGGCGACT CCTACCGTCT ATCAATGACA 
15121  CTTCACAGTT CTATTGGCCA GACCAACGTC ACTCTAGATG CTTCCCAATG ATTGGTTGAA 
15181  AATGCTGTCG GTCCCCAATG TACCAAGCGT TCATTGGTAA AAGCTGCCGT CGCTCGGGCG 
15241  GTGGCGGGCT CCGGGATTGG CGGGTGCTAG GCGGGCGGTG TCAGGCTCTC GGTGGCGGCG 
15301  GAGGCGGCGG AGGCCAGGGA GGAAGATGTC GTAATGAGCG GTGGGTCCTG GCGTCTGCCG 
15361  GCGGCGTCTT CCCGGCCCTC AAGGGTCGGG AAGACGGACA GAGGCCTCGG GGAGGGGAGG 
15421  CCGGAACCGG GGGTGCCCCC CTGGGACTGG GACTGGCGCC GGGGCCCGGC TACGGGAGGG 
15481  GCGGGGGAGG AAGGATTCCC GCCCGGAGGA GGAGCGCGGC TGGCCGGCCG GGCGGAGGCA 
15541  CCCGGAAGGG GGCGTTAGAC TCCCCGCCCC TCGGAGCCCC GGGCGGGAGG GCGGCGCTTC 
15601  CGGGGCTGGC AGGCGGCGCG GGCAGCAGGG CGAGCCTGAT AACCCCCTTC GCCCCCTCAG 
15661  CTTGGGTCGC GCCGGGCCTT CAGCCTGCGC CCGAGTTTGC TCCACGCAGG CGGCCGACGC 
15721  CCCCTCGGGC TCGTCCTGTG GGCAGCCCAG GCTTGGGACC CAGGTGGTGC CAGTCAGATG 
15781  GGCCCTGCTG GTCTGAACTG CAGCCTGCTG GCCGGGCCAC CGCAGTCCCA GAGGGTGGCA 
15841  GGATTGGAGG GAACGCCCTA GGCAGATGAC TGCTGAACGA AAAACCGACT TTTAATGTTT 
15901  ATACCTGGAT CCTTGAGCCT GCGGCTAGTA TCTGCAAGCT CTTGGAATTT TAGAAGTTTG 
15961  GAGAACTTGT GGACAGAGCT CCCAGGCTAT GGCCCGATGC CCCTTGCGGG NNNNNNNNNN 
16021  NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN 
16081  NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN 
16141  NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN 
16201  NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN 
16261  NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN 
16321  NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN TGTGTACTGG CAGGAACAGA CTACAGCTGT 
16381  TCCATGCTGT GCCCTAGAAG GCCCTTGGCA TTACAGAGGA CAAAACCCTG AGTTGAGACA 
16441  CCCCCCCCAC CCCCCGTGGT GATGAAGGTT GAATCCACAA ATGTTGGACA AGCACCTCTA 
16501  CGGCTGAGCT GTCTTGGAGG GCTAGAAAGG TTAGGGTGAG CCAGCTCACA GTGAACTGGC 
16561  ACAGGGGATG ACAAGAGCCC AGACCACACA GTAGCATTTT CCATTATTGA CACAAAGAAG 
16621  TCCATTGTCT GTAGCGATGA GTATAACTGC AGTGTCTTGT TTTCTTTTAA ATTCTTAAGG 
16681  ACAATGAACA GCGCGGATCT CAGAACCTCC CAATAGGGCT TATGTCAGTG TTGCAGTGGT 
16741  TTCTTATTTA GGTGGTAGGG TGTTGGAGCC TGGTCTTGCT GTGAAGCCCT GGCTGGCGTG 
16801  TGTTTGTCCT GTGATCTGTG TAGGCCTTGA ACTTGAGATC TCTATGCTCC AGCCTCAGCC 
16861  TCCCAAGTGC CGAGGTTATG GGTGTGTACC AATTTGCTTG GTTTCTAGTG ACCAGGCAGA 
16921  CGTCAATCAA TACCAGTGAC CATGAGTTAT CTTTGGCTGA AGTGACGGAT GAGCTGTCTA 
16981  GTTCCAGTCC TCCTACTTGC CTCTTTGAGT AAAATCAACA GCCATTGGGA AAAATAAGCT 
17041  GCTCTGACAC CATTGTGAGC TCCGCAAGCT AGGCTGCTAA AGACACAGGC TCTTTGCCAA 
17101  AGAAAACTAA CTAGGATTTG TCCATAACCG GATCTTCCCC TGGGCACCCA GCTGCTCTGA 
17161  GGGGAAGAGT TTGACATCCC TGCTGATACT ACATAGATGA CCTCTACTTA GATTTGATTT 
17221  AAACATTGGG CCAGGATCAC TGAGAAGGCC CAGTGGGTAA AGACACTTGT TGCCAAGTCT 
17281  GATTACCTGA GTCCTTGTGT CTCACCTGGA AGGAAAGAAA CAACTTCAAT ACTGTTGCAC 
17341  ACAAAGATAC ATACACACAG AGGGAGGGAG GGAGCACAAA ACCAATACAT GAATTAGAAG 
17401  ATATCAAAAA ATGTGGGCCT GTGGAGGCCT GTTAAAGAGA AGAGAAGCAG TAAAAAGATT 
17461  ATACGGCAGA TGTTTGGTTA AAAAGCCCAT CCATGCTGGG CGTGGTGGCG CACGCCTTTA 
17521  ATCCCAGGAG GCAGAGGCAG GTGGATTTCT GAGTTGGAGG CCAGCCTGGT CTATAAAGTG 
17581  AGTTCCAGGA CAGCTAGGGC TACAGAGAAA CCCTGTCTCA AAACAAACAA ACAAACAAAA 
17641  AAAAAGCCTA TCCATTCCAG CAGGTAGAGA AGTTAGTATT TTGGTCTTGA CTATCTTAGT 
17701  TCTTCTAAGT GGTTAAGTGT TTTGGAGAAG TTATAATCCC TTGTAGCAAG CAGTGTCAAG 
17761  TCTGACCGTT GACGCATATG TGGCAATCCC CAAGCTTTCT TTAAGCAAGT GTTGCCCAAC 
17821  CATGGCCCTT AGAACGACTT TTAAAGTTTC TTGCAGCCAG CTAGTAGACT CTAGCAGTTT 
17881  TCTAGACCCT GAGCACTCCA CTGCTGTAAA AATGGGACTT TTTTTTTCTA AGTTTCCTTC 
17941  AGTCCGTCTC TTCTTTGTTC TATCTACACT CCAACTGGAA GCTTTGCTTG CAGATATTGA 
18001  AAGTATCAGT CATTATTTTG GAACAAGTGG ATAATGGGCA CAGAGAGAAA GAGGCAGAGA 
18061  GACCTTATTG TGAAGGTGTT GTGGAGTGTT GTGAGAGCCT CTGGGTTGAC AGCATTATGT 
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18121  AGCCTCATTT TAAGCCTTGT GGGCTGTGAA TTTGGAGTAA TCTGTTAGGA GATCATATAC 
18181  TTCCTTATAT GTTTACTGGG TGGCATGTCT GGACTGTACT TTTGGGTGAT TTAAAGGGTG 
18241  TGTAAACTTC TTCCCAGGAT GTTCTAAACC AGGGGCCCAG GCTGGGGATG GTTGATGCAC 
18301  GTAATCCTAA CATATTCAAG GTTAAGGCAG GAAGATTGAG AGTTTGAGTC TACCCTAGGT 
18361  TACTTATCGA GTTGCAGGCT AGCCTGGGCA TAGCAAGACC TTGTCTCAAA TGAACAAACA 
18421  CAAGGAAATT ATACCCACAG GATGGCCCAA ATGAGTGGTT CTGCTGGGAG CTTCAGTCAC 
18481  CCGAGCCGTT GGTGCTTCTC TGTACTGCTG TGCAGACTCA GGCATGGCCC ATCTCCCTCC 
18541  TGTCCTTCTT TCTCCTTTCC TTCCACAGCC AACTCTCAGG TCTTTGTTTC TGAAATGTAG 
18601  ATGCAGTTCT GTCTCTTAGG GAGCTTTCTT CATTACCAAC CAATGTTTTC ATGAGCAGCT 
18661  TTTCCGAAGA CCCCAGGGCA GAAGGTTCTT TTGGAGCCTG GTGGGAAGGT AAAAGTGGTT 
18721  GAAAGTATGG GGCACGCCAG GCTAAGCAAG AATGAGGCTG GAGGAGGGGC TGGAGGAGGG 
18781  GGTGGGGGTG TCACTCTCGA GAAGCTTCCC TGGTGTCAGT GGTGGACTTG TTCCAGTTGA 
18841  CAAATGGTGA AGTAGAAAAC TTTTTCTACT GCTTCATGGG ACTCTGAAGG TAAAAACAAA 
18901  ACACAGGCGC AAGTTCAGAA TTGGCACCAG CAGCCAGACC TCTCAGTATG CTTCTGGACT 
18961  GCTCTCTGTC CCTGGCACAA GCATCACTGT GCCTTTCCTC GGGGTGCACT CCAGACTGGC 
19021  ATGCTCTAAG CTGAGACATT GCCCAGTACA GGGCTGAGGG TGGGCAGAGT ATCCCATCTT 
19081  GCTGTTTCTC TGTGTGCCCA GAGGGAGCTC CTGGCAGCAT GGAGACATGA AGCTGTCACA 
19141  TCACTGTACA AGCTAGCTGA AGCCCAGCTG TTGGAGTCGG ATGATGGGCA TCTCATCCCT 
19201  CAGCTACCTC TCTTTCTGCA TCAAGACTGC TTGCTGGGAC CGGCCAGCAG CTGCTGAGTT 
19261  ACAGTGCAGA GATTTAGCTT GGGTGGCGAA GGCTAAGTCC TTTGAGAGGC CAGTTTCCCT 
19321  CTGTGTGGTG ATTTAGGCCC TTCAGGTGCC ATTCATGTCA GCCACAGGGC AAAATTGGGA 
19381  AGAATTAGCA GTCATTGCAC GTTTCTAAAT GTCTCTCTAG AACTTGTTTG TTGGGGTTGT 
19441  CATCTCTCCT GTGGGATTTG GTAAAAATCA CAAAGTGGCT CTTGAGACTG GGAACGGGAA 
19501  TTAGGAAATA GCTAGTAGGT CATGCGATTA GAAGTGAAAT AATTCTGCCT CATGGTTTAT 
19561  GTTTAATTGG AAATTGGAGG AGGAAAACAA CCAAGAAACA GACAAAGGCT TTTCCCGGGT 
19621  TTTAGAAGAG TAAATGGAAG CCAGCCTTCC TCTCTTCTCC AGGGAAATGA AGTCACTATT 
19681  CATTTCAGAA GCTGATCCTA GCCTGGGGGA GCTCAAAGAG TGACTCACGA AGACATTGCC 
19741  TAAGCAAAAA AGGCAGCATG TTTGTGTAGA AGGAGATTCT TGGGGGGGAC TCCTGCTTTT 
19801  CTCTATGACG GAATTCTGAG TTCCAGTGTT CTTTTTTTTT TTTTCTTTTT TAAGATTTAT 
19861  TTATTTATTT TACATATATG AGTACTCTAG CTGTCTTCAG ATACACCAGA AGAGGGCATT 
19921  GAATCTCATC ACAGATGGTT GTTCCTAATT GGAAAGGCCT TGCATGGTTT CCTGGGGCTG 
19981  GTCCCATCAT GCTTAAGAGT TCCCATCATC CCGGGGCCCC CACATTGATG CCCTGTGACT 
20041  CAGGCCACAA GCAAACTAGG ACTGACAGCA GTCATGCTTG GACGAAAATA GTCCAGAATG 
20101  AGACAGACCA AGTGTTCACA TTTAGACGCT CTAGTGTATG GTCTGACCTA ATGTCCCCCA 
20161  TTCTCGTGCT AACTGGAAAT GGTAAGAGTG TAGCCTGGAG CTGTAGTGCC GTCTGTGGGT 
20221  TGACGTGCTT GCAATGAAGT GTCTGCCCTG CTACAGCTCA CAGGCATGGC CACACTTAAT 
20281  GGATTGGGTA CTGGGGATGG GACCCGGGCT TGGTGCTCGA TAGGAAAGCA TGCCAGCAAT 
20341  TGAGCCACAC CCCAGCCCTC CTTGGTCTCT AAACTCCATT TAGCATCACT CCCTCTTTGT 
20401  TCCTTCAGGA TTCATTTATT CACAAGTGTA TTAAGCAAAT ATAGAAGGCT CCAACTGTGT 
20461  GCTAAGTTCT AGAGGTACAA GAGAAACCCT TGCCTTTAGG AAATTTGCAT TCTTAATAAG 
20521  ACAGTAATTA AGTAACTAAT GAGTACTTGC TGGGAAGTGG TAAGTGCTAA GGATAAAAAT 
20581  AGGGAGGGAG GGAGGGGAAA TGTGTGGGAG AGGCAGTTAC ACAGGGTGTT CAGGGACATA 
20641  GTGAGATGGG GACTTCATGG AACCCTGAAA GTGACGGGCA TTGAACCAGT TCTGTCTAGA 
20701  GTGAGGGGAG GAGGCTGAAC CATGCAGATG TGGGAGCAAC AGAAGGACCT GGCACAAGAG 
20761  CCCAGAAGCT CTGGGGAGGA CAGGAAGTCA GATCACATAG GCCTGTGCGT GATGGTTGGA 
20821  GCGTCGGCTG TCTGATGGGA TGCTATTGAC CCCTCAACAG AGTGATGATG TGGCTTCATT 
20881  TATGTTTGAT GTGTTGAGAA TAAACTGACA GATCAGTGCC TGTCTCAGCT GCCCAGGAAC 
20941  AGACATGGAT TAGGTGATGG CGTCAGGGTG AACGCCTCAT GTTTGGAATG TGTTTTGAAG 
21001  TTAGAGCTAG AAGTGTTTGC TTCCACATGT GGAAAAAAAA AAAAAACAAA AATCAAAGAC 
21061  AATTCCAAGG TCTTAGGGCC GAGCAGCTGG GTGGATGTGG TTAGCCTTCG CAGTGGGGAA 
21121  TACCTGAAAA AGCATGGAAT CAGGAGCCAT CGGAAACGTG ATTCAGGGCT GCTTACATTC 
21181  AAGGTGCCCA CTGCTGTAAA AGAGAAGATG CCGGCAGGAG GTGGTCTGGA GATAGAAACT 
21241  CAGGTCCTCT TTATTCAGTA TCTGTGAAGC ATTGGCTTTG AAAGCCATGA GAGCTGGCAA 
21301  AATCACCAGA AAGCAGAGAA GACAGAAATG TAGGTCCTGA AATGGATTCT GGAGCTTAGA 
21361  GTTTAACTGC CTAGAATTTG ACAAGAGGGG AAAAACCACC AGAGATTTAG AAGAAACCTG 
21421  CAGAGCAGGA GGCTGTCTTG GGCACATAAA ATAACTGTTT CCAGGACCAA GAACAGTCAG 
21481  CTCTCAGATC ACAAGACAAG GGCTCAGGTC TCGGAGTTAG CAGTTAGATT CAGAAACATG 
21541  AGGCCTGGTA GCATTGGCAG TTTGGGGAGG ATGAATGACG TGTACAGCCT GATTGGAGCC 
21601  ACGCTCAGGA ATGATTGTGG AGAGTAATGA GGAGCAGCAA GTGCACAGCC TGCTGGGCTT 
21661  AGGGTAGAGC TGTCCTTTGC ACAATTGTTT GTTTGTTTGT TTGTTGTGTT TTTCAAGAAA 
21721  GGATTTCCTA GCTGTCCTGG ACTTGCTTTG TAGGCCAGGC TGGCCTCCAA CTCATAGAAA 
21781  TCTGCCTGCC TCTGCCTCCT GAGTGCTGGG ATTAAAGGCG TGCGCCACCA CTGCTCAGCA 
21841  AACTGCTCAG CAAACATGCA TTTTAATATA CCTAGCCTTC CCAATATTAC AGCAAATGTT 
21901  ACACTGGTTT AAAAAACAGG TGTAGTGATG CACATCTGTA TTCACAGCAC TCCAGAGGTG 
21961  GAGGCTGGAG GACCAGGAGT TAAAGGCCAT GCTTGGATCC ATAGTGAATT TGAGGCCAGC 
22021  TTGAACTCCA TGAGACCCTA TCTCAGAAAC CAAAGACTAC TTAGGTTTGC TGAGAGTCAG 
22081  ACAAAGTCAT TTGCCACAAC GTGTTTTATA ACAAAGTGTA TATCATGTAA CTTACTGGAT 
22141  ACTGTACTAA ACTTAGAAAA CATAATTATG AGTGTGCTTT CATGTACTAT GACATTGAAA 
22201  AATGAAGTTG GAAGCCTGCC GGGTAGCTCA GTGCTTCAAG GTGTTAGCCT GTCATGTCAG 
22261  GCTGAGTCTG ACACCACGGA TTCAACCCCA GCACCCACAT GGGGGAAGGG GAGAAACAAC 
22321  TTGTAAAAGT TGTCCTCTGA CCTCATGTTG GCCATGGCAT GTGTGTAGCC ATACACAGAT 
22381  GTCCACACAT ATACACACAA ATAAAATATG TTTAAGGTGA GAAAAAAAGA AAGTTAAGTT 
22441  GAACCAGAGG AGTAAGGAGT CTCCTTGGTG ACTGAGGAGT TAGAGAGGTT AGGAATCCCG 
22501  GCTCAGAAAG GAAGGGTAAC TGCTTGATAA AGTCCTGTGT GTATCTCAGG GTCATGGCGG 
22561  AGCGGTGGGG TCAGGCTTGG GCTGGAGAGG GGATCTGCTC TCTCCTCTTG GCCTGTGGCG 
22621  TTAGCAGCCT CTGCTCAGAG TTCTGCAATG AAAGGCATGA ACTAAATCTT CCTGTGTGTG 
22681  GTTGCTGGGT TCAGTTTTCG GGACAGTTTG GAGCCTGTCC CAGCTCAGCT TGCTCCCTCC 
22741  ACCCTCCATC CAAGCTGATT CATTCACTAG TTTCCCTAGA GGTCCAGTTT TGTTCTTTAA 
22801  AACCAGCTGT AGCTTGCTTT TTCCTCACCA GCTCTGAGTT CTTCCAGGCT AGGCAACTGG 
22861  GAAAGCCTGG CCTTAGAAAC TGCTTTACTG GCTTCTGGCC CAGCCAGACT GACCAAAATA 
22921  GCCACCAGAA GGACTGTTTG TGCAGAGTGA AATTCCTGCT GGGGAAATAC CATAGTGGAG 
22981  GGCTAAGGAA GCCATAGTTG GGAAGGGTTT AAAAAAAAAA AAAAGCCCAG TAGCCTAGGG 
23041  TCTAAGTGTG GACTTTGAGC CCCGTTCCAT CCTAGGATAA CCTGATAATC AGGGCTCAGG 
23101  GTCCTTCCTA TTATGTTCTC CCAACCCAAT CGGCCAGAGA AAGCCCACCC CCTCCAGCGT 
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23161  AGAGCCATCT ATGCTCCCTG CTCTGTGGTG AGGCCAGCAT TGCCAAGGGT GCTACAGGAG 
23221  TGTGCACTGG CACCCAACAA GGTCATCTGC TTCTGGAGAG TAAGTGAGAA ACAACCTCTA 
23281  GGGATTATAA GTGGCCAAAG GAGAGCGCTG GCTTCAGGCT CCCAGGAGAG AGAATGGCAG 
23341  GCGAGGAGGG AGGAGGCTGG GTGCTTGGTC CCTCTAAGCT TATCAGAAGA GCTTCCGAAG 
23401  AAAACTATGG GGGAGGTGTG GTCAGGGGAG AGGGTAGAAG GGTTCTGGGT TTGCAAAGAT 
23461  AGTCTTCCAA AAGTGAACTG GCTGGATAAA GGGAAGTGGG CCAGAGGCTG AAAGCTGCCC 
23521  TGGAGGCTGT GGATGGGAGC TCTGCCTGAG CCTGAGGGGT CATTTAAGCA ATGCCTTGGG 
23581  ATTACTGAAC AGCAAGGAGA GAAACTTGTA CCAAGAATGA GGAGGACCCA GTTACCCACC 
23641  AGGAGGGTGA TGCTCAGGGT CCTGCTGAGA TTGCAACTAC ATATTCCAAA GACTCTATTC 
23701  TCCCCACTCT TGCGGAACTG TACCAGGAAC CAGTGAAGAC CAAGCAGCAG CACAGCTTAC 
23761  TCAAAGAGCA GGCCCTTACT CCCATCCCTT AGGCTGCTCT CACTGTAATG GGCACTGGAT 
23821  GCTAGCAAAA GTCCTGACTT CATCTCAGTC CAGAAAGGAC CCAAGGAGAC GATATACCTG 
23881  TTACAAAATG GCTGTCAATA AATTTTGCTA GGGAGGAAAA TGAAAAGTGG CCTAAAGGTG 
23941  CAAGCATCAG CTGGAAAAGT CAGAAGAGCC CTAAGCAAGG GAAGGGTAAC AGAGATAAGC 
24001  TCCTGGGATC CAAAGGGAGG GCTGCGGAGG CTGGGGAGGG GAAAGAACAA ACAGGCCAGG 
24061  AGGGAATGCT CTGGGTTGGG AGTGTCTGGC TGACCCAGTG AAGGGCCACA GAGGGCTGGG 
24121  CTGAACACAG CCCTGGGAGC GAGCCTGTGG AAGCAGTCTG AAGCCACGTG AACAGACACA 
24181  GTCCCCCAAG GAAAGAGGTC TTGGGTGAGA AGGGTCGTTT GTTGAAGAAT ATCAGTATTT 
24241  CAGTGATGGA GTGAATTTGG AGGGGGCGGC AGCCTCGAGA GAGGTCTGGT GACCTGGTAG 
24301  AAGCAGCCCT CTGAGTGTGG AGGGAGGTGT GGAGGGGACG GCAGCGTGAG GCAGGAGGAG 
24361  AAGGCTGTAC TGGAGGGCAA GAGATGGAGG CGGATGCTCT TAAGAGTCTG GACATTAGGT 
24421  GCTTTTCTCT CTGTCTTGGG TTCTGTTCGG CCCTCAGTTA CCTGATACTC CTTCCTCCCT 
24481  GCTGCCTTGT TCACACCCTC AGGACTTTTC CTTAGGACAG AGATGTGCCG GTCATTATTG 
24541  CTTGTATCAA AGATCACTGC CACACTTCAG CTTAGAGACT TGGGGACGTT TTAGCTGAAA 
24601  TGAATGATAA AATCCAGATT CTACAACTGA GAGACACGCA CTTTTTTCTT TCAAGAATAT 
24661  TTAGTAAGTG TGTGTGATAT GGCTCAGCAG ATAAGGTGAT TGCTGCCAAA CTTGATAACC 
24721  AGGGTTCAGT CCCTACAGAA CCCACGTGGT GGAAAGAACT GGTTCCAAAT TGTTCTGTGA 
24781  CTTTCATATG TGTTCAAACA CACACAAAAT AAATAAATGT AAAAAAGGAG AAAAATGCAG 
24841  TAATCCTTAT TACCCATATT GCTAAGTTGT AGGTTTCAGT GACCACATAC TACGGTACTA 
24901  TTAAAATTTG GTGGCTGTGC TGGAGATGGC TCAGGGGTAT AGCATTTGCT GTGCGTGTGT 
24961  GAGGCCCTGA GTCAAACCCC TAGAACAGGA AGAAGACCGT GTAGCATAGT GGAAGTGGTG 
25021  TGAAGTGATT ACAGAATCAG AGCTGAGCCC CTCTGTGGCT TTCTATCCCA CTCTGCAGTG 
25081  CTCTCAGTAG CGTGGAGGAG CATCAAGCAT GACTTACATC ACATTACACA CGCTAAACAC 
25141  AGGGTTCCAG GTGGAGTGAG GCTGCTCGGA GAATCTGTGG GTACGTGTCT GCCTCTCCTT 
25201  ATCCACATCC ACTGCCTCAC ACCAGCCAGA AGTGCTTCTC TCTTTCTTCT TCTTTCTCTT 
25261  TCCAGAGTAG AATTCTGCAG TGGCAGGGAA ATGTTTCTCC CATTTTTGCC CAGGGGCCAC 
25321  ACAAAGCTCT CAGTGACAAT AGGAGACAGC CATAGTGGTT TTAGACTAAA GAAGTATTTC 
25381  ATGAGCCAGC TGGGGAAGAA AATGAAACTA GGATGAGGTG TGCAGCCGGA AGCAGCAGCC 
25441  CGCAGCCTCC GCAGTAGGCT CTGCTTTACC CTCTGACCCA GTGGCTCTCA ACCTTCCTAC 
25501  CACTGCGACC AGCTGATACA GTTCCTCGTG GAGTGACCGC CAACCATAAA ATTATTTTGT 
25561  TGCCACTTCA TAATTGTAAT TTTGCTATTA TGACTCGCAA TACAAATATC TGATATGCAG 
25621  AATATCTCAT ATGTGGCTCC TACAAAAGGG CCGACTGACA TCCCTTCAGG GGTCATGACT 
25681  CACAGGCTTA AACTCTGGAG TTCAACCAGG TTTCCACACC GATCGATCCA GGGCTACAGA 
25741  GGGAGAGCGA AGCGGTTAGG AAGTGCTGGT CTGTCTTTGT TCCACTTCCT TTTACTCTGC 
25801  CCACTGCAAG TCTCTGTGTT TCGTAATACA GGAAGGACAT CATTCACTAA GTTTTGTTAA 
25861  GTAAACTTGA ATCCTTGAGA GCCTCCTAAG AGACCTTTGT GGGGCTTTTG TTTTGTTTTT 
25921  AAAGATTTAT TTATTTTATT GTATGTGAGT ACACTGTAGC TGTCTTCAGA CACACCAGAA 
25981  GAGGGCATCA GATCTCATTA CGGATAGTTG AGCCACCATG TGGTTGCTGG GAATTGAACT 
26041  CAGGACCTCT GGAAGAGCAG GCAGTGCTCT TAACCGCTGA GCCATCTCTC CAGCCCCAAC 
26101  CTTTGTGTTT TCATCAGCAC AACCTGGACT GAAAATTTTT TGTTTGTTTT GTTTTACTGT 
26161  GCTAGGTATG TAACCAGGGA CCTTGCACAT GTGAGGCAGG GTCTCTCCCA CCTGATCCAC 
26221  ACCCTTGCGC CTCAGGATAA ACATTTGAAA GAAAATGTAG TCCAACTTTT CACCCCACCT 
26281  CTATCCCATC TCCAACAATA TACATCTTGT CTCTGGTTAA ACAATTTTAG AGAAAGGGAG 
26341  ACATCACCCC CTCTGAGACA ACTGGTTCAG TCTTTCAAAG GTATCTTTGA GTTAAACAGA 
26401  AACCTGGCTT CTTGAACATC TACACGGGTG GCTTGCTTTT GTCCTTTGAA CTTACAGAGT 
26461  GTGGTCAGAA GCTTGAAAGT CTCTCGTTGG AAATACCCCT TAGAATGGGC CCAAGACTGA 
26521  ATATAACCCA GTGTGGGGAG TAATATATAG GGAATATTAT TTTTCTTGTC TTATAATTGT 
26581  ATTTTTTAGT TTTTTTAAAA ATAGTTTTTG TTAGCCAAAC ATGGTGGTGC ATGACTTAAA 
26641  TTCCAGCAGT CGGAGGCAAA GGCTAGACTA ATGTGATATT CAGTGAGTAA ATAGTTAATT 
26701  AATTAAAATG ACAATTACCA TAAGGAAAAA AATGTCAGTC AAAAGACCCA AGATGCCTGG 
26761  CCATGGTGGT GCACGCCTTT AATCCCAGCA CTTGGGAGGC AGAGGCAGGC GGATTTCTGA 
26821  GTTCGAGCCA GCCTGGTCTA CAAAGTGAGT TCCAGGACAG CCAGGGCTAC ACAGAGAAAC 
26881  CCTGTCTCAA AAAACCAAAA ACAAACAAAC AAAAAAAGAC CCAAGATGCC TGTGGCCCCT 
26941  GGTCCTGAGC CAAATCTGAG TTGGATACCT TGGCTCGTAC CCACCAACCC TTAGCCCCAA 
27001  ATGATATGAT CACCTTCATT TCCTCCTCCT TGTTCACAAA AATACTATAA GCACTACAAT 
27061  GTCAGGTGAA ACAGAATGTG TGGTGCATGT CTTTTACAGA TGGGCCCATC CAGAACCTTT 
27121  AAAAGCAAAT GGCTGTGCTT ACAGGACTAG TTTTTGCAAT TGCATGCTTT TTTCTGTAGT 
27181  TGTTCCTTCA TAACTGCAAT GATTTTACAG GGATCCGTGT CTGTAATATC CTAGAATCTA 
27241  TGTGTCCACT GCGCAGAACC ATCCACTGGC CTCCCAGTTG GCAGCATCGC AGGATCACCC 
27301  TTGTTCTGCT GCATCTCATG GCTTGGGGCC TGGTGACCAC TGAAGGCACT GTGTTGCTTC 
27361  CTGGCCAGCC AGCCTGCCTG TTTCTCTTTC TTTACCTTCT ACCTTTCAGG GGCCTGAAAA 
27421  AAGCCATGAA TGGTGGTACT TCTGTCCTCA CCAAACTATA GTTCTGTTTC TGCCTGAGCT 
27481  CTGTCCTCAT AGACTCCTGA CTTGGGGTCA GTTCCTGAGC TTCTGTCCCT TGAGTCTTCC 
27541  CCATCTCTCT GTTTCCTGGA ATTTGCTTTC TTAATGTCTA AGATACCAGC CTGACTTCCC 
27601  AGTTGCTTTG CCTTAGTGAT TTATGACTCT TACCATGGCA GAGTCTTCAC CCAGAGCTCT 
27661  TAGGGCTTCA TTTTCCTTTC TTTCTTCTTT TTCTTTCTTT TTTTGTTTGT TTGTTTTTTG 
27721  TTTTTTGGAT TTTTTTTAAT GGGCTCACTA TGTAGACCAG GCTGGCTTCA AACTCCTAGA 
27781  GATCCAGTTT CCCCTGCCTC CCATGTGCTG AGATTAAAGG CGTGTGCCAC CACATCCAGC 
27841  CTCTTGCTTG CCCTTTATTT GTTTAAAATG CTATGTGTAT GGGTTTTCCC CTGCATGTAC 
27901  GTTTTACACC ACTTGCATAT GTGCATCCTG CACTGGAGGC TAGAGGAGGC CAGCCCTTGG 
27961  AACTGGAGTT ACAGAGGATT GTGATGACCA TGTGGGTGCT GGGACTTGAA CATGGGTCTT 
28021  CTGGAAGAAT AGCCAGTACT CTTAGTTTCT CTCTTATCAA AAGTAAGCGG CTGGGCCTGG 
28081  TGGCACACAC CTGTAATCCC AGCCCTTGAG AGACTAGTAA ACGAGTCCCA GGCCAACCTG 
28141  GGATATGGTG CAAGATTCCT GTCTCAAATA AAGTAAAATT AAAGTTTAAA AATTATAGGA 
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28201  GGATACAGTG ATCCTTTGGT ACCCACAGGA GCTCCTGGAG ATTCCAGAAC CCGTAGATGC 
28261  TCAAGACTTA TATATAATGT ATAGAAGTTA CCTGTAAGTT GCACATCTGC CGCATACCTT 
28321  AAGTCATCTG CAGATTATGT AGCACCAACA TTTCTTGATG CATGGTTGGT TGAATCTGTG 
28381  GCTACAGAAC CTGTTGATAT GGAGGTCAAC TATCCAGTTG TGGGGAAATG AGAAGAGAAA 
28441  AATTCTGCCA GCTATTACTG CATATACACA AAAGTGGAAA GTGTTCATTC TTCCATGTAG 
28501  TTGTTAGCCC TGCTGAGTCT ATGACCTACA CAGTCAGATC AGTTGTCCTG GGTAAAGGGG 
28561  TTAGTCCACT TAAGGCAGCG CTTCTCAGCC TTCCTTACGC AGCAACCCTT TAGTGCAGTC 
28621  CCTCATGTTG TGGTGACCCC CAAACATAAC ATTATTTTTT CTGCCACTTC ACAGCCATAC 
28681  TTTTGCTACT CTTACGAAGT GTCATGTAAA TACTTTTGGA GAGGTTTGCC AAATGGGTCA 
28741  CGACCCATAG GCTGAGAACT GCTGGCTTAA AGGAGTTGCC GTCTTCTGGT TCCTGGAGGC 
28801  CCTTGTGTCT CTGTGTGAAG GTTGTGAAGG TTGAGCAGAC AGACAGCCTT TAGAGTAGGA 
28861  CAGCTATGTC CTGCTGCTCA GGAATGCTGG CCTTGCCTTT CTTCTTTCCC AGACTGGCTT 
28921  GCATCTAGCT CCCGCTGGAT TGAGCTGGTA GCCTGCCTTA GCACAAGCCT AGAGGCTCTG 
28981  CCCCAATGAA GAGATTCAGA TTTAGAGGGC TACCAGTGTC CACCAGGGGG CACTCTGGAC 
29041  TCAGCACAGC CGGACCGACA CACGAGTCTC CCAGTTCTCC TCATCTTAGA TGGTGTGGGG 
29101  AGTGTGGTGA AGGCAGGCCT GGCCTGAATC GATGAGTGTA AGCAAAGGAA AAGCTCACCC 
29161  TGGCAAGCCT GGGGCTGGGA TGCTCGAGCG GGGCCTTGCA GGAAAAGCTC TTAACCTGTT 
29221  GGAAAAGCAA CAACAGAGGC AAAAAAAAAA ATTAATTTAA TTTAAAAAGC GGAGGCAAGG 
ATCC 29281  GGCCTTGGGT TCTCCTGTGG TGTGTTTCTT ACATCATTCC ATCTTTCTCC CAGCAG
29341  ACAGATGAGC ATGGCCGCCA CTGCTGCTGT CAGTCCCAGT GACTACCTGC AGCCTGCTGC 
29401  TGCTACTACC CAGGCAAGTG CACGGTGCTC TCTGAGGGCA GGGCCAGAGC CCGGCGGGTT 
29461  GATGAAGTGG GTTTTCTGCC TTACTCAGAC CCGCTCGCTC TCACTGCAGA CACCCAGGGA 
29521  GATTCACTTG TTCTCATTTC TGAACTAAGA CATAGACACC TGTCTAAGAT GTCAAAGTTG 
29581  GGTCAGGCAA AAAGAGTTGT GTTACCCGTG ACCTCTGGGG CTGGGGCCAT GGCTCTTAGT 
29641  AAAGTTGCTG CACATGCATG AGTTCTTGAG TTCAATTCCA AGTTCCCGTG TAAACCGCTG 
29701  GGCTGGGCTT GGTAGTACAC ACCTATAATC CTGGCATTCG AGAGGCAGAC AGAGGGGCTC 
29761  CACTGGGCTT ACTGGCCAAC TAGTCTTGCC CAGTCAGTGA GTTTCAGATT CAGTAAGAGA 
29821  CCCTGTCTCA AAAATGACGG CAAAGGAGGT GGAGAGAGCC AGGCGTGGTG GCGCATGTCT 
29881  TTAATCCCAG CACTCGGGAG GCAGAGGCTG GCGGATTCCT GAGTTCGAGG CCAGCCTGTT 
29941  CTACAAAGTG AGTTCCAGGG CTACACAGAG AAACCCTGTC TTGAAAAGCC AAAAAGAAAA 
30001  AAAGAGGTAG AGAGGTGCTC AGTGGCTTAA GAGCGCTGGC TGCTCCTCCA GAGGCCTGGG 
30061  TTTGATATGA TAGCTCATAC TCCAGGATCA AGTGATCTGA CACCCTCTCT GGCCTCTGAA 
30121  AGCACCAAGT ACAAGTACTT GAGTAAGGCA TAGACATACA TGTGGGAAAA ACACCCACAT 
30181  ACATTAAATA AATAACAATT TAATAAACAA GGGAGAGTCA AAGAGTGAGA CTTCATTAAC 
30241  ATATCTGGCC TCTACCTACT CCACCTATGC TGATTCGGCT ATACCCACAC ACCCTCCACA 
30301  TGAACACATA CATGTATATA ATACACACTC CAGAACAAAA CCAGAAACCT TTTACCGAGA 
30361  GCAAGTTCAT GTCATCTTCC CTCCCCATCA GCTCTCCTCT CCTCCTTGTA CTGAGTTGGT 
30421  AGAATTCCAA CTGATACCTG GGTGTGTTGT TATCCCTGCC GACACTAGGC CAGCAGGGCG 
30481  GGTGGAGGGG GGGGAGAACA GCCTGTGTTG TTGCTGTGTG GTGTCCAAGG CTGCTTCTGG 
30541  GGGGTTTTAC ACTGAGTTCC TTCACTTCAT GGAGAAACCA GCAGGAGCCA ATGAGCCAAT 
30601  GCAGGACACA CGCACGTGTG TGCGCACGTG TGTGTGTGTG TGTGTGTGTG TGTGTGTGTG 
30661  TGTGAGTGAT AGCTTGCCAC AGGGGTGGGG AAGCTGCTGA GAAGAGAGGC TCGTGAGGGC 
30721  AGAGTGTCTG GCTAGTCAGC CCATCTCACT CCTTTCTTCT GTTGATTTTT GCAGGACTCC 
30781  CAGCCATCTC CCTTGGCCCT GCTTGCTGCG ACATGTAGCA AAATTGGCCC CCCAGCTGTT 
30841  GAAGCTGCAG TGACACCTCC TGCTCCCCCC CAGCCTACCC CAAGGAAACT GGTCCCTATC 
30901  AAACCCGCTC CTCTCCCTCT CAGTCCCTGC AAGAATAGCT TTAGCATCTT ATCATCTAAA 
30961  GGAAATATAC TTCAGATTCA GGGCTCCCAG CTGAGTACCT CCTACCCTGG AGGGCAGTTT 
31021  GTGTTTGCAA TCCAGAACCC CACCCTGATC AACAAAGGGA GCCGATCAAA TGCAAGTATC 
31081  CAGTACCAAG TCCCTCAGAT CCAAGGGAAC AGTTCCCAGA CCATCCAGGT GCAGCCCAGT 
31141  CTCACCAACC AGATCCAGGT CATCCCAGGC ACCAACCAAG CCATCATCAC CCCGTCAACA 
31201  TCTGGTCATA AGCCTGTCCC CATCAAGCCA GCTCCTGTCC AGAAGTCAAG TACGACTACC 
31261  ACCCCTGTGC AGAGCGGGGC CAACGTGGTG AAGCTGACAG GCGGGGGTAG CAACATGACG 
31321  CTCACCCTGC CGCTCAACAA CCTGGTGAAC ACCAGCGATA TTGGGGGCCC TGCTCAGCTC 
31381  CTCACTGAGA GCCCCCCCAC CCCACTGTCT AAGACTAACA AGAAAGCTAG GAAGAAGAGC 
31441  CTCCCTGTGT CACAGCCATC CGTAGCTGTG GCTGAGCAGG TGGAGACGGT GCTGATAGAG 
31501  ACCACGGCAG ACAACATCAT CCAGGCAGGA AACAACCTGC TGATCGTCCA GAGCCCTGGC 
31561  GGGGGCCAGC CAGCTGTGGT CCAGCAAGTC CAGGTGGTGC CACCCAAGGC TGAGCAGCAG 
31621  CAGGTGGTCC AGATCCCCCA GCAGGCACTG CGGGTGGTGC AAGCTGCCTC TGCCACCCTC 
31681  CCCACCGTCC CCCAGAAGCC CTCTCAGAAC TTTCAGATCC AGACAACTGA ACCAACACCA 
31741  ACCCAGGTAC CATAGTCCCT CTGCCCTGCC TCCCCTCCTC TGCTCACCCT TTTGGCTTGC 
31801  TTTTGAAACT GAGGCAGATC ATCGTCAGAT CTTACGGGAA GCTGGAGTCA CCATCATTTG 
31861  GGGTGGGCAG GAAATGGCTT CTCCCCTGGA GTCTCTTCAG GTCTTAGGCC AAGTAGTCCT 
31921  GACCTGTAGA AATCAGATGG AACAGGGATA TCTGGTCTGT TTTATTCTTT CCTTATGGGG 
31981  TAGCTCTGGG GGCATAATGG GGTAGATCTG TATACTGTCA TAATAAAGTA TTTTTAATGT 
32041  AAGAGTATAT ATAACAGCAA GAATGAGAAT TCGAACTAGA ACCATAGAAT CTGCTGTAAA 
32101  GTAGGAAAGT TCAAGAGAAA AAAATGCTGG CCTCTGCTAA AGACAAGAGC AATAGCAGTG 
32161  GGGCAGCCAG GCCTTTTCCT TTCTGAGACA GGTCTCCCTG TGGGTCCCAG GTGGGCCTTT 
32221  ACCTCGCTGC ACAGCCCAAG CTGGCTTCAC TCGCTGCACA GCCCAAGCTG GCTTCAGACA 
32281  TGGGACCCTC CTGCTCCAGC CTCAGTGCAG TGCTGGGGTC GCATGTGTGA GCTGTAGCCT 
32341  TGCTTCTTTG CACCCCTGTT TATCCTCCCC GAGAGGGGGT TGTCCTTCTG CTTCCTTCAC 
32401  TGTGTGTGCA TGTGGCCACT GAGCGTGTGT TTTCCCCTCT AGTCTAGATC CCTCCTAAGG 
32461  GAGAAGACAT TCGTCTTCCT GAGCCTGCCA TGTTCCACTC ACCATGATGA CCTCTGGGTT 
32521  CTGGAGTGTG CTCACGGCTG CTTTTGCTTC TGCTGCTGTC AGGGCAGCTG GCCATTCTGC 
32581  CAGCTGTCAA CTCTTGTCTT TTTAGCTGCC CTGTGGCCGC CATCTTGCTG CTTTGGTAGC 
32641  CTGCCCTGCC GGCTGCTTAG CTCTCTGGTC ACTTTGCAGT CTCTGCTGCT GCTTTTTTCT 
32701  TCCTTCCCTT TTTTTTTTTC TGTAGCCCAG GCTGGCCTGA GACTCAGAAA TCTGCCTACC 
32761  TCTGCCTCCT GAGGGCTGGG ATTAAAGGCG TCATCACCGC CACTCAGCTG TTGCTCCTTT 
32821  ATGTTACCAG CTCAGCCCAC TCTAAAAGCA GACAAGAACA GACAGAGCCC AGTGTTGCTC 
32881  AAGACAGACG GGGCAGTAAA GGAGACTCCA GCAGCCATGG GAGTCAAACT GCTCCATTCC 
32941  CCAGTGTCTC TGCTGATTTA CAGGGAAATG GCCATGAGAA GGAGTGCTCA AAATGATCGT 
33001  TTAAAACTTG AGTCAGGTGC TCTGGTGCAC ATCTGTAAAC ATGCATTCAG GGGGCTGAGG 
33061  CAGGACTGAC ATGCGTTGTC ACCAGGCCCA GCAATGGGGC TTGAGCGATG GGTTGTGGTT 
33121  GACTCGCCGC TTTTTCCAGA GGTTCCAAGG TTGATTCCCA GCACTCACGT GGCTCTCAAC 
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33181  CAGCTGTAAC TCCACTCCCA GAGGATTCCG AGTCCTCCTG TAGTCTCCAT CTGCACATGA 
33241  TAAACAAATG TGATAAAGAC ATTAGACAAA GCACCCCCAC ACAGTCAGGT AATAATAAAA 
33301  CAAACAGTGC TTAACACCCA CTCAGTACCC ACCAAGGGAG CAGTGGGCCC TCGCCTGACT 
33361  CAGGGTGTCT GAGGCTAGCA GAAGAGAAGA CAGAAGGGGC AGGTCCTCTC CTTCCTGCGC 
33421  CCCAGTTACT CAGCCAGCCA TTTACTACCT CAGAGAAAAA ACAAGTACAA CATGGTAAGG 
33481  TTTTTAAATG GGGTACATAT ACAGAACTGG AAAGGGACCT GAGGCTTCTA TATGTATTAA 
33541  GGGATGGCAG GTTCAGATGT TATCCTTTAA CTAAAAGTCT TCAGTATCCA GGAATTAAAT 
33601  ATAACCCCAG TTAAAATCAG TCTTACAAAG GATTTTTTTC TCCCTGGATC ATTTAAACAT 
33661  AAACTGCCAC CATGATCCCC CTCCCACTTG CAAATGCTTT AATTCTCCCA CACAGGCACA 
33721  GCCCCTGCGC ACACCGCAGC CTTCAAGCCT GAAACTCACT AGTGAACTGC TGGTGTCTAT 
33781  CGGGGAGGTA CCATTCAGGT CTCACCACAT GCTTCGGATA GTAATTCCAA CGCTGCCTAA 
33841  GGACTCTGTC CACCTTACAT GTAGTTGTCG CATCTCTCTG GTCAGATCTC TCTTTCAGAA 
33901  AGAATTCCTC GCATCCCCCA CCTCCATGGA GCTGGAAATT AAACCAGGGC TTCGTGGATC 
33961  CTAGGCACTT AAGTGTCCTA CCCTGAACTA CATCCTCAGC CCCACTTCCT CTTTAATGTG 
34021  GCAGTCAACC TTGCTGCTGT TGAAGGCCAC AGGCTAGTTG TTTTGTAGAA TGTCCTTTAG 
34081  TTTGTTTATG TGATGTCCCA TGAGTGGATT GCATTTGCCA TCCCAGTGCT CATACAGAGA 
34141  GAGGTGAGAG CAGAAACAGG AGGACCAGAC AGGAACCAGC CAGCCTGGCA TATGCAGTAG 
34201  CGAACAAGAA GCCCTACTTA CAGGAAGGCA AGGTTGTCCT GTGACTTCCA CAAGTGTGCT 
34261  GTAGCACATG CGTACCCATA CTCTCACACA TAAACACATA CACACACACA CATACACACA 
34321  CAACATAAAA TTTTTTCCTC CTTGTATTTC ATTAGTATTT TGAAGAGAGA CATTTTGGGA 
34381  TAAGATAAAT ATCGAGTTCC TCTTAAACAA TTTGCTTAGA TTATTTTATT ATATATATAT 
34441  ATGTATGTAT ATATANNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN 
34501  NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN 
34561  NNNNNNNNNA GGTTCGCTTG CATATATATG TACGTGTACT ATGCCTAAAC ATAGTATGTG 
34621  AACATGCCTC ATGCCTGAGA AGGTCGGCAG AGGGCATCAG CTCCCCTAGA ACTGGAGTTA 
34681  GGGATGACTG TAAGCTACTG TGTGGATGCT GGGAAATCTG GGTCCTCTGG AAGAGCAGCC 
34741  AGTACTCGTA ACCTCAGGCC CATCTCTCCA GCCCCTGCTG TTTAAAGATA GTTTACTGTG 
34801  TGGTTAAGCT GGCTCCACAT CACTTTGTAG CCCATGCTGG TGGTGTGCTT TTTTATTCAT 
34861  CTTCCAGTTT TGAGATTTAG CAGTTAATAT TTTTCCATGC TAAGCAGATT AAAAGTTTGG 
34921  TTGCAGGTCA GTAACCAGCT CATGCCGATT GAGTGCAGGG CAGCATCGGC CCTGTTAAAC 
34981  ATGAGTAGTG CACAAGTGTG TTCTTGGGCT GGATGAGATG ACAGAGGTGT CCCAGTTCTC 
35041  CCTCGGACAA GGAAGGTCAT GCTGCCATCT GTCTTAGAGC ACTCTCTTTT CTCTGGCCCC 
35101  TCAGGTTTAT ATCCGTACAC CTTCTGGTGA GGTACAGACA GTCCTTGTCC AGGACAGCCC 
35161  CCCAGCAACA GCTGCAACCA CATCAACCGT CACCTGTAAC AGCCCTGCAC TCCGAGCTCC 
35221  CCATCTGAGT GGCACCAGCA AAAAACATTC AGCTGCCATT CTCCGAAAAG AGCGGCCCCT 
35281  GCCAAAGATT GCACCTGCTG GGAGCATCAT CAGCCTGAAC GCCGCACAGC TGGCAGCAGC 
35341  TGCTCAGGCC ATGCAGACCA TCAACATCAA TGGTGTCCAA GTCCAGGGTG TGCCTGTCAC 
35401  CATCACCAAC ACTGGCGGTG AGGGAAAGGC CTGAAGCCAG GAGGGTACTG GGAGCAGGGC 
35461  TTTGCATTCA GCATATGGGA ATCCTGAGCC GGGCCCCTGG GGTTTCCAGG GTCAGCCAGG 
35521  AGGATGCTCA GCTTGCTCCT GGTCCCTGCC AGCCTCAGGT CATATCTGTC TTCACACTTG 
35581  GTCCTTACAG TAATACTGTG AGATAGGAAG TCACATGACC ACATGATAAC TGCAGATGTT 
35641  GAATAGAGAC TGAGAAAATA GATGTGTCCA AGTAATATAC AAATTCACAT TAATTTGGCT 
35701  GGTCACTTGC CCAGGTCAGG TAGCTAAGGG CTGTACCTAA TGTAAAGGAA GTCAAGGCTT 
35761  CTTTTGGGGG TCAGGGGTAG TGTTTCGAGA CAGTGATTCT GTATAGTCCT GGCTTTCCTG 
35821  GACCACTGTA GACCAGAACA GCGTCTGCCT CCTGAGCGCT ATTATTAAAG GCATGTGCCA 
35881  CCACCGTCCA GCTAAGGACG GCTGCTGTTG AGAGTGGGAG GCAGGGGAGG GCGTCCTGGG 
35941  CAGCAGGACC AGCTTACACT GCACCAGAGC TGATGATGAT ACATTCTGCG AGTGCAGCTT 
36001  TGAGAAAAAG GGAAAGCGAC TTGGGAGATG GCTCAGTGCT CAGCAACACC GGCTGCTCTT 
36061  CCAGAGCCTG TGTTTCATTC CCAGCACCCA CATGGCAGCT CACAACAGTC TAGTCCCATA 
36121  GGATCTAATG CCCTTTCCTG GTATGTAGAC ATACACACAG ACAAAACATC CATATACATA 
36181  AAATACATAA AAAAATCTTT AAAAAAATAA AAAAATGAAG AGAGAGGGAA GGAGGGAGGG 
36241  AGGGAGAGCT GAGGCTGCCT AGCGAAGCAG GCTGCATCTG CACCTGGGAG TCTGCAGCGC 
36301  CCCCGGCGGC GGCGAGAGCT CACGGCTTTC CACATCCCTA ATAAACGTCG AGCATCTTAG 
36361  GCATTTGCTT GGTCCACAGA ACAAAAATTC TTAGGCGAGT TTCCTGCTAG CAGGGGCAGA 
36421  ATCTCAGGGA GGCCTCTGGC CCTCACTGCC CTCCAGTGTA TTAGGCTCCA TGAGTCTTCC 
36481  TCAGCCAGAG AGAGGGAGAG GGAGGGAGAG AGGGATAGCC TGGGCTTCCT TTCCTGAACC 
GGCAGCAGC AGCTGACCGT GCAGAACGTT TCTGGAAACA 36541  ACACCCTTTT CTCTCCCACA G
36601  ACCTGACTAT CAGTGGGCTG AGCCCCACCC AGATCCAGCT GCAGATGGAG CAGGCTCTAG 
36661  CCGGAGAGGC CCAGCCTGGG GAGAAACGGC GGCGCATGGC CTGCACGTGT CCCAACTGCA 
36721  AGGATGGGGA GAAGAGGTAA TATGCCCGAC CCTGGCCATA CCCACACCCC TGTTCCACAG 
36781  GTCACTCGGG GACAAGTCTT GGCCTGACCT CCCGTGCTTC TCTCCCTTCC CTCTTCCCAA 
36841  CTCCTCCCCC TACTCTGAAC CCAACCCCTC AGGTCTGGGG AGCAGGGCAA GAAGAAGCAC 
36901  GTGTGCCACA TCCCGGACTG CGGGAAGACT TTCCGGAAGA CATCCTTGCT CCGGGCCCAC 
36961  GTCCGCCTGC ACACTGGCGA GCGGCCCTTT GTCTGCAACT GGTTCTTCTG TGGAAAGAGA 
37021  TTCACTCGGA GCGATGAACT CCAGCGACAT GCTCGAACCC CACACAGGTC AGTTCCCCCA 
37081  TGCCCTTGTC TGTCCTTTGT ACACTGTCAC CCATGCCTGT TCGGGGCTTC ACCATCCACA 
37141  CTACCCAGAC CCAAAATCAA AACCAAACCA AACCCAAGCA GTGATGAGAA ATGCCAAATG 
37201  CTGTGTGTAG CATTTTCAGA TAAGTTAGTC CCAGGAAGGC CTTGGAGGGT TACCTCAGTG 
37261  CCAGCCACCT GGCTGAGGTT TGGATAAGTG GCTAGTGGTG GGCAAGCTGG GCTCCTACCC 
37321  AAGCCCTGGG CTCTCAAGGC CACATACTTT GTAAATGCTT TGTTTTAGGA CTTAAGGTCC 
37381  CTCTGTCTCC ACCTCTGTAA AGCCCTGTGA ACTAAGCCAC CAAGCTGGCC TCCAGTCTTG 
37441  GTTTTGGAGA GAGAGCGATA ACAAGATTGA GCCAAGTGTT CAGGCTGCCC TTGCAGCAGT 
37501  CCTGCCTCAG ACTCCAGCTG TTGGGATTAC AGGTGTGAGT CACCACACCC AACTCTTTTT 
37561  GTTTGTTTTA AGACAACATT TTGCTGTACA GCCCAGGTTT ACCTTAAACT CGTGGCACTT 
37621  CTCCTATCTC CTTAATGCTG AGATTACAGG CCTGCTCCGA CATGCATGGC CTACTGCAGG 
37681  CCTGCCTCCA TGGCAGCCTA AGTTTACTAT TAAGGTTGCT ATCACTATTA TGTGCTTTAA 
37741  TGCACCCGAT AGAAGGTGCC TTAAAGATGT CCTGGGCATG CCCAGTGGTC CACTGGCAGA 
37801  TGCTGTTGTA GGGAATGATG CCCTGCTGAG CAGACACTGA GGTGGGGGAC ATGCCTCAGC 
37861  TCCTGGTGAG TCACACCCAT CGCAAGCAGA AGCATACACA CCCTGATACA GGGTGGGTCG 
37921  CTGTGGTCCA GACTCAGGGG CTCAGGGCTG AGATGTCTTC CTGTAAGGAG GAAGGTGTAA 
37981  AGTCCCTGGG ACACAGTCCA GAATGAAGCA GGTATGCAGA GGCTCAAGGA CAAGCAGCCT 
38041  GGGCAAAGAC CAGAGTGTAC CCAAGAACGG AGTGTAGAGA GGTAGATTAG ACGGGGCAGC 
38101  TGGGGCAGAG AGGTGCGACC AATAGACGAC AGGAGGAGGC TGTTAGTGGA GTGCAGAGAC 
38161  AAGGCCAAGT TGGCCTTTCC AGGGGCTCTC ACTTTCTGGA GCTTCTCCTT TCTGGGACTG 
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38221  GGGCAGTGAT ACTGCATGCC CTCTTTGGTA AAAGATATTT CTTCTTCCCA GGGGACAAGC 
38281  GCTTTGAGTG TGCCCAATGT CAGAAGCGCT TCATGAGGAG TGACCACCTC ACCAAGCATT 
38341  ACAAGACCCA CCTAGGCACG AAGGGCTTGT AAGGCCAACT GAGGCAGGAG GCCCTGAAGA 
38401  TGGAACACCT CCCATCTGAT TGGCCCTGGG TCCATGATGG ACAGGTGCCC ACGACTGCCC 
38461  TGGGCAGCCC TCACCCCACT CCTGTTCTGT GGCTGTGTCC CTGCAGAGAG GGACTCTGTT 
38521  CCTGTGTTCT CCTCCTTCCA AAGGCTCTGC CCCTCTCACC GTGAGCTCCT GGCCTGCCCA 
38581  GGCCATGGAC ACTGGCCATG CCCAATGAGA CGTTCTAACC CAGGACGCGT GGGGACCCTT 
38641  ATTTCCAAAG GAAAAACATA CATTTCACTC CGTCGAGGAG CAAAGTGAGC CCCCCATCCC 
38701  CACCCCATCC CCTTCCTCAA CACTGCCGGA GTCCCATTGT GCCATGCCCC CTCCCCCACC 
38761  GTGCCTCCTT GTCCCCCTCA ATTAACTCCT CCTGGGCCGC TAGGGACACC CAGGGGCCCT 
38821  GTACCCAGCC TCCCACTGAC ACCCCCCACC GGGGAGGTGG GAGGCTGCCT CCACTCCACT 
38881  GCCCAGCCCT GCCACGGCTC TCCTCCAGAC ATTCCAACTT CCTATGAAAG GTCAGACGCC 
38941  GAGGACCTGC CCTCCCTCTT TTCTACGGAG AACGTTGCCT TATACTCACT TCAGATGATG 
39001  ACACTGTGGA CGTGTGTGCT TTAACCACAT TTTATTTAAT TGCTCCCTTC CTCTCTTTGC 
39061  TAGACGCCTC CCCCTTGCTT GCATTCAGTT TAGGGTTTTG GGGGCAATGC TGAGCATAGG 
39121  AGGGTCTTTT TTTTTTTGCT ATTTTTTTTC TCACTTTAAC AATTCTTTTC TAAATGACAC 
39181  ATTTCAACTC AAATCTGGAC TCACCTGAGA ACACCTTCCA TCCTGACCCC GCCACGCCCT 
39241  CATCTCCCCC TGCCCAAGCT CCACTGTGTA CAGTGTATAT TGTATAATAG ACTATTGTGT 
39301  CTAAGACATG TTTTAAAAAC ATATTGCTTG TTATTTTTGA GGCTTTTAAA TTAAACAGAA 
39361  ATCCAACTTT ATTTTCGTTG TAACTGCTTG AGGATGTTTT ATTAATTAAG TGAAGATTTG 
39421  TTATCCTTTA TTAACGATGT ATTTTGTTGG TCAGTACTGG GCTGACAAAA AGTTTCTTGC 
39481  TAATAAATTT AGTTGCCCAA GGCAAAGTCT GCGTTTGGCA GTTGGGCTTC CTTTGTCTGT 
39541  GATGTCAGAG GTCTTACAGA AGGATTCCTG AGGCGGGAAC TGTGGACTCA ATTTACCCTC 
39601  CTGGTCCTGG TCCCAAAGGA GACCGGCTCT CAGAGCACCT GGGGGCCTCT GGAGCCAGAG 
39661  CCCAGTGCAG TCTCTGCTTT TTTCTCCCAC TCCCAGTCTT GCTTCAGCCA CAGAGGCGAA 
39721  CCCTAGAAGA ACTTCCTGAG CTGGCCGACT GTTGTACCTC CCACCCCAGC CCCGAGGAAG 
39781  GCACTGCCTC CCAGTCTGTG AGAAGCTAGA GGAGTCAAAA GCCTTAGCCC ACAAGGTTGG 
39841  GTTTGCAGAA AATACTGTTC CCACAGGGTG GGAGGGAAGT CTGGGACCAA GCAGGTTCCT 
39901  CAGGGTCGGC TCTGGGTTTG AGTAGAGTTG CAGAGTGGAA ACTGTATTGG GGGGCACCTT 
39961  TTCATTTTGG CAGAACTACA GAGAAAGAAG TCAGGGATTG TGACTTACTC AGATTTAAAG 
40021  CCACAAGCGT TGGGGGCCTG AAAAGCAGCA GCCAGGCTGG AGGAAGAGGC CAGTGTGCCT 
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